<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000515.pub3" GROUP_ID="STROKE" ID="858699072310402422" MERGED_FROM="" MODIFIED="2012-07-23 15:17:49 +0100" MODIFIED_BY="Hazel Fraser" REVIEW_NO="00180001" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.2">
<COVER_SHEET MODIFIED="2012-07-23 15:17:49 +0100" MODIFIED_BY="Hazel Fraser">
<TITLE MODIFIED="2012-04-29 16:07:07 +0100" MODIFIED_BY="Martin M Brown">Percutaneous transluminal balloon angioplasty and stenting for carotid artery stenosis</TITLE>
<CONTACT MODIFIED="2012-07-23 15:17:49 +0100" MODIFIED_BY="Hazel Fraser"><PERSON ID="7235" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Martin</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Brown</LAST_NAME><POSITION>Professor of Stroke Medicine</POSITION><EMAIL_1>martin.brown@ucl.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Brain Repair &amp; Rehabilitation</DEPARTMENT><ORGANISATION>UCL Institute of Neurology</ORGANISATION><ADDRESS_1>Box 6, The National Hospital</ADDRESS_1><ADDRESS_2>Queen Square</ADDRESS_2><CITY>London</CITY><ZIP>WC1N 3BG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7829 8753</PHONE_1><PHONE_2>+44 20 7676 2194</PHONE_2><FAX_1>+44 20 7833 8613</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-07-23 15:17:49 +0100" MODIFIED_BY="Hazel Fraser"><PERSON ID="71406078076224379990110119135409" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Leo</FIRST_NAME><MIDDLE_INITIALS>H</MIDDLE_INITIALS><LAST_NAME>Bonati</LAST_NAME><POSITION>Consultant Neurologist</POSITION><EMAIL_1>bonatil@uhbs.ch</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>University Hospital Basel</ORGANISATION><ADDRESS_1>Petersgraben 4</ADDRESS_1><CITY>Basel</CITY><ZIP>CH-4031</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+4 61 556 5442</PHONE_1><FAX_1>+41 61 265 5644</FAX_1></ADDRESS></PERSON><PERSON ID="5783" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Philippe</FIRST_NAME><LAST_NAME>Lyrer</LAST_NAME><POSITION>Head of Stroke Program</POSITION><EMAIL_1>plyrer@uhbs.ch</EMAIL_1><URL>strokeunit.ch</URL><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>University Hospital Basel</ORGANISATION><ADDRESS_1>Petersgraben 4</ADDRESS_1><CITY>Basel</CITY><ZIP>4031</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+41 61 2652525</PHONE_1><FAX_1>+41 61 2655644</FAX_1></ADDRESS></PERSON><PERSON ID="4DE77D0B82E26AA20187B79632291C03" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jörg</FIRST_NAME><LAST_NAME>Ederle</LAST_NAME><POSITION>Clinical Research Fellow</POSITION><EMAIL_1>j.ederle@ion.ucl.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Brain Repair &amp; Rehabilitation</DEPARTMENT><ORGANISATION>UCL Institute of Neurology</ORGANISATION><ADDRESS_1>Box 6, The National Hospital</ADDRESS_1><ADDRESS_2>Queen Square</ADDRESS_2><CITY>London</CITY><ZIP>WC1N 3BG</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="17161" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Roland</FIRST_NAME><LAST_NAME>Featherstone</LAST_NAME><SUFFIX>PhD</SUFFIX><EMAIL_1>r.featherstone@ion.ucl.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Brain Repair &amp; Rehabilitation</DEPARTMENT><ORGANISATION>UCL Institute of Neurology</ORGANISATION><ADDRESS_1>Box 6, The National Hospital</ADDRESS_1><ADDRESS_2>Queen Square</ADDRESS_2><CITY>London</CITY><ZIP>WC1N 3BG</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="7235" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Martin</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Brown</LAST_NAME><POSITION>Professor of Stroke Medicine</POSITION><EMAIL_1>martin.brown@ucl.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Brain Repair &amp; Rehabilitation</DEPARTMENT><ORGANISATION>UCL Institute of Neurology</ORGANISATION><ADDRESS_1>Box 6, The National Hospital</ADDRESS_1><ADDRESS_2>Queen Square</ADDRESS_2><CITY>London</CITY><ZIP>WC1N 3BG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7829 8753</PHONE_1><PHONE_2>+44 20 7676 2194</PHONE_2><FAX_1>+44 20 7833 8613</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-05-08 16:28:47 +0100" MODIFIED_BY="Leo H Bonati">
<UP_TO_DATE>
<DATE DAY="26" MONTH="4" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="24" MONTH="1" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="10" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="1997"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2012-06-25 16:29:37 +0100" MODIFIED_BY="Martin M Brown">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-06-25 16:29:35 +0100" MODIFIED_BY="Martin M Brown">
<DATE DAY="26" MONTH="4" YEAR="2012"/>
<DESCRIPTION>
<P>For the 2012 update of this review, results from three trials cited in the previous version as ongoing studies have now been published and included (<LINK REF="STD-Regensburg-2008" TYPE="STUDY">Regensburg 2008</LINK>; <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK>; <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>). We have identified and included one additional trial which met the inclusion criteria (<LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK>). We analysed the data of patients with symptomatic and asymptomatic carotid stenosis from one previously included trial separately (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>). We analysed data from another previously included trial separately because the trial enrolled patients considered at increased risk for complications with surgery (<LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK>). New long-term follow-up data were available from three previously included trials (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>), as well as from one new trial (<LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK>). The present update of this review includes data for a total of 7572 patients from 16 trials. The objectives of the review have been amended to include comparisons of outcomes according to age and sex. We had access to individual patient data from five trials (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>; <LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK>; <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>) and used reported outcomes of individual patients (<LINK REF="STD-Leicester-1998" TYPE="STUDY">Leicester 1998</LINK>) or patient subgroups (<LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK>) from two other trials, to perform subgroup analyses according to age and sex. The <LINK TAG="BACKGROUND" TYPE="SECTION">Background</LINK>, <LINK TAG="STUDY_DESCRIPTION" TYPE="SECTION">Description of studies</LINK>, <LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK>, <LINK TAG="RESULTS" TYPE="SECTION">Results</LINK> and <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK> sections have been substantially revised to incorporate the new data. We have updated the 'Risk of bias' tables using the new tool in Review Manager 5.1</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2012-06-25 16:29:37 +0100" MODIFIED_BY="Leo H Bonati">
<DATE DAY="26" MONTH="4" YEAR="2012"/>
<DESCRIPTION>
<P>The conclusion of the review is that the comparison of short-term risk of stroke or death clearly favours endarterectomy over endovascular treatment. However, this effect is strongly dependent on age: outcomes were similar with both treatments in patients below the age of 70 years. Other outcome events, such as myocardial infarction, cranial nerve palsy and haematoma, favoured endovascular treatment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-12-19 23:39:25 +0000" MODIFIED_BY="Leo H Bonati">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-12-19 23:39:25 +0000" MODIFIED_BY="Leo H Bonati">
<DATE DAY="19" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>The format of the review was amended according to the current requirements.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-09-22 14:13:41 +0100" MODIFIED_BY="Hazel Fraser">
<DATE DAY="11" MONTH="7" YEAR="2007"/>
<DESCRIPTION>
<P>For the 2007 update of this review, two trials cited in the previous version as ongoing studies have been included (EVA-3S 2006; SPACE 2006) and five new studies have been identified and included (BACASS 2006; Beijing 2003; Kentucky 2004; TESCAS-C 2006; Wallstent 2001). The results of one trial have been updated with the final published data (SAPPHIRE 2004). A total of 3227 patients were treated within the 12 included trials. The 'Description of studies', 'Methodological quality of included studies', 'Results' and 'Discussion' sections have been substantially revised to incorporate the data from the new included studies. The objectives of the review have been amended to reflect improving knowledge and technology since the previous version. The conclusion of the review is that some analyses favour surgery and others favour endovascular treatment. Results have to be interpreted with great caution since there was significant heterogeneity between the trials and much of the evidence comes from trials that were terminated early.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2011-12-19 21:38:12 +0000" MODIFIED_BY="Leo H Bonati">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2011-12-19 21:38:12 +0000" MODIFIED_BY="Leo H Bonati">
<SOURCE>
<NAME>The Stroke Association</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Department of Health</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Reta Lila Weston Trust for Medical Research</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Medical Research Council</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2011-12-19 21:36:12 +0000" MODIFIED_BY="Leo H Bonati">
<NAME>National Institute of Health Research</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2011-12-19 21:38:12 +0000" MODIFIED_BY="Leo H Bonati">
<NAME>Swiss National Science Foundation</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-07-23 14:43:30 +0100" MODIFIED_BY="Martin M Brown">
<SUMMARY MODIFIED="2012-04-27 08:39:11 +0100" MODIFIED_BY="Martin M Brown">
<TITLE MODIFIED="2012-03-16 12:52:14 +0000" MODIFIED_BY="Hazel Fraser">Catheter balloons and metal tubes for narrowing of neck arteries</TITLE>
<SUMMARY_BODY MODIFIED="2012-04-27 08:39:11 +0100" MODIFIED_BY="Martin M Brown">
<P>Carotid stenosis, a narrowing of one of the major blood vessels which carries blood to the brain, can cause a stroke. The standard treatment is to remove the narrowing by a surgical operation (carotid endarterectomy). An alternative treatment (balloon angioplasty) uses a fine catheter tube which has a small balloon at its tip. This catheter is passed through the skin and into the blood vessel until the balloon reaches the point of narrowing in the carotid artery in the neck. The balloon is briefly inflated to stretch the artery and reduce the degree of narrowing. More recently a metal tube (stent) is placed inside the artery to prevent it narrowing down again after the catheter is removed. The procedures of balloon angioplasty and stenting are called endovascular treatment. This review included 16 trials involving 7572 participants and showed that endovascular treatment causes more strokes or death around the time of the procedure than conventional surgery. This risk was mainly seen in elderly patients over the age of 70 years. Heart attacks, injuries to the nerves in the neck and bleeding at the site of treatment are less common with endovascular treatment. After the initial treatment the risk of stroke or death is similar with endovascular treatment compared with conventional surgery, although treated arteries are more likely to narrow down again after endovascular treatment. Further follow-up is needed to see which treatment provides the best chance of long-term freedom from stroke.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-06-28 12:13:40 +0100" MODIFIED_BY="Martin M Brown">
<ABS_BACKGROUND MODIFIED="2012-06-26 14:52:12 +0100" MODIFIED_BY="Leo H Bonati">
<P>Endovascular treatment by transluminal balloon angioplasty or stent insertion may be a useful alternative to carotid endarterectomy for the treatment of atherosclerotic carotid artery stenosis. This review updates a previous version first published in 1997 and subsequently updated in 2004 and 2007.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-06-28 12:13:40 +0100" MODIFIED_BY="Leo H Bonati">
<P>To assess the benefits and risks of endovascular treatment compared with carotid endarterectomy or medical therapy in patients with symptomatic or asymptomatic carotid stenosis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-06-26 14:50:17 +0100" MODIFIED_BY="Leo H Bonati">
<P>We searched the Cochrane Stroke Group Trials Register (last searched January 2012) and the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2010, Issue 4), MEDLINE (1950 to January 2011), EMBASE (1980 to January 2011) and Science Citation Index (1945 to January 2011). We also searched ongoing trials registers (January 2011) and reference lists and contacted researchers in the field.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-06-26 14:50:30 +0100" MODIFIED_BY="Leo H Bonati">
<P>Randomised trials comparing endovascular treatment (including balloon angioplasty or stenting) with endarterectomy or medical therapy for symptomatic or asymptomatic atherosclerotic carotid stenosis.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-06-26 14:50:59 +0100" MODIFIED_BY="Leo H Bonati">
<P>One review author selected trials for inclusion, assessed trial quality and extracted data. A second review author independently validated trial selection and a third review author independently validated data extraction. We calculated treatment effects as odds ratios (OR) and 95% confidence intervals (CI), with endovascular treatment as the reference group. We quantified heterogeneity using the I² statistic.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-06-26 14:51:03 +0100" MODIFIED_BY="Martin M Brown">
<P>We included 16 trials involving 7572 patients. In patients with symptomatic carotid stenosis at standard surgical risk, endovascular treatment was associated with a higher risk of the following outcome measures occurring between randomisation and 30 days after treatment than endarterectomy: death or any stroke (the primary safety outcome) (OR 1.72, 95% CI 1.29 to 2.31, P = 0.0003; I² = 27%), death or any stroke or myocardial infarction (OR 1.44, 95% CI 1.15 to 1.80, P = 0.002; I² = 7%), and any stroke (OR 1.81, 95% CI 1.40 to 2.34, P &lt; 0.00001; I² = 12%). The OR for the primary safety outcome was 1.16 (95% CI 0.80 to 1.67) in patients &lt; 70 years old and 2.20 (95% CI 1.47 to 3.29) in patients &#8805; 70 years old (interaction P = 0.02).</P>
<P>The rate of death or major or disabling stroke did not differ significantly between treatments (OR 1.28, 95% CI 0.93 to 1.77, P = 0.13; I² = 0%). Endovascular treatment was associated with lower risks of myocardial infarction (OR 0.44, 95% CI 0.23 to 0.87, P = 0.02; I² = 0%), cranial nerve palsy (OR 0.08, 95% CI 0.05 to 0.14, P &lt; 0.00001; I² = 0%) and access site haematomas (OR 0.37, 95% CI 0.18 to 0.77, P = 0.008; I² = 27%).</P>
<P>The combination of death or any stroke up to 30 days after treatment or ipsilateral stroke during follow-up (the primary combined safety and efficacy outcome) favoured endarterectomy (OR 1.39, 95% CI 1.10 to 1.75, P = 0.005; I² = 0%), but the rate of ipsilateral stroke after the peri-procedural period did not differ between treatments (OR 0.93, 95% CI 0.60 to 1.45, P = 0.76; I² = 0%).</P>
<P>Restenosis during follow-up was more common in patients receiving endovascular treatment than in patients assigned surgery (OR 2.41, 95% CI 1.28 to 4.53, P = 0.007; I² = 55%). In patients with asymptomatic carotid stenosis, treatment effects on the primary safety (OR 1.71, 95% CI 0.78 to 3.76, P = 0.18; I² = 0%) and combined safety and efficacy outcomes (OR 1.75, 95% CI 0.92 to 3.33, P = 0.09; I² = 0%) were similar to symptomatic patients, but differences between treatments were not statistically significant. Among patients not suitable for surgery, the rate of death or any stroke between randomisation and end of follow-up did not differ significantly between endovascular treatment and medical care (OR 0.22, 95% CI 0.01 to 7.92, P = 0.41; I² = 79%).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-06-26 14:51:41 +0100" MODIFIED_BY="Martin M Brown">
<P>Endovascular treatment is associated with an increased risk of peri-procedural stroke or death compared with endarterectomy. However, this excess risk appears to be limited to older patients. The longer term efficacy of endovascular treatment and the risk of restenosis are unclear and require further follow-up of existing trials. Further trials are needed to determine the optimal treatment for asymptomatic carotid stenosis.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-06-25 16:32:58 +0100" MODIFIED_BY="Martin M Brown">
<BACKGROUND MODIFIED="2012-06-25 16:30:11 +0100" MODIFIED_BY="Martin M Brown">
<CONDITION MODIFIED="2012-05-30 11:28:24 +0100" MODIFIED_BY="Martin M Brown">
<P>Stenosis of the carotid artery is usually caused by focal atherosclerosis, typically at the site where the internal carotid artery - the main conduit of blood supplying the brain - originates from the common carotid artery. The prevalence of asymptomatic severe carotid stenosis ranges from 0.1% in men below the age of 50 to 3.1% in men and 0.9% in women 80 years or older (<LINK REF="REF-De-Weerd-2010" TYPE="REFERENCE">De Weerd 2010</LINK>). Carotid stenosis causes about 10% to 15% of ischaemic strokes.</P>
</CONDITION>
<INTERVENTION MODIFIED="2012-06-25 16:30:09 +0100" MODIFIED_BY="Martin M Brown">
<P>Carotid stenosis is conventionally treated by carotid endarterectomy. Multicentre randomised controlled trials have shown that endarterectomy significantly reduces the risk of ipsilateral stroke in patients with severe symptomatic carotid stenosis. The European Carotid Surgery Trial (ECST) showed a reduction in ipsilateral stroke with symptoms lasting longer than seven days (including peri-operative events) in the surgically treated patients from 20.6% to 6.8% at three-year follow-up (P &lt; 0.0001) (<LINK REF="REF-ECST-1998" TYPE="REFERENCE">ECST 1998</LINK>). In the North American Symptomatic Carotid Endarterectomy Trial (NASCET), the risk of any ipsilateral stroke (again including peri-operative events) was reduced from 26% to 9% after two years among patients with severe stenosis (&#8805;70% narrowing; P &lt; 0.001) (<LINK REF="REF-NASCET-1991" TYPE="REFERENCE">NASCET 1991</LINK>), and from 22.2% to 15.7% after five years among patients with moderate stenosis (50% to 69% narrowing; P = 0.045) (<LINK REF="REF-NASCET-1998" TYPE="REFERENCE">NASCET 1998</LINK>). In the Asymptomatic Carotid Atherosclerosis Study (ACAS), surgery for asymptomatic carotid stenosis was shown to significantly reduce the overall five-year risk of ipsilateral stroke or any peri-operative stroke or death from 11% to 5.1% (P = 0.004), but not the risk of major ipsilateral stroke or any peri-operative stroke or death (6.5% in the medical group, 3.4% in the surgical group; P = 0.12) (<LINK REF="REF-ACAS-1995" TYPE="REFERENCE">ACAS 1995</LINK>). The Asymptomatic Carotid Surgery Trial (ACST) showed a significant reduction in the risk of any stroke or peri-operative death from 10.9% to 6.9% (P = 0.0001) after five years, and from 17.9% to 13.4% (P = 0.009) after 10 years, respectively (<LINK REF="REF-ACST-2010" TYPE="REFERENCE">ACST 2010</LINK>).</P>
<P>Endovascular techniques for treating carotid stenosis by advancing a catheter inserted in the femoral artery have been developed over recent years. Initially, percutaneous transluminal balloon angioplasty was used. Later, stents specifically designed for insertion in the carotid artery were invented and have been used to treat carotid stenosis either with or without prior balloon angioplasty. Primary stenting has replaced balloon angioplasty as the endovascular treatment most often used in clinical practice. Stenting might be safer in experienced hands than simple balloon angioplasty, because dissection and occlusion of the carotid artery are less likely to occur (<LINK REF="REF-Dietrich-1996" TYPE="REFERENCE">Dietrich 1996</LINK>; <LINK REF="REF-Roubin-2001" TYPE="REFERENCE">Roubin 2001</LINK>). If dissection occurs, adverse consequences might be minimised, because the stent maintains laminar flow across the stenosis and seals the site of dissection, preventing a free intimal flap. Superior dilation achieved by stenting compared with balloon angioplasty might also reduce the risk of stroke in the early post-treatment period, and the rate of residual or recurrent stenosis. In the coronary circulation, stenting has been shown to produce superior outcomes compared with balloon angioplasty (<LINK REF="REF-Fischman-1994" TYPE="REFERENCE">Fischman 1994</LINK>; <LINK REF="REF-Serruys-1996" TYPE="REFERENCE">Serruys 1996</LINK>).</P>
<P>Endovascular treatment may be a useful alternative to carotid endarterectomy. Potential advantages include avoidance of general anaesthesia, avoidance of an incision in the neck with the risk of cranial and cutaneous nerve damage, and a reduction in the rate of general complications of surgery, e.g. myocardial infarction. Surgically inaccessible lesions can be treated and both the procedure and admission time are usually shorter than for surgery. However, endovascular treatment does not remove the atherosclerotic lesion and may dislodge emboli during catheterisation, causing peri-procedural stroke.</P>
<P>Some evidence on the risks and benefits of endovascular treatment comes from non-randomised case series, non-randomised trials and registries. A large post-market surveillance registry enrolled 3500 patients at high surgical risk who underwent treatment of carotid stenosis with the Carotid RX Acculink/Accunet stent including embolic protection in the US (<LINK REF="REF-CAPTURE-2007" TYPE="REFERENCE">CAPTURE 2007</LINK>): 482 patients had symptomatic and 3018 had asymptomatic carotid stenosis. Patients were followed up to 30 days by neurologists who were not involved in the procedure. The risk of death or any stroke occurring within 30 days of treatment was 10.6% in patients with symptomatic and 4.9% in patients with asymptomatic stenosis. In a German registry involving 2921 procedures in symptomatic and 2412 procedures in asymptomatic patients, in-hospital stroke or death rates following carotid stenting were 4.3% in the former and 2.7% in the latter group (<LINK REF="REF-Pro_x002d_CAS-2008" TYPE="REFERENCE">Pro-CAS 2008</LINK>). No restrictions on the indications for stent treatment, types of stents, or use of protection devices were made. However, follow-up was not done by independent neurologists and did not include the full 30-day peri-procedural period. Because of differences in patient selection and follow-up, these figures are difficult to compare with 30-day stroke or death rates observed in the large endarterectomy trials, which were 6.7% in NASCET and 7.0% in ECST among patients with symptomatic carotid stenosis, and 2.3% in ACAS and 2.9% in ACST among asymptomatic patients (<LINK REF="REF-ACAS-1995" TYPE="REFERENCE">ACAS 1995</LINK>; <LINK REF="REF-ECST-1998" TYPE="REFERENCE">ECST 1998</LINK>; <LINK REF="REF-NASCET-1998" TYPE="REFERENCE">NASCET 1998</LINK>; <LINK REF="REF-ACST-2010" TYPE="REFERENCE">ACST 2010</LINK>).</P>
<P>Concern regarding the risk of distal embolisation of debris being dislodged from the atheromatous plaque during stent deployment and resulting in neurological deficit, has led to the introduction and increasing use of cerebral protection devices. This concept was first described in the series by <LINK REF="REF-Theron-1996" TYPE="REFERENCE">Theron 1996</LINK>. There are now many case series in the literature reporting experience of endovascular treatment with temporary cerebral protection, with reported complication rates ranging from 1% to 9% (<LINK REF="REF-Reimers-2001" TYPE="REFERENCE">Reimers 2001</LINK>; <LINK REF="REF-Bonaldi-2002" TYPE="REFERENCE">Bonaldi 2002</LINK>; <LINK REF="REF-Guimaraens-2002" TYPE="REFERENCE">Guimaraens 2002</LINK>; <LINK REF="REF-Reimers-2004" TYPE="REFERENCE">Reimers 2004</LINK>; <LINK REF="REF-Bush-2005" TYPE="REFERENCE">Bush 2005</LINK>; <LINK REF="REF-Gray-2006" TYPE="REFERENCE">Gray 2006</LINK>; <LINK REF="REF-Safian-2006" TYPE="REFERENCE">Safian 2006</LINK>; <LINK REF="REF-White-2006" TYPE="REFERENCE">White 2006</LINK>; <LINK REF="REF-CAPTURE-2007" TYPE="REFERENCE">CAPTURE 2007</LINK>). In a systematic review of non-randomised case series including patients with symptomatic and asymptomatic carotid stenosis, 30-day stroke or death rates were 1.8% in patients stented with and 5.5% in patients stented without protection devices (P &lt; 0.001) (<LINK REF="REF-Kastrup-2003" TYPE="REFERENCE">Kastrup 2003</LINK>). Another systematic review reported higher rates of silent ischaemic brain lesions on diffusion-weighted magnetic resonance imaging (MRI) with unprotected stenting than with protected stenting (<LINK REF="REF-Schnaudigel-2008" TYPE="REFERENCE">Schnaudigel 2008</LINK>). However, some of the included studies used historical control groups or were prone to selection bias. There remains considerable uncertainty whether protection devices increase the safety of carotid stenting.</P>
<P>The main aim of treating carotid stenosis is the prevention of stroke in the long term. Carotid endarterectomy has been shown to be effective at preventing ipsilateral stroke over long-term follow-up periods of 10 years or longer (<LINK REF="REF-ECST-1998" TYPE="REFERENCE">ECST 1998</LINK>; <LINK REF="REF-ACST-2010" TYPE="REFERENCE">ACST 2010</LINK>). To provide an effective alternative, carotid stenting needs to have similar long-term effectiveness.</P>
<P>A particular concern about endovascular treatment has been that restenosis will limit the efficacy of the procedure in the medium to long term. Restenosis after coronary angioplasty occurs in 25% to 35% of patients (<LINK REF="REF-McBride-1988" TYPE="REFERENCE">McBride 1988</LINK>) and causes a recurrence of angina in a significant percentage of patients. However, this is related to the high demands of the coronary circulation for haemodynamic increases in flow; restenosis might be less likely to cause ischaemia in the cerebral circulation unless it leads to emboli.</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2012-06-25 16:30:11 +0100" MODIFIED_BY="Martin M Brown">
<P>Only randomised trials can answer the question whether endovascular treatment is equivalent to endarterectomy in patients fit for surgery - or better than medical care in patients unfit for surgery - in terms of treatment safety and long-term prevention of stroke in patients with carotid stenosis. We therefore aimed to systematically review all randomised controlled trials comparing carotid angioplasty and stenting with carotid endarterectomy or medical care. The present review updates a previous version first published in 1997 (<LINK REF="REF-Crawley-1997" TYPE="REFERENCE">Crawley 1997</LINK>) and subsequently updated in 2004 (<LINK REF="REF-Coward-2004" TYPE="REFERENCE">Coward 2004</LINK>) and 2007 (<LINK REF="REF-Ederle-2007" TYPE="REFERENCE">Ederle 2007</LINK>). In the 2007 update, there was significant heterogeneity between trials for most of the main comparisons. The primary endpoint, any stroke or death occurring within 30 days of treatment, favoured surgery in the fixed-effect but not in the random-effects model. The review authors therefore concluded that there was insufficient evidence to justify a change in policy of recommending endarterectomy as the revascularisation treatment of choice for patients with carotid stenosis suitable for surgery.</P>
<P>In the meantime, two further large randomised trials and one small randomised study comparing stenting with endarterectomy have completed randomisation and published results (<LINK REF="STD-Regensburg-2008" TYPE="STUDY">Regensburg 2008</LINK>; <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK>; <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>), three previously identified trials reported new data on long-term follow-up (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>, <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>, <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>), and one additional trial was identified (<LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK>), more than doubling the number of patients available for comparison and justifying an update of this review. In addition, previous research has suggested that age and sex may have a differential impact on peri-procedural risks of endovascular treatment and endarterectomy (<LINK REF="REF-Bond-2002" TYPE="REFERENCE">Bond 2002</LINK>; <LINK REF="REF-Rothwell-2004" TYPE="REFERENCE">Rothwell 2004</LINK>; <LINK REF="REF-Bond-2005" TYPE="REFERENCE">Bond 2005</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>; <LINK REF="REF-Touz_x00e9_-2009" TYPE="REFERENCE">Touzé 2009</LINK>; <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK>; <LINK REF="REF-CSTC-2010" TYPE="REFERENCE">CSTC 2010</LINK>; <LINK REF="REF-Brown-2011" TYPE="REFERENCE">Brown 2011</LINK>). We therefore planned to compare the treatments according to age and sex as well.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-06-01 10:16:49 +0100" MODIFIED_BY="Martin M Brown">
<P>The overall objective of this review is to determine whether for treatment of symptomatic or asymptomatic carotid artery stenosis, endovascular treatment might be a safe and effective alternative to carotid endarterectomy in patients suitable for surgery, or superior to medical treatment in patients unsuitable for surgery. Secondary objectives were added at the time of the previous update (<LINK REF="REF-Ederle-2007" TYPE="REFERENCE">Ederle 2007</LINK>) (marked with a single asterisk), as well as for the current update (marked with a double asterisk), to reflect changes in technology and treatment approach, and recent insights into variation in treatment risks in patient subgroups.</P>
<P>We addressed two primary research questions in this review as we were interested in both the safety and efficacy of endovascular treatment compared with endarterectomy.</P>
<OL>
<LI>To determine whether endovascular treatment for carotid stenosis has a significantly different risk of peri-procedural stroke or death compared with endarterectomy.</LI>
<LI>To determine whether endovascular treatment for carotid stenosis is effective in preventing stroke ipsilateral to the procedure and in other territories.</LI>
</OL>
<P>Additionally, we planned the following secondary analyses to examine whether:</P>
<OL>
<LI>age modifies the effect of endovascular versus surgical treatment on peri-procedural stroke or death;**</LI>
<LI>sex modifies the effect of endovascular versus surgical treatment on peri-procedural stroke or death;**</LI>
<LI>the differential risks between treatments observed in trials are dependent on the level of experience in endovascular treatment;**</LI>
<LI>endovascular treatment reduces the risk of cranial neuropathy;</LI>
<LI>the rates of other vascular complications (myocardial infarction, access site haematoma) differ between endovascular treatment and endarterectomy;</LI>
<LI>stenting with cerebral protection devices has a lower rate of treatment-related ischaemic events than stenting without cerebral protection devices;*</LI>
<LI>there is any significant difference in restenosis rates following endovascular or surgical treatment and whether restenosis leads to recurrent stroke;</LI>
<LI>endovascular treatment is as safe and effective as endarterectomy in asymptomatic patients;*</LI>
<LI>endovascular treatment is as safe and effective as endarterectomy in patients considered to be at increased surgical risk;**</LI>
<LI>in patients unsuitable for surgery, endovascular treatment is more effective in preventing stroke than medical care alone.</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2012-06-25 16:30:30 +0100" MODIFIED_BY="Martin M Brown">
<SELECTION_CRITERIA MODIFIED="2012-06-25 16:30:20 +0100" MODIFIED_BY="Martin M Brown">
<CRIT_STUDIES MODIFIED="2012-03-23 16:47:07 +0000" MODIFIED_BY="Martin M Brown">
<P>We attempted to identify all unconfounded, truly randomised trials comparing endovascular treatment by carotid angioplasty or stenting or both with conventional carotid endarterectomy, and also trials comparing endovascular treatment with medical therapy alone. We included trials in which the exact method of randomisation was still uncertain after communication with the authors. We excluded studies of carotid revascularisation procedures without control groups and studies without random allocation of treatment.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-06-25 16:30:15 +0100" MODIFIED_BY="Leo H Bonati">
<P>We considered trials including patients of any age or either sex with symptomatic or asymptomatic carotid stenosis eligible for inclusion in the review.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-06-25 16:30:17 +0100" MODIFIED_BY="Martin M Brown">
<P>We reviewed trials that allowed any acceptable technique for carotid endarterectomy (for example, use of a shunt or not, patching or not, local or general anaesthesia) and which allowed any acceptable endovascular technique for treatment of carotid stenosis (for example, simple balloon angioplasty, use of a stent or not, any type of cerebral protection device).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-06-25 16:30:20 +0100" MODIFIED_BY="Martin M Brown">
<P>We identified the following primary and secondary outcome measures. Outcome measures that were changed or added at the time of the previous update (<LINK REF="REF-Ederle-2007" TYPE="REFERENCE">Ederle 2007</LINK>) are marked with a single asterisk, and those changed or added for this current update are marked with a double asterisk.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-04-27 14:11:13 +0100" MODIFIED_BY="Martin M Brown">
<OL>
<LI>The primary outcome measure for evaluation of treatment safety was the combined outcome of death or any stroke occurring between randomisation and 30 days after treatment. For patients who did not undergo carotid revascularisation, this period was defined as the first 30 days after randomisation, or according to the definition used in the trial.</LI>
<LI>The primary outcome measure for evaluation of combined safety and long-term efficacy was the combined outcome of death or any stroke occurring between randomisation and 30 days after treatment, or ipsilateral stroke occurring thereafter until the end of follow-up.**</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-06-25 16:30:20 +0100" MODIFIED_BY="Martin M Brown">
<P>Secondary safety outcome measures included the following events occurring between randomisation and 30 days after treatment:</P>
<OL>
<LI>the combined outcome of death or major or disabling stroke;</LI>
<LI>death of any cause*;</LI>
<LI>any stroke*;</LI>
<LI>the combined outcome of fatal, major or disabling stroke**;</LI>
<LI>myocardial infarction**;</LI>
<LI>the combined outcome of death or any stroke or myocardial infarction;</LI>
<LI>cranial nerve palsy;</LI>
<LI>the combined outcome of death or neurological complications (including stroke and cranial nerve palsy)*;</LI>
<LI>access site haematoma (including cervical haematoma arising from surgical incision in endarterectomy or groin haematoma arising from skin puncture in endovascular treatment) requiring surgery, blood transfusion, or prolonging hospital stay**.</LI>
</OL>
<P>Secondary efficacy outcome measures were:</P>
<OL>
<LI>the combined outcome of death or any stroke occurring between randomisation and end of follow-up;</LI>
<LI>ipsilateral stroke occurring during follow-up (excluding strokes occurring between randomisation and 30 days after treatment, and excluding patients dying within this period);</LI>
<LI>any stroke occurring during follow-up (excluding strokes occurring between randomisation and 30 days after treatment, and excluding patients dying within this period);</LI>
<LI>severe restenosis equivalent to or greater than 70% luminal narrowing according to the measurement used in the <LINK REF="REF-NASCET-1991" TYPE="REFERENCE">NASCET 1991</LINK> trial, determined by Doppler or duplex sonography, catheter angiography, or non-invasive (magnetic resonance or computer tomography) angiography at defined intervals.</LI>
</OL>
<SUBSECTION>
<HEADING LEVEL="4">Outcome event definitions</HEADING>
<P>Stroke was defined as an acute deficit of focal neurological function with symptoms lasting for longer than 24 hours, resulting from intracranial vascular disturbance (ischaemia or haemorrhage). Visual loss, resulting from retinal ischaemia that lasted for longer than 24 hours, was included within the category of stroke (<LINK REF="REF-CSTC-2010" TYPE="REFERENCE">CSTC 2010</LINK>). Stroke was classified as disabling if leading to a loss of functional independence, characterised by a score of three or more on the modified Rankin scale (<LINK REF="REF-Van-Swieten-1988" TYPE="REFERENCE">Van Swieten 1988</LINK>) or the Oxfordshire Handicap Stroke scale (<LINK REF="REF-Bamford-1989" TYPE="REFERENCE">Bamford 1989</LINK>). If no measure of disability was provided we included major stroke, according to the definition used in the trials, in the combined category of disabling or major stroke.</P>
<P>We expected differences between trials in definitions of disabling or major stroke, myocardial infarction, as well as in the severity of cranial nerve palsy and access site haematoma required in order to qualify as an outcome event. We included these outcome events as reported in the trials.</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-06-01 10:37:18 +0100" MODIFIED_BY="Leo H Bonati">
<P>See the 'Specialized register' section in the <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/STROKE/frame.html">Cochrane Stroke Group</A> module.</P>
<ELECTRONIC_SEARCHES MODIFIED="2012-06-01 10:36:10 +0100" MODIFIED_BY="Hazel Fraser">
<P>We searched the Cochrane Stroke Group Trials Register, which was last searched in January 2012. In addition, we searched the following bibliographic databases: Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library </I>2010, Issue 4) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), MEDLINE (1950 to January 2011) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), EMBASE (1980 to January 2011) (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>) and Science Citation Index (1945 to January 2011) (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>). We developed the MEDLINE search strategy with the help of the Cochrane Stroke Group Trials Search Co-ordinator and adapted it for the other databases.</P>
<P>We also searched the following ongoing trials registers (January 2011):</P>
<UL>
<LI>Stroke Trials Registry (<A HREF="http://www.strokecenter.org/trials/">www.strokecenter.org/trials/</A>);</LI>
<LI>ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov/">http://www.clinicaltrials.gov/</A>);</LI>
<LI>Current Controlled Trials (<A HREF="http://www.controlled-trials.com/">www.controlled-trials.com</A>).</LI>
</UL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2012-06-01 10:34:59 +0100" MODIFIED_BY="Hazel Fraser">
<P>We searched reference lists of relevant articles and contacted individuals active in the field.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-06-25 16:30:30 +0100" MODIFIED_BY="Martin M Brown">
<STUDY_SELECTION MODIFIED="2012-06-01 10:38:16 +0100" MODIFIED_BY="Leo H Bonati">
<P>One review author (LHB) screened the titles and abstracts of the records identified from the searches of the electronic bibliographic databases and excluded obviously irrelevant studies. We obtained the full text of the remaining studies and two review authors (LHB, RLF) independently selected relevant trials based on the review inclusion criteria, and assessed trial quality. We resolved disagreements by discussion and consultation with the other authors if necessary.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-06-25 16:30:21 +0100" MODIFIED_BY="Martin M Brown">
<P>Two review authors (LHB, PL) extracted trial data. We resolved disagreements by consensus. We identified data in published articles and sought additional information from the principal investigators of the included trials. We had access to individual patient data from five trials (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>; <LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK>; <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>) and used reported outcomes of individual patients (<LINK REF="STD-Leicester-1998" TYPE="STUDY">Leicester 1998</LINK>) or patient subgroups (<LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK>) from two other trials, to perform subgroup analyses. For trials where access to individual patient data was available, we extracted short-term outcome events used for comparison of treatment safety according to the definition of the peri-procedural period used in this review (i.e. events occurring between randomisation and 30 days after treatment).</P>
<P>We extracted the following data:</P>
<OL>
<LI>the number of symptomatic and asymptomatic patients originally allocated to each treatment group to allow an intention-to-treat analysis;</LI>
<LI>inclusion and exclusion criteria;</LI>
<LI>mean age and sex distribution of study participants;</LI>
<LI>mean degree of stenosis of the relevant carotid artery at randomisation;</LI>
<LI>intervention characteristics, including technical aspects of procedures (endovascular: balloon angioplasty alone or routine insertion of stents, use of protection devices, pre-dilation and post-dilation of the stenosis; endarterectomy: surgical method, type of anaesthesia, use of patches, shunting) and peri-procedural medications;</LI>
<LI>the level of experience required from interventional physicians and surgeons performing the procedures, expressed as the number of endovascular procedures or endarterectomies for treatment of carotid stenosis performed before the trial;</LI>
<LI>outcome measures as specified above;</LI>
<LI>definitions of outcome measures;</LI>
<LI>nature and intervals of follow-up assessments.</LI>
</OL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-06-25 16:30:23 +0100" MODIFIED_BY="Leo H Bonati">
<P>One review author (LHB) assessed risk of bias in included studies using the tool recommended by The Cochrane Collaboration (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Assessment of risk of bias was independently validated by a second review author (PL). We resolved disagreements by consensus.</P>
<P>We extracted then analysed the following trial data to assess risk of bias:</P>
<OL>
<LI>the method of generation of a random sequence of treatment assignments;</LI>
<LI>whether the randomising doctor might have anticipated the allocated treatment (allocation concealment);</LI>
<LI>whether patients were followed-up by study personnel who were not involved in the revascularisation procedures and whether outcome events were adjudicated blinded to treatment;</LI>
<LI>the number of patients excluded from analysis or lost to follow-up;</LI>
<LI>whether the reported primary analysis had been pre-specified in a study protocol.</LI>
</OL>
</QUALITY_ASSESSMENT>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-06-01 10:42:39 +0100" MODIFIED_BY="Leo H Bonati">
<P>We quantified heterogeneity among trial results using the I² statistic. We considered a value greater 50% as representing substantial heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-06-25 16:30:29 +0100" MODIFIED_BY="Martin M Brown">
<P>We analysed outcomes following the intention-to-treat principle, i.e. we compared all patients who were randomised and in whom any information on outcome was reported according to their randomly assigned treatment, irrespective of whether they received this treatment or not. The comparison of outcomes between endovascular treatment with use of a cerebral protection device versus treatment without use of a protection device was carried out per-protocol, i.e. we included patients in whom endovascular treatment was initiated as randomly allocated only.</P>
<P>For trials comparing endovascular treatment with endarterectomy, we analysed separately the data from patients with symptomatic and asymptomatic carotid stenosis and data from trials enrolling patients considered at increased surgical risk, whenever possible. For the outcome measures cranial nerve palsy (and its combination with stroke or death) and access site haematoma, we provided pooled treatment effects including all trials with available data because we did not expect any difference in treatment effects according to symptom status or surgical risk. However, we also analysed separately the treatment effects for patients with asymptomatic carotid stenosis or those perceived to be at increased risk for vascular events with surgery.</P>
<P>We analysed summary data of all patients randomised and analysed in the included studies with Mantel-Haenszel random-effect models. We reported the treatment effects as odds ratios (OR), that is, the odds of an unfavourable outcome in patients treated by endovascular intervention compared with the corresponding odds in patients treated surgically or medically, with a 95% confidence interval (CI). We chose P &lt; 0.05 as the level of significance.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-06-25 16:30:30 +0100" MODIFIED_BY="Leo H Bonati">
<P>Among the six trials with available individual patient data (<LINK REF="STD-Leicester-1998" TYPE="STUDY">Leicester 1998</LINK>; <LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>; <LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK>; <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>), we calculated the OR for the primary safety outcome measure separately for patients 70 years or older (which was at or near the mean age of the patient populations of most included trials) and younger patients. We also performed subgroup analysis by sex including the six trials above as well as the <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK> trial, which recently published outcomes for men and women separately. In addition, we investigated for heterogeneity according to the required number of carotid endovascular procedures interventionists needed to have performed before joining the trials, separating the trials at an arbitrary cut-off of up to 10 procedures, or more. We formally tested interactions between treatment effect and subgroup variables using a standard test for heterogeneity across subgroup results (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-06-25 16:32:36 +0100" MODIFIED_BY="Martin M Brown">
<STUDY_DESCRIPTION MODIFIED="2012-06-25 16:31:47 +0100" MODIFIED_BY="Martin M Brown">
<SEARCH_RESULTS MODIFIED="2012-06-01 14:44:03 +0100" MODIFIED_BY="Leo H Bonati">
<P>To date we have found 16 randomised controlled trials involving 7572 patients with available outcome data that fulfilled the inclusion criteria. Ten of the trials either completed enrolment of the planned number of study participants, or no sample size calculation was performed or reported (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-Kentucky-2001" TYPE="STUDY">Kentucky 2001</LINK>; <LINK REF="STD-Beijing-2003" TYPE="STUDY">Beijing 2003</LINK>; <LINK REF="STD-Kentucky-2004" TYPE="STUDY">Kentucky 2004</LINK>; <LINK REF="STD-TESCAS_x002d_C-2006" TYPE="STUDY">TESCAS-C 2006</LINK>; <LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK>; <LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK>; <LINK REF="STD-CAVATAS_x002d_MED-2009" TYPE="STUDY">CAVATAS-MED 2009</LINK>; <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK>; <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>), whilst six trials terminated recruitment before the originally planned minimum sample size was reached (<LINK REF="STD-Leicester-1998" TYPE="STUDY">Leicester 1998</LINK>; <LINK REF="STD-Wallstent-2001" TYPE="STUDY">Wallstent 2001</LINK>; <LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK>; <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>; <LINK REF="STD-Regensburg-2008" TYPE="STUDY">Regensburg 2008</LINK>). Details of study design are provided in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table and summarised here.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2012-06-25 16:31:47 +0100" MODIFIED_BY="Martin M Brown">
<SUBSECTION>
<HEADING LEVEL="4">Design, sample size, setting and participants</HEADING>
<P>A trial of stenting versus endarterectomy in patients with symptomatic carotid stenosis of &#8805; 70% was carried out at Leicester Royal Infirmary, UK (a university teaching hospital) (<LINK REF="STD-Leicester-1998" TYPE="STUDY">Leicester 1998</LINK>). The trial randomised 23 patients between June and September 1996, but was then stopped by the data monitoring committee for reasons of safety. The results were published in 1998. Four of 11 patients randomised to endovascular treatment and two of 12 patients randomised to endarterectomy did not receive their allocated treatment and were excluded from analysis in this trial.</P>
<P>An industry-funded multicentre randomised trial of stenting versus endarterectomy in the USA was stopped early by the sponsor for reasons of safety and futility after enrolling 219 patients with symptomatic stenosis of &#8805; 60% (<LINK REF="STD-Wallstent-2001" TYPE="STUDY">Wallstent 2001</LINK>). Results were presented at the 2001 International Stroke Conference and were only available in the form of an abstract for the present review. Numbers of patients with outcome events were derived from percentages provided in the abstract. Further results from this trial have not been published to date.</P>
<P>The Carotid And Vertebral Artery Transluminal Angioplasty Study (CAVATAS) was an international randomised multicentre study incorporating two separate trials of carotid stenosis and one trial of vertebral artery stenosis. In the first trial, 505 patients with symptomatic or asymptomatic carotid stenosis considered to require revascularisation and equally suitable for both procedures were randomised between endovascular treatment (252 patients) or endarterectomy (253 patients) between March 1992 and July 1997 (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>). Ninety per cent of randomised patients had ischaemic symptoms associated with the randomised carotid artery in the six months prior to randomisation, and all had at least a moderate degree of stenosis. Initial results were published in 2001, and long-term results up to 11 years after randomisation were published in 2009. One patient was randomised to endovascular treatment in error and was excluded from the analysis. In 240 patients in the endovascular arm and 246 patients in the surgery arm treatment was initiated as randomly allocated.</P>
<P>In the second CAVATAS trial, 40 patients with symptomatic or asymptomatic carotid stenosis warranting treatment, but who were considered unsuitable for endarterectomy because of surgical or medical contraindications, were randomised between endovascular treatment and best medical care (20 patients) or best medical care alone (20 patients) between April 1992 and May 1997 (<LINK REF="STD-CAVATAS_x002d_MED-2009" TYPE="STUDY">CAVATAS-MED 2009</LINK>). Results including follow-up to 10 years after randomisation were published in 2009. Treatment was initiated as randomly allocated in 16 and 19 patients in the two arms respectively.</P>
<P>A single-centre trial at a community hospital (Central Baptist Hospital) in Lexington, Kentucky, USA, randomised 104 patients with symptomatic carotid stenosis of &gt; 70% between stenting (53 patients) or endarterectomy (51 patients) (<LINK REF="STD-Kentucky-2001" TYPE="STUDY">Kentucky 2001</LINK>). The same group conducted a single-centre trial comparing the two treatments in 85 patients with asymptomatic carotid stenosis of &gt; 80% (stenting: 43 patients, endarterectomy: 42 patients) (<LINK REF="STD-Kentucky-2004" TYPE="STUDY">Kentucky 2004</LINK>). In both trials, all randomised patients were treated and no mention of patients crossing over from the randomly allocated treatment to the alternative one was made.</P>
<P>A single-centre trial conducted at Xuanwu Hospital in Beijing, China, randomised 21 patients with &gt; 70% carotid stenosis on one side and contralateral occlusion - who were apparently considered unsuitable for surgery - to endovascular treatment (eight patients) or medical care alone (13 patients), between 2001 and 2003 (<LINK REF="STD-Beijing-2003" TYPE="STUDY">Beijing 2003</LINK>). Results were published in 2003.</P>
<P>Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) was a multicentre randomised trial in the USA (<LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK>). From August 2000 until July 2002, 334 patients with &#8805; 50% symptomatic carotid stenosis or &#8805; 80% asymptomatic stenosis, who had at least one condition considered to potentially increase the risk of surgical complications, were randomised between endovascular treatment or endarterectomy (167 patients in each arm). The trial was terminated early because of a drop in recruitment numbers. One hundred and fifty-nine patients in the endovascular arm and 151 patients in the surgery arm received the allocated treatment. Results were published initially in 2004 and upon completion of long-term follow-up, in 2008. Although cumulative incidences of the primary endpoint, a composite of peri-procedural death, stroke or myocardial infarction or death or ipsilateral stroke during follow-up, were reported for symptomatic and asymptomatic patients separately, numbers of separate outcome events according to symptom status were not provided.</P>
<P>A Chinese multicentre trial, also led by Xuanwu Hospital in Beijing, reported the results of 166 patients with severe symptomatic or asymptomatic carotid stenosis randomised between endovascular treatment (82 patients) and endarterectomy (84 patients) (<LINK REF="STD-TESCAS_x002d_C-2006" TYPE="STUDY">TESCAS-C 2006</LINK>). The original study was published in Chinese in 2006 with only the abstract available in English. We extracted data for the present review from the abstract and the website (<A HREF="http://www.trialresultscenter.org">www.trialresultscenter.org</A>) but details of the trial were not available because we were unable to obtain a translation of the article.</P>
<P>A French multicentre randomised trial called Endarterectomy versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) was started in November 2000 and randomised patients with &#8805; 60% symptomatic carotid stenosis between endovascular treatment and endarterectomy (<LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>). The trial was stopped early by the safety committee because of safety and futility concerns in September 2005, after 527 patients had been enrolled (endovascular treatment: 265 patients, endarterectomy: 262 patients). Two hundred and sixty patients and 257 patients received the randomly allocated treatment in the two arms respectively. Results up to six months after randomisation were published in 2006, and up to four years after randomisation in 2008.</P>
<P>The Stent-supported Percutaneous Angioplasty of the Carotid artery versus Endarterectomy trial (SPACE) trial randomised 1214 patients with symptomatic carotid stenosis of &#8805; 50% or &#8805; 70% (depending on the method of measurement) between endovascular treatment (613 patients) or endarterectomy (601 patients) in Germany, Austria and Switzerland, from March 2001 until February 2006 (<LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>). Following an interim analysis, the trial was then stopped by the steering committee for reasons of futility and lack of funding. The randomly allocated treatment was initiated in 591 and 567 patients in the two arms respectively. Short-term outcomes were published in 2006, and results up to two years after randomisation in 2008.</P>
<P>A singe-centre trial conducted at the University Hospital Basel, Switzerland (Basel Carotid Artery Stenting Study - BACASS) randomised a total of 20 patients with symptomatic carotid stenosis of &#8805; 70% to endovascular treatment (10 patients) or endarterectomy (10 patients) between November 1998 and February 2002 (<LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK>). Recruitment was stopped when the centre started randomising patients in <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>, and results, including long-term follow-up over a median of four years after treatment, were published in 2008. All patients received the randomly allocated treatment.</P>
<P>A single-centre trial was started in August 1999 at the University Hospital Regensburg, Germany, enrolling patients with &#8805; 70% symptomatic carotid stenosis (<LINK REF="STD-Regensburg-2008" TYPE="STUDY">Regensburg 2008</LINK>). The trial was stopped in April 2002 after randomisation of 43 patients to endovascular treatment and 44 patients to endarterectomy when the multicentre <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK> trial, which had a similar design, started. All randomised patients were treated. The paper did not specify whether the applied treatment was always the one randomly allocated, but did not report any cross-overs.</P>
<P>Another single-centre trial conducted in China randomised 40 patients with symptomatic carotid stenosis of &#8805; 50% or asymptomatic stenosis of &#8805; 70% between endovascular treatment or endarterectomy from May 2004 and December 2006 (20 patients undergoing 23 procedures in each arm - three patients in each arm had bilateral disease) (<LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK>). The original study was published in Chinese in 2009 with only the abstract available in English, which we used to extract data. We were unable to obtain a translation of the article.</P>
<P>The International Carotid Stenting Study (ICSS) randomised 1713 patients with symptomatic carotid stenosis of &#8805; 50% to endovascular treatment (855 patients) or endarterectomy (858 patients) between May 2001 and October 2008 in Europe, Australia, New Zealand and Canada. Short-term results up to 120 days after randomisation were published in 2010 (<LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>). The randomised procedure was initiated in 828 and 821 patients in the two arms respectively. Long-term follow-up in this trial ended in 2011 and the results will be available in the second half of 2012.</P>
<P>The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) was a multicentre randomised trial conducted in the USA and Canada (<LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK>). Between December 2000 and July 2008, 2522 patients with carotid stenosis were randomly assigned to endovascular treatment (1271 patients) or endarterectomy (1251 patients). The trial initially enrolled only patients with symptomatic carotid stenosis, but the eligibility criteria were changed in 2005 to include asymptomatic patients in addition to symptomatic patients. The final population consisted of 1321 patients with symptomatic and 1181 patients with asymptomatic stenosis. Results up to four years after randomisation were published in 2010. The randomly assigned treatment was initiated in 1152 and 1194 patients in the two arms respectively.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Endovascular treatment</HEADING>
<P>Details of endovascular treatment and endarterectomy in the included trials are provided in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> tables. The included trials varied in endovascular techniques. In the <LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK> trial, all patients enrolled in the endovascular arm before 1994 received percutaneous balloon angioplasty without insertion of stents. Stents suitable for the carotid artery became available during the course of the study. From 1994, stenting was allowed at the discretion of the intervening radiologist. Stents were used in 55 patients (22% of those allocated endovascular treatment), usually after unsatisfactory results with prior balloon angioplasty. In all the other trials, stents were routinely used in the endovascular arms, alone or in addition to balloon angioplasty.</P>
<P>There were also differences in use of cerebral protection devices during endovascular treatment among the included trials. Protection devices were either not yet available or were not used in the <LINK REF="STD-Leicester-1998" TYPE="STUDY">Leicester 1998</LINK>, <LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>, <LINK REF="STD-Kentucky-2001" TYPE="STUDY">Kentucky 2001</LINK>, <LINK REF="STD-Wallstent-2001" TYPE="STUDY">Wallstent 2001</LINK>, <LINK REF="STD-Kentucky-2004" TYPE="STUDY">Kentucky 2004</LINK>, <LINK REF="STD-Regensburg-2008" TYPE="STUDY">Regensburg 2008</LINK>, and <LINK REF="STD-CAVATAS_x002d_MED-2009" TYPE="STUDY">CAVATAS-MED 2009</LINK> trials. Use of protection devices was mandatory or part of routing practice in the <LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK>, <LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK>, <LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK> and <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK> trials. The <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK> trial briefly interrupted randomisation in 2003 and made protection device use compulsory following an interim analysis; protection devices were used in 227 (87%) of all 260 stent procedures initiated as randomly allocated (per protocol). In the <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK> trial, protection devices were optional and used in 154 of 591 per-protocol stent procedures (26%). In <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>, deployment of a protection device was recommended, wherever it was considered safe and feasible; protection devices were used in 593 of 828 per-protocol stent procedures (72%). No information on protection device use was available from the <LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK> and <LINK REF="STD-TESCAS_x002d_C-2006" TYPE="STUDY">TESCAS-C 2006</LINK> trials.</P>
<P>A consultant radiologist, who had performed eight successful stent procedures in the carotid artery before the trial, performed all endovascular procedures in the <LINK REF="STD-Leicester-1998" TYPE="STUDY">Leicester 1998</LINK> trial. There were differences among the large multicentre trials in the amount of pre-trial experience in endovascular treatment required for a centre to join. In the <LINK REF="STD-Wallstent-2001" TYPE="STUDY">Wallstent 2001</LINK> trial, interventional physicians needed to have performed at least 10 carotid stent procedures. In the <LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK> and <LINK REF="STD-CAVATAS_x002d_MED-2009" TYPE="STUDY">CAVATAS-MED 2009</LINK> trials, prior expertise in endovascular treatment was required, albeit not in the carotid artery, as this was considered an entirely new treatment for carotid stenosis at the beginning of the trial. In the <LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK> trial, interventionists had performed between 20 and 700 carotid stent procedures in total before the trial. Interventional physicians in the <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK> trial had to have performed at least 12 carotid stenting procedures or at least 35 stenting procedures of the supra-aortic trunks including five carotid stents before joining the trial. Less experienced interventionists were still allowed to join but had to perform all procedures under supervision until sufficient numbers had been achieved. Of 260 per-protocol stent procedures, 101 (39%) were carried out under supervision. In the <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK> trial, interventionists had to show proof of at least 25 successful consecutive percutaneous transluminal angioplasty or stent procedures in the carotid artery. In <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>, interventional physicians were required to have carried out at least 50 stent procedures, 10 of which in the carotid artery. Centres with less experience (so-called supervised centres) were allowed to join the trial under the condition that procedures were supervised by an experienced interventionist. Of all 855 patients randomised in the stent arm, 102 (12%) were enrolled at supervised centres. In the <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK> trial, interventionists with fewer than 30 carotid stent procedures were required to complete a specific training program. Interventionists' eligibility to participate was based on evaluation of their performance during an average of 20 procedures in a non-randomised lead-in phase to the trial.</P>
<P>Among the singe-centre studies, interventionists had prior experience of eight carotid stent procedures in the <LINK REF="STD-Leicester-1998" TYPE="STUDY">Leicester 1998</LINK> trial, and at least 15 carotid stent procedures in the <LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK> trial. Detailed numbers of pre-trial experience in endovascular treatment were unknown for the <LINK REF="STD-Kentucky-2001" TYPE="STUDY">Kentucky 2001</LINK>, <LINK REF="STD-Beijing-2003" TYPE="STUDY">Beijing 2003</LINK>, <LINK REF="STD-Kentucky-2004" TYPE="STUDY">Kentucky 2004</LINK>, <LINK REF="STD-Regensburg-2008" TYPE="STUDY">Regensburg 2008</LINK> and <LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK> trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Follow-up</HEADING>
<P>Length of follow-up and frequency of follow-up visits varied between trials. All trials except one (<LINK REF="STD-Beijing-2003" TYPE="STUDY">Beijing 2003</LINK>) pre-specified a clinical assessment for peri-procedural complications one month or 30 days after treatment. Most trials also included a clinical assessment soon after the procedure, ranging from one to seven days after treatment (<LINK REF="STD-Leicester-1998" TYPE="STUDY">Leicester 1998</LINK>; <LINK REF="STD-Wallstent-2001" TYPE="STUDY">Wallstent 2001</LINK>; <LINK REF="STD-Kentucky-2001" TYPE="STUDY">Kentucky 2001</LINK>; <LINK REF="STD-Kentucky-2004" TYPE="STUDY">Kentucky 2004</LINK>; <LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK>; <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>; <LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK>; <LINK REF="STD-Regensburg-2008" TYPE="STUDY">Regensburg 2008</LINK>; <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK>).</P>
<P>Prospective follow-up was continued beyond one month in all trials except one (<LINK REF="STD-Leicester-1998" TYPE="STUDY">Leicester 1998</LINK>), and went up to six months (<LINK REF="STD-TESCAS_x002d_C-2006" TYPE="STUDY">TESCAS-C 2006</LINK>), 12 months (<LINK REF="STD-Wallstent-2001" TYPE="STUDY">Wallstent 2001</LINK>; <LINK REF="STD-Regensburg-2008" TYPE="STUDY">Regensburg 2008</LINK>), 18 months (<LINK REF="STD-Beijing-2003" TYPE="STUDY">Beijing 2003</LINK>; <LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK>), two years (<LINK REF="STD-Kentucky-2001" TYPE="STUDY">Kentucky 2001</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>), three years (<LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK>), four years (<LINK REF="STD-Kentucky-2004" TYPE="STUDY">Kentucky 2004</LINK>; <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>, median 43 months; <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK>, median 2.5 years), or without pre-defined maximum length of follow-up (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>, median five years; <LINK REF="STD-CAVATAS_x002d_MED-2009" TYPE="STUDY">CAVATAS-MED 2009</LINK>, median 4.5 years in the endovascular arm and 3.5 years in the medical arm; <LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK>, mean 48 months in the endovascular arm and 44 months in the surgical arm; <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>, median four years). In its final publication, the <LINK REF="STD-Regensburg-2008" TYPE="STUDY">Regensburg 2008</LINK> trial included results of a retrospective extension of follow-up with a median of 66 months in the endovascular and 64 months in the surgical arm.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome measures</HEADING>
<P>The definition of stroke specified for the present review was also used in most trials which provided their definitions (<LINK REF="STD-Leicester-1998" TYPE="STUDY">Leicester 1998</LINK>; <LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>; <LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK>; <LINK REF="STD-Regensburg-2008" TYPE="STUDY">Regensburg 2008</LINK>; <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK>; <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>). The stroke definition used in the <LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK> trial initially included only events with symptoms lasting more than seven days. However, in the final analysis including long-term follow-up, peri-procedural strokes lasting seven days or less were counted as well (beyond 30 days after treatment, all recorded stroke outcome events lasted longer than seven days). These events were also included in the present review. Where definitions of stroke were unavailable, the review authors assumed that the same definition as in the present review was used.</P>
<P>The majority of trials classified stroke severity according to functional disability; this was defined by a score of three or more on the modified Rankin Scale (mRS) (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>; <LINK REF="STD-CAVATAS_x002d_MED-2009" TYPE="STUDY">CAVATAS-MED 2009</LINK>; <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>), or on the Oxfordshire Handicap Stroke score (<LINK REF="STD-Leicester-1998" TYPE="STUDY">Leicester 1998</LINK>). In the <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>, an increase in level of disability over the baseline level of at least two points on the mRS was required in addition; a single even was re-classified by the EVA-3S investigators for a previous pooled analysis omitting the additional criterion (<LINK REF="REF-CSTC-2010" TYPE="REFERENCE">CSTC 2010</LINK>), and numbers of disabling strokes were extracted accordingly.</P>
<P>Three trials classified strokes as minor or major. In the <LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK> trial, this was done based on the National Institutes of Health Stroke Scale (NIHSS), the Barthel Index, and the Rankin Scale, but cut-off levels on these scales to classify a stroke as major were not provided. In <LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK> an increase in NIHSS score by four or more points, or symptoms including aphasia or hemianopia lasting for more than 24 hours were required for major stroke; one single stroke occurred fulfilling this definition, but the authors stated that 30 days after stroke onset the mRS was one. Thus, the event was not included as a major or disabling stroke in the present review. The definition for major stroke used in <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK> included a score on the NIHSS of nine or more, 90 days after the procedure, or was made "on the basis of clinical data", without further specification.</P>
<P>The <LINK REF="STD-Wallstent-2001" TYPE="STUDY">Wallstent 2001</LINK> and <LINK REF="STD-Regensburg-2008" TYPE="STUDY">Regensburg 2008</LINK> trials used a combination of Barthel Index, Rankin Scale or mRS, and NIHSS, and the <LINK REF="STD-Kentucky-2001" TYPE="STUDY">Kentucky 2001</LINK> trial used a combination of Barthel Index and mRS to assess functional outcome. Functional assessment was not specified in the remaining trials (<LINK REF="STD-Beijing-2003" TYPE="STUDY">Beijing 2003</LINK>; <LINK REF="STD-Kentucky-2004" TYPE="STUDY">Kentucky 2004</LINK>; <LINK REF="STD-TESCAS_x002d_C-2006" TYPE="STUDY">TESCAS-C 2006</LINK>; <LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK>). Numbers of disabling or major strokes were not available from those trials, although no strokes at all were reported to have occurred in the <LINK REF="STD-Kentucky-2001" TYPE="STUDY">Kentucky 2001</LINK> and <LINK REF="STD-Kentucky-2004" TYPE="STUDY">Kentucky 2004</LINK> trials.</P>
<P>The protocol of one trial explicitly stated that visual loss lasting longer than 24 hours which resulted from retinal ischaemia (i.e. retinal stroke) was included in the outcome definition of stroke (<LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>); correspondence with investigators from two other trials also confirmed that retinal strokes were included (<LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>). Retinal strokes were assessed but initially excluded from reports of the <LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK> trial; they were included in the definition of stroke for the present review.</P>
<P>Trials also differed in assessment and definitions of myocardial infarction (MI). Among trials which reported MI as an endpoint, two used the WHO definition (<LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>), which includes two out of the following three criteria: prolonged typical chest pain, elevation of specific cardiac enzymes more than twice the upper limit of normal, and specific ECG abnormalities. In <LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK>, MI was defined solely on the basis of a creatine kinase elevation higher than two times the upper limit of normal with a positive MB fraction. This implied that enzymes were routinely measured after treatment. The trial provided the numbers of patients with Q-wave infarction separately, but in the composite outcome measures of which MI was part, all types were included. In the <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK> trial, patients were routinely screened with ECG and cardiac enzyme measurement before and after treatment. MI was defined by a creatine kinase MB or troponin level that was twice the upper limit of normal plus either chest pain or symptoms consistent with ischaemia, or ECG evidence of ischaemia. The <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK> trial did not include MI as a pre-defined endpoint, but for the purpose of a previous pooled analysis, the investigators re-assessed all adverse event reports and did not find any reported MIs in the peri-procedural period fulfilling WHO criteria (<LINK REF="REF-CSTC-2010" TYPE="REFERENCE">CSTC 2010</LINK>). Two trials reported numbers of MIs without providing definitions (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK>). The <LINK REF="STD-Kentucky-2001" TYPE="STUDY">Kentucky 2001</LINK> trial reported that one patient died of an MI immediately after endarterectomy but did not specify inclusion of non-fatal MI as an outcome measure; this trial was therefore excluded from the comparison of all MI in this review. No information on MI was available from the remaining trials.</P>
<P>Cranial nerve palsies of any severity were reported in 10 trials (<LINK REF="STD-Leicester-1998" TYPE="STUDY">Leicester 1998</LINK>; <LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-Kentucky-2001" TYPE="STUDY">Kentucky 2001</LINK>; <LINK REF="STD-Kentucky-2004" TYPE="STUDY">Kentucky 2004</LINK>; <LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK>; <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK>; <LINK REF="STD-Regensburg-2008" TYPE="STUDY">Regensburg 2008</LINK>; <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK>; <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>). In the <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK> trial, only cranial nerve palsies not resolving for at least one month after treatment were counted. Five trials reported numbers of patients with access site haematoma requiring surgery, blood transfusion, or prolonging hospital stay (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-Kentucky-2001" TYPE="STUDY">Kentucky 2001</LINK>; <LINK REF="STD-Kentucky-2004" TYPE="STUDY">Kentucky 2004</LINK>; <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>). We also included access site haematomas reported in the <LINK REF="STD-Regensburg-2008" TYPE="STUDY">Regensburg 2008</LINK> and <LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK> trials in the present review, although no definition of severity was provided. The <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK> trial did not report on cranial nerve palsy and haematoma initially, but adverse event reports were reassessed for the aforementioned pooled analysis (<LINK REF="REF-CSTC-2010" TYPE="REFERENCE">CSTC 2010</LINK>), and numbers of patients with these outcomes were extracted for the present review. The <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK> trial reported several types of bleeding complications, but it was not possible to extract the numbers of patients with access-related bleeding events in both arms.</P>
<P>Twelve trials specified that carotid ultrasound was performed at regular intervals during follow-up to detect restenosis (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-Wallstent-2001" TYPE="STUDY">Wallstent 2001</LINK>; <LINK REF="STD-Kentucky-2001" TYPE="STUDY">Kentucky 2001</LINK>; <LINK REF="STD-Kentucky-2004" TYPE="STUDY">Kentucky 2004</LINK>; <LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK>; <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>; <LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK>; <LINK REF="STD-Regensburg-2008" TYPE="STUDY">Regensburg 2008</LINK>; <LINK REF="STD-CAVATAS_x002d_MED-2009" TYPE="STUDY">CAVATAS-MED 2009</LINK>; <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK>; <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>). The <LINK REF="STD-Beijing-2003" TYPE="STUDY">Beijing 2003</LINK> trial carried out a single ultrasound examination to assess restenosis 1.5 years after treatment. In addition, the <LINK REF="STD-TESCAS_x002d_C-2006" TYPE="STUDY">TESCAS-C 2006</LINK> and <LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK> trials specified restenosis as a secondary outcome in the English abstracts, albeit without any information how this was assessed. Numbers of patients with restenosis were available from six trials comparing endovascular treatment with endarterectomy (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>; <LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK>; <LINK REF="STD-Regensburg-2008" TYPE="STUDY">Regensburg 2008</LINK>; <LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK>). The <LINK REF="STD-Kentucky-2001" TYPE="STUDY">Kentucky 2001</LINK> and <LINK REF="STD-Kentucky-2004" TYPE="STUDY">Kentucky 2004</LINK> trials reported mean peak systolic velocity ratios between the internal and the common carotid artery but did not provide numbers of patients with moderate or severe restenosis. No data on restenosis have been published from the remaining trials, at the time of writing of this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Analysis of data</HEADING>
<P>Six trials specified that the primary analysis followed the intention-to-treat principle as defined above (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>; <LINK REF="STD-CAVATAS_x002d_MED-2009" TYPE="STUDY">CAVATAS-MED 2009</LINK>; <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK>; <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>). One trial used a modified intention-to-treat approach for analysis of peri-procedural outcomes, excluding patients who received neither endovascular nor surgical treatment (<LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>). A per-protocol analysis was carried out in the <LINK REF="STD-Leicester-1998" TYPE="STUDY">Leicester 1998</LINK> trial, excluding patients who did not receive the randomly allocated treatment. In the <LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK> trial no statistical analysis was performed due to the small number of patients enrolled, but it was stated that all patients received the randomly allocated treatment. Three further trials stated that all randomised patients received treatment, but it was not specified whether this was always the randomly allocated treatment (<LINK REF="STD-Kentucky-2001" TYPE="STUDY">Kentucky 2001</LINK>; <LINK REF="STD-Kentucky-2004" TYPE="STUDY">Kentucky 2004</LINK>; <LINK REF="STD-Regensburg-2008" TYPE="STUDY">Regensburg 2008</LINK>); however, no mention of any patients crossing over to the alternative treatment was made in these trials. Numbers of patients receiving treatment were unknown in the other four trials (<LINK REF="STD-Wallstent-2001" TYPE="STUDY">Wallstent 2001</LINK>; <LINK REF="STD-Beijing-2003" TYPE="STUDY">Beijing 2003</LINK>; <LINK REF="STD-TESCAS_x002d_C-2006" TYPE="STUDY">TESCAS-C 2006</LINK>; <LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK>).</P>
<P>Three trials specified a non-inferiority hypothesis in which stenting was considered as non-inferior to endarterectomy when the 90% or 95% confidence interval of the absolute difference in the risk of the primary outcome measure with stenting minus the risk of the primary outcome measure with surgery was below a pre-defined margin (<LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK>; <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>).</P>
<P>For the analysis of treatment safety, the peri-procedural period was defined as the first 30 days after treatment in the majority of trials (<LINK REF="STD-Leicester-1998" TYPE="STUDY">Leicester 1998</LINK>; <LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-Kentucky-2001" TYPE="STUDY">Kentucky 2001</LINK>; <LINK REF="STD-Wallstent-2001" TYPE="STUDY">Wallstent 2001</LINK>; <LINK REF="STD-Kentucky-2004" TYPE="STUDY">Kentucky 2004</LINK>; <LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK>; <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-TESCAS_x002d_C-2006" TYPE="STUDY">TESCAS-C 2006</LINK>; <LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK>; <LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK>; <LINK REF="STD-CAVATAS_x002d_MED-2009" TYPE="STUDY">CAVATAS-MED 2009</LINK>). Among those, two trials reported events occurring between randomisation and treatment and excluded those from analysis of peri-procedural outcomes (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>). One trial reported that some patients did not receive the allocated treatment because of "deterioration of their condition", but it was unclear whether this was a consequence of pre-specified endpoints such as stroke or myocardial infarction (<LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK>). In three trials, the observation period for analysis of short-term outcome started at randomisation, and lasted up to 30 days after treatment, or 30 days after randomisation in patients receiving no revascularisation (<LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>); up to 30 days after treatment or 36 days after randomisation in patients receiving no revascularisation (<LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK>); or up to 120 days after randomisation in all patients (<LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>).</P>
<P>The <LINK REF="STD-Regensburg-2008" TYPE="STUDY">Regensburg 2008</LINK> trial separately reported outcome events occurring during the prospectively defined 12-month follow-up period and the retrospective extension of follow-up, but without specifying how many events occurred within 30 days of treatment. The review authors assumed that the reported myocardial infarction, cranial nerve palsy and access site haematoma occurred peri-procedurally; however, the trial was excluded from comparisons involving peri-procedural stroke.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ongoing and planned studies</HEADING>
<P>We are aware of seven planned or ongoing randomised trials investigating treatment of asymptomatic carotid stenosis: two large ongoing multicentre trials (<LINK REF="STD-ACT-I" TYPE="STUDY">ACT I</LINK>; <LINK REF="STD-ACST_x002d_2" TYPE="STUDY">ACST-2</LINK>), and two smaller trials which are ongoing (<LINK REF="STD-Carmel-Medical-Center" TYPE="STUDY">Carmel Medical Center</LINK>) or in which recruitment status is unknown (<LINK REF="STD-Agostoni" TYPE="STUDY">Agostoni</LINK>), randomise patients between stenting or endarterectomy; one large ongoing multicentre three-arm trial randomises patients between stenting, endarterectomy, or best medical treatment alone (<LINK REF="STD-SPACE_x002d_2" TYPE="STUDY">SPACE-2</LINK>);  two smaller trials compare endarterectomy (<LINK REF="STD-AMTEC" TYPE="STUDY">AMTEC</LINK>) or stenting (<LINK REF="STD-Vienna-General-Hospital" TYPE="STUDY">Vienna General Hospital</LINK>) versus best medical treatment alone, the latter with unknown recruitment status.</P>
<P>A further trial, the Second European Carotid Surgery Trial (<LINK REF="STD-ECST_x002d_2" TYPE="STUDY">ECST-2</LINK>) which is about to begin recruitment, will compare revascularisation by endarterectomy or stenting versus best medical treatment alone in patients with asymptomatic or low-to-intermediate risk symptomatic carotid stenosis. A specific carotid artery risk score identifies patients eligible to participate.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-06-25 16:31:56 +0100" MODIFIED_BY="Martin M Brown">
<ALLOCATION MODIFIED="2012-06-25 16:31:53 +0100" MODIFIED_BY="Leo H Bonati">
<P>All included trials stated that allocation of treatment was randomised. The method of randomisation was given for 12 trials. In the large multicentre trials, central randomisation services were accessed by telephone, fax, or automated telephone response systems (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK>; <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>; <LINK REF="STD-CAVATAS_x002d_MED-2009" TYPE="STUDY">CAVATAS-MED 2009</LINK>; <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK>; <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>). Some trials specified that the random allocation sequence was generated with a computer or pseudo-random number generator (<LINK REF="STD-Wallstent-2001" TYPE="STUDY">Wallstent 2001</LINK>; <LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK>; <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>). In the <LINK REF="STD-Wallstent-2001" TYPE="STUDY">Wallstent 2001</LINK> trial, each centre received its own randomisation sequence and treatment was assigned in sequentially-numbered sealed envelopes. Among the single-centre studies, sequentially-numbered sealed envelopes with random treatment assignments were used in two trials (<LINK REF="STD-Leicester-1998" TYPE="STUDY">Leicester 1998</LINK>: 300 envelopes; <LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK>: 50 envelopes), while treatment assignment was performed in two other trials using a "random key" (<LINK REF="STD-Regensburg-2008" TYPE="STUDY">Regensburg 2008</LINK>), or a random table (<LINK REF="STD-Beijing-2003" TYPE="STUDY">Beijing 2003</LINK>). For these 12 trials, random sequence generation and allocation concealment were judged to be adequate and the risk of selection bias low. We were unable to obtain detailed information regarding method of randomisation from the authors of four trials (<LINK REF="STD-Kentucky-2001" TYPE="STUDY">Kentucky 2001</LINK>; <LINK REF="STD-Kentucky-2004" TYPE="STUDY">Kentucky 2004</LINK>; <LINK REF="STD-TESCAS_x002d_C-2006" TYPE="STUDY">TESCAS-C 2006</LINK>; <LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK>) in which the risk of selection bias was judged to be unclear.</P>
<P>Restricted randomisation was reported in some trials, by use of a minimisation algorithm, taking account of centre and timing of symptoms (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-CAVATAS_x002d_MED-2009" TYPE="STUDY">CAVATAS-MED 2009</LINK>), or sex, age, contralateral carotid occlusion and side of the randomised carotid stenosis (<LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>); or by use of randomly permuted blocks, stratified by centre and degree of stenosis (<LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>), or by centre and symptomatic status (<LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK>). The <LINK REF="STD-Regensburg-2008" TYPE="STUDY">Regensburg 2008</LINK> stated that randomisation was stratified according to age, degree of stenosis, and presence of coronary heart disease, without detailing the method of restriction.</P>
</ALLOCATION>
<BLINDING MODIFIED="2012-06-25 16:31:54 +0100" MODIFIED_BY="Leo H Bonati">
<P>Due to study design and the nature of the interventions patients, health workers, and assessors were not blinded to treatment or outcome in any of the trials included in this review. Moreover, patients treated by carotid endarterectomy were often managed post-operatively on surgical wards where minor neurological events may be missed or misinterpreted. Analyses restricted to disabling stroke or death were assumed to be the least affected by this bias. We excluded transient ischaemic attacks from the analysis because they are likely to be the most affected by this bias.</P>
<P>Nonetheless, in most trials patients were followed-up by neurologists or clinicians who were not directly involved in the procedures (<LINK REF="STD-Leicester-1998" TYPE="STUDY">Leicester 1998</LINK>; <LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-Kentucky-2001" TYPE="STUDY">Kentucky 2001</LINK>; <LINK REF="STD-Wallstent-2001" TYPE="STUDY">Wallstent 2001</LINK>; <LINK REF="STD-Kentucky-2004" TYPE="STUDY">Kentucky 2004</LINK>; <LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK>; <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>; <LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK>; <LINK REF="STD-Regensburg-2008" TYPE="STUDY">Regensburg 2008</LINK>; <LINK REF="STD-CAVATAS_x002d_MED-2009" TYPE="STUDY">CAVATAS-MED 2009</LINK>; <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK>; <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>); in addition, the large multicentre trials adjudicated outcome events centrally, blinded to treatment (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK>; <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>; <LINK REF="STD-CAVATAS_x002d_MED-2009" TYPE="STUDY">CAVATAS-MED 2009</LINK>; <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK>; <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>). In those trials, the risk of detection bias was considered low. In three trials, no information on independent follow-up or blinded adjudication was available and the risk of detection bias was considered unclear (<LINK REF="STD-Beijing-2003" TYPE="STUDY">Beijing 2003</LINK>; <LINK REF="STD-TESCAS_x002d_C-2006" TYPE="STUDY">TESCAS-C 2006</LINK>; <LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2012-06-25 16:31:56 +0100" MODIFIED_BY="Martin M Brown">
<P>In five trials, some patients were randomised but later excluded from analysis: in <LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK> one patient was shown to have carotid occlusion after randomisation; 18 patients randomised in <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>, and three patients randomised in <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK> immediately withdrew consent after randomisation; 20 patients randomised in <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK> at a single centre were excluded owing to scientific misconduct. The risk of attrition bias arising from these exclusions was considered to be small. In the <LINK REF="STD-Leicester-1998" TYPE="STUDY">Leicester 1998</LINK> trial, four out of 11 patients randomised to endovascular treatment and two out of 12 patients randomised to surgery did not receive their allocated treatment (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> tables for reasons) and were excluded from analysis in this trial. Outcome events occurring after randomisation were not systematically reported for these patients and it was unclear whether the patients refusing the allocated treatment crossed-over to receive the alternative treatment. Risk of attrition bias in this trial was therefore considered unclear. The patients excluded from analysis in those five trials were also excluded from the present review, as no outcome data were available from them.</P>
<P>Most trials which followed up patients beyond 30 days after treatment provided the numbers of patients at risk for the primary outcome measure at various time points during follow-up and/or numbers of patients with available long-term follow-up (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK>; <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>; <LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK>; <LINK REF="STD-Regensburg-2008" TYPE="STUDY">Regensburg 2008</LINK>; <LINK REF="STD-CAVATAS_x002d_MED-2009" TYPE="STUDY">CAVATAS-MED 2009</LINK>; <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK>; details are provided in the 'Risk of bias' tables in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> section). In general, we assumed that censoring in these trials was non-informative, i.e. unbiased in the sense that treatment effects were assumed to be the same in patients censored before the end of scheduled follow-up and those with complete follow-up (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The <LINK REF="STD-Beijing-2003" TYPE="STUDY">Beijing 2003</LINK> trial reported that at 1.5 years follow-up, the patients without outcome events "had not changed". The risk of attrition bias resulting from incomplete follow-up in these trials was considered low.</P>
<P>From the remaining trials, neither numbers of patients at risk during follow-up nor numbers of patients with available long-term follow-up were provided, and the risk of attrition bias was deemed unclear (<LINK REF="STD-Wallstent-2001" TYPE="STUDY">Wallstent 2001</LINK>; <LINK REF="STD-Kentucky-2001" TYPE="STUDY">Kentucky 2001</LINK>; <LINK REF="STD-Kentucky-2004" TYPE="STUDY">Kentucky 2004</LINK>; <LINK REF="STD-TESCAS_x002d_C-2006" TYPE="STUDY">TESCAS-C 2006</LINK>; <LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2012-06-06 11:36:00 +0100" MODIFIED_BY="Leo H Bonati">
<P>Most of the larger trials reported the primary outcome analysis as defined before in a separately published study protocol (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-Wallstent-2001" TYPE="STUDY">Wallstent 2001</LINK>; <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>; <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK>; <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>). Other trials made no references to study protocols, but reported major outcome events (i.e. strokes and deaths) as expected in general (<LINK REF="STD-Leicester-1998" TYPE="STUDY">Leicester 1998</LINK>; <LINK REF="STD-Kentucky-2001" TYPE="STUDY">Kentucky 2001</LINK>; <LINK REF="STD-Wallstent-2001" TYPE="STUDY">Wallstent 2001</LINK>; <LINK REF="STD-Beijing-2003" TYPE="STUDY">Beijing 2003</LINK>; <LINK REF="STD-Kentucky-2004" TYPE="STUDY">Kentucky 2004</LINK>; <LINK REF="STD-TESCAS_x002d_C-2006" TYPE="STUDY">TESCAS-C 2006</LINK>; <LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK>; <LINK REF="STD-CAVATAS_x002d_MED-2009" TYPE="STUDY">CAVATAS-MED 2009</LINK>). In the <LINK REF="STD-Regensburg-2008" TYPE="STUDY">Regensburg 2008</LINK> study the primary outcome measure was specified to include events up to 30 days after treatment, but the final publication did not include a comparison of peri-procedural events. However, the risk of reporting bias in all those trials was considered low.</P>
<P>The <LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK> trial cited a protocol, albeit one that was published only a few months before the initial results of the trial. Expected major outcome events were reported, but not for symptomatic and asymptomatic patients separately. We could not exclude the possibility of reporting bias for this trial.</P>
</SELECTIVE_REPORTING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-06-25 16:32:36 +0100" MODIFIED_BY="Martin M Brown">
<P>Detailed results are provided in the <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK> section. Except where stated, treatment effects are expressed as odds ratios (OR), with lower and upper limits of 95% confidence intervals in brackets.</P>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1: Endovascular treatment or endarterectomy for symptomatic carotid stenosis</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Standard surgical risk</HEADING>
<P>Seven trials compared endovascular treatment with endarterectomy in patients with symptomatic carotid stenosis (<LINK REF="STD-Leicester-1998" TYPE="STUDY">Leicester 1998</LINK>; <LINK REF="STD-Wallstent-2001" TYPE="STUDY">Wallstent 2001</LINK>; <LINK REF="STD-Kentucky-2001" TYPE="STUDY">Kentucky 2001</LINK>; <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>; <LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK>; <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>), while four trials included both patients with symptomatic and asymptomatic stenosis (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-TESCAS_x002d_C-2006" TYPE="STUDY">TESCAS-C 2006</LINK>; <LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK>; <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK>). Where possible, only data from symptomatic patients enrolled in <LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK> and <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK> were included in this comparison; in the <LINK REF="STD-TESCAS_x002d_C-2006" TYPE="STUDY">TESCAS-C 2006</LINK> and <LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK> trials, outcome events from symptomatic and asymptomatic patients were not available separately, and were included as a whole. These trials did not specifically include patients perceived to be at increased risk from surgery.</P>
<SUBSECTION>
<HEADING LEVEL="5">Safety analysis: outcome events occurring between randomisation and 30 days after treatment</HEADING>
<P>Data on the primary safety outcome measure of this review, death or stroke of any severity occurring between randomisation and 30 days following the procedure, were available from patients with symptomatic carotid stenosis randomised in 11 trials. Data from two of these trials also included asymptomatic patients (<LINK REF="STD-TESCAS_x002d_C-2006" TYPE="STUDY">TESCAS-C 2006</LINK>; <LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK>). There was a significant excess of the primary safety outcome measure in the endovascular treatment group (OR 1.72, 95% CI 1.29 to 2.31, P = 0.0003; I² = 27%) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<P>Among the six trials with available individual patient data, the primary safety outcome was compared in subgroups according to age. There was a significant interaction between treatment effect and age: among patients younger than 70 years, the OR of the primary safety outcome was 1.16 (95% CI 0.80 to 1.67, I² = 0%); in patients 70 years or older, the OR was 2.20 (95% CI 1.47 to 3.29, I² = 18%; P value for interaction 0.02) ( <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>Seven trials provided data for subgroup analysis according to sex. Treatment effects in men (OR 1.86, 95% CI 1.19 to 2.91, I² = 56%) and women (OR 1.53, 95% CI 1.02 to 2.29, I² = 0%) did not differ significantly from each other (interaction P value 0.52) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<P>The minimum amount of pre-trial experience in endovascular treatment was specified in eight trials. Among the five trials which required 10 or fewer procedures in the carotid artery, the summary treatment effect on the primary safety outcome (OR 2.11, 95% CI 1.43 to 3.12, I² = 31%) did not differ significantly from the treatment effect observed in the three trials requiring higher levels of interventional experience (OR 1.39, 95% CI 0.86 to 2.25, I² = 34%; interaction P value: 0.19) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>There was no significant difference in the combined outcome measure of death or major or disabling stroke between endovascular treatment and endarterectomy, which was reported in seven trials (OR 1.28, 95% CI 0.93, 1.77, P = 0.13; I² = 0%) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
<P>Death from any cause up to 30 days after treatment was reported in 11 trials; from three of these trials, both symptomatic and asymptomatic patients were included in the comparison because mortality outcomes were not provided separately (<LINK REF="STD-TESCAS_x002d_C-2006" TYPE="STUDY">TESCAS-C 2006</LINK>; <LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK>; <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK>). There was a non-significant increase in all-cause mortality among patients randomised to endovascular treatment compared with those assigned surgery (OR 1.59, 95% CI 0.94 to 2.70, P = 0.09; I² = 0%) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
<P>Among the nine trials separately reporting peri-procedural stroke, endovascular treatment was associated with a significant increase in the risk of stroke of any severity between randomisation and 30 days after treatment compared with endarterectomy (OR 1.81, 95% CI 1.40 to 2.34, P &lt; 0.00001; I² = 12%) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). There were more fatal, disabling or major strokes in the endovascular groups, but the difference did not reach statistical significance (eight trials; OR 1.37, 95% CI 0.99 to 1.89, P = 0.06; I² = 0%) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
<P>The risk of fatal or non-fatal myocardial infarction up to 30 days after treatment was lower in patients assigned to endovascular treatment than in the endarterectomy arms, among eight trials with available data (OR 0.44, 95% CI 0.23 to 0.87, P = 0.02; I² = 0%) (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). Combining myocardial infarction with peri-procedural death or stroke favoured endarterectomy, though (six trials, OR 1.44, 95% CI 1.15 to 1.80, P = 0.002; I² = 7%) (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Combined safety and efficacy analysis: outcome events occurring between randomisation and end of follow-up</HEADING>
<P>The primary combined safety and efficacy outcome measure, the combination of death or any stroke occurring between randomisation and 30 days after treatment or ipsilateral stroke until the end of follow-up could be extracted from eight trials, one also including patients with asymptomatic stenosis (<LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK>), albeit with different lengths of follow-up. The combined outcome occurred significantly more often among patients randomised to endovascular treatment than among those allocated endarterectomy (OR 1.39, 95% CI 1.10 to 1.75], P = 0.005; I² = 0%) (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>). The occurrence of death or any stroke between randomisation and end of available follow-up, which was reported in eight trials, two of which also including patients with asymptomatic stenosis (<LINK REF="STD-TESCAS_x002d_C-2006" TYPE="STUDY">TESCAS-C 2006</LINK>; <LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK>), was also more common in endovascular treatment (OR 1.41, 95% CI 1.07 to 1.84, P = 0.01; I² = 0%) (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Efficacy analysis: outcome events occurring after the peri-procedural period</HEADING>
<P>In the comparison of treatment efficacy regarding prevention of recurrent strokes, events occurring in the peri-procedural period (i.e. between randomisation and 30 days after treatment) were excluded, and patients who died in the peri-procedural period were subtracted from the total numbers of patients analysed. The <LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK> and <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK> trials separately reported numbers of strokes occurring during follow-up which excluded events occurring within 30 days of treatment, whilst also providing the numbers of patients who suffered a stroke between randomisation and treatment. For the <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK> and <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK> trials, we calculated the numbers of non-procedural strokes by subtracting the numbers of peri-procedural events (which in those trials were defined as having occurred between randomisation and 30 days after treatment) from the numbers of all events occurring between randomisation and end of follow-up. For the <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK> trial, we could not exclude patients who died in the peri-procedural period, because numbers of peri-procedural deaths were not provided for symptomatic and asymptomatic patients separately.</P>
<P>Excluding events occurring between randomisation and 30 days after treatment, there was neither a significant difference in the occurrence of strokes in any territory (six trials, OR 1.26, 95% CI 0.77 to 2.04, P = 0.36; I² = 33%) (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>), nor in ipsilateral strokes (seven trials, OR 0.93, 95% CI 0.60 to 1.45, P = 0.76; I² = 0%) (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>) during follow-up. Both comparisons included the <LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK> trial which included patients with symptomatic and asymptomatic carotid stenosis.</P>
<P>Six trials reported numbers of patients with severe restenosis (equivalent to 70% or more according to the measurement of stenosis used in the NASCET trial) detected on ultrasound during follow-up. Two of these trials also included patients with asymptomatic stenosis (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK>). The overall comparison showed higher restenosis rates among patients randomised to endovascular treatment compared with patients assigned to surgery (OR 2.41, 95% CI 1.28 to 4.53, P = 0.007; I² = 55%) (<LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>). The point estimate of the treatment effect was lower among the five trials using primary stenting (OR 1.97, 95% CI 0.67 to 5.79, I² = 58%) than in the <LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK> trial, in which most patients were treated by balloon angioplasty without stent insertion (OR 3.48, 95% CI 1.99 to 6.07). However, confidence intervals of treatment effects of balloon angioplasty versus surgery and primary stenting versus surgery overlapped, and the interaction was not significant (interaction P = 0.36).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Elevated surgical risk</HEADING>
<P>A single trial compared endovascular treatment versus endarterectomy in patients with symptomatic or asymptomatic carotid stenosis who were considered to be at increased risk of complications from surgery (<LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK>); peri-procedural outcomes are provided in <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>, <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>, <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>, <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK> and <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>, but were not pooled with the data from the other trials. These outcomes were not reported for patients with symptomatic or asymptomatic stenosis, separately. The <LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK> trial reported no significant difference in the occurrence of the composite outcome of death or any stroke within 30 days after treatment or ipsilateral stroke or death from neurological causes up to three years after treatment, with cumulative incidences of 9.3% in the endovascular and 10.0% in the surgical arm.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 2: Endovascular treatment with or without protection for symptomatic carotid stenosis</HEADING>
<P>The rate of the primary safety outcome was compared between patients receiving stent treatment with use of a cerebral protection device, and patients undergoing unprotected stenting, including data available from three trials (<LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>; <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>). This non-randomised comparison was restricted to patients receiving stenting as randomly allocated (per-protocol). There was no significant difference in the occurrence of death or any stroke within 30 days of stent treatment according to protection device use (OR protected versus unprotected stenting 0.95, 95% CI 0.38 to 2.41, P = 0.92; I² = 78%) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 3: Endovascular treatment or endarterectomy for asymptomatic carotid stenosis</HEADING>
<P>Outcomes were available from one trial including patients with asymptomatic carotid stenosis only (<LINK REF="STD-Kentucky-2004" TYPE="STUDY">Kentucky 2004</LINK>), and from subgroups of patients with asymptomatic stenosis enrolled in two other trials (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK>).</P>
<P>There was no significant difference in the occurrence of the primary safety outcome between endovascular treatment and endarterectomy (OR 1.71, 95% CI 0.78 to 3.76, P = 0.18; I² = 0%) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>), but the point estimate of the odds ratio was nearly identical to the same comparison in symptomatic patients (OR 1.72, 95% CI 1.29 to 2.31) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Adding ipsilateral strokes occurring during follow-up to these peri-procedural complications, resulting in the primary combined safety and efficacy outcome, there was a similar non-significant difference favouring surgery (OR 1.75, 95% CI 0.92 to 3.33, P = 0.09; I² = 0%) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 4: Access complications in endovascular treatment or endarterectomy</HEADING>
<P>Rates of cranial nerve palsy, which were reported in 11 trials, were significantly reduced among patients treated endovascularly compared with the surgical groups (OR 0.08, 95% CI 0.05 to 0.14, P &lt; 0.00001, I² = 0%) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
<P>From eight trials, the numbers of the combined outcome of death or any neurological complication (including stroke or cranial nerve palsy) between randomisation and 30 days after the procedure could be extracted. There was a non-significant reduction of this outcome with endovascular treatment (OR 0.76, 95% CI 0.54 to 1.07, P = 0.12, I² = 44%) (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>). Access site haematoma (requiring surgery, blood transfusion or prolonging hospital stay, where severity was defined) was significantly less common with endovascular treatment than with endarterectomy (nine trials, OR 0.37, 95% CI 0.18 to 0.77, P = 0.008, I² = 27%) (<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>).</P>
<P>Treatment effects in these comparisons did not appear to differ between patients with symptomatic or asymptomatic stenosis or those at increased surgical risk.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 5: Endovascular treatment or medical care in patients not suitable for surgery</HEADING>
<P>Data were only available from two very small studies (<LINK REF="STD-Beijing-2003" TYPE="STUDY">Beijing 2003</LINK>; <LINK REF="STD-CAVATAS_x002d_MED-2009" TYPE="STUDY">CAVATAS-MED 2009</LINK>). There was no significant difference in the occurrence of stroke or death between randomisation and the end of follow-up (OR 0.22, 95% CI 0.01 to 7.92, P = 0.41; I² = 79%) (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-06-25 16:32:57 +0100" MODIFIED_BY="Martin M Brown">
<P>Randomised controlled trials have shown that the addition of carotid endarterectomy to medical therapy is effective in reducing the risk of stroke among patients with moderate or severe carotid stenosis. Data from non-randomised studies suggest that carotid angioplasty and stenting may be performed with comparable risks and benefits. The purpose of this review was to determine whether evidence from randomised trials has shown that endovascular treatment of internal carotid artery stenosis might be a safe and effective alternative to carotid endarterectomy.</P>
<SUMMARY_OF_RESULTS MODIFIED="2012-06-25 16:32:37 +0100" MODIFIED_BY="Martin M Brown">
<P>In patients with symptomatic carotid stenosis, endarterectomy was associated with a lower risk of death or any stroke (the primary safety outcome), death or any stroke or myocardial infarction, as well as any stroke, occurring between randomisation and 30 days after treatment. Age significantly modified the treatment effect on the primary safety outcome: rates of death or any stroke between randomisation and 30 days after treatment did not differ significantly in patients younger than 70 years, but were significantly increased with endovascular treatment compared with surgery in the older age group. The rate of peri-procedural death or major or disabling stroke did not differ significantly between treatments. There were non-significant differences in favour of endarterectomy in the comparisons of all-cause mortality, and fatal, disabling or major stroke in the peri-procedural period. Endovascular treatment was associated with lower risks of myocardial infarction, cranial nerve palsy, and access site haematomas.</P>
<P>Including events occurring during long-term follow-up, endarterectomy was superior to endovascular treatment in the comparison of death or any stroke occurring up to 30 days after treatment combined with ipsilateral stroke beyond the peri-procedural period (the primary combined safety and efficacy outcome), as well as in the comparison of death or any stroke between randomisation and the end of follow-up. Excluding events that occurred between randomisation and 30 days after treatment, the rates of stroke in any territory and ipsilateral stroke did not differ significantly between treatments. Endovascular treatment was associated with a higher risk of severe restenosis during follow-up.</P>
<P>In patients with asymptomatic carotid stenosis, there was no significant difference between endovascular treatment and endarterectomy in the occurrence of death or any stroke between randomisation and 30 days after treatment, but the numbers of events available for analysis were small and the odds ratio was similar to the odds ratio favouring surgery in symptomatic patients. The combination of this outcome with ipsilateral stroke occurring during follow-up also showed a non-significant difference in favour or surgery.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-06-25 16:32:46 +0100" MODIFIED_BY="Leo H Bonati">
<SUBSECTION>
<HEADING LEVEL="3">Does endovascular treatment for carotid artery stenosis have a significantly different risk of peri-procedural stroke or death compared with endarterectomy?</HEADING>
<P>With regard to the first main research question, there is now strong evidence that in patients with symptomatic carotid stenosis who can undergo surgery safely, endovascular treatment is associated with a higher risk of the combined outcome of death or stroke of any severity in the short term than endarterectomy.</P>
<P>There is also strong evidence that the excess risk associated with endovascular treatment is dependent on age. A significant interaction was found between patients' age and the summary treatment effect on the primary short-term outcome observed among six trials with available access to individual patient data: treatments yielded broadly similar results in patients younger than 70 years while older patients had more than twice the odds of death or stroke up to 30 days after treatment. Age was previously recognised as an important risk factor for stroke associated with carotid stenting (<LINK REF="REF-Touz_x00e9_-2009" TYPE="REFERENCE">Touzé 2009</LINK>), but had little effect on stroke risk in endarterectomy (<LINK REF="REF-Rothwell-2004" TYPE="REFERENCE">Rothwell 2004</LINK>; <LINK REF="REF-Bond-2005" TYPE="REFERENCE">Bond 2005</LINK>). A previous pooled analysis of three large European stenting trials (<LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>; <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>) suggested that the excess in stroke risk of stenting over surgery increased linearly with patients' age (<LINK REF="REF-CSTC-2010" TYPE="REFERENCE">CSTC 2010</LINK>), a finding that was supported by a similar analysis in the <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK> trial. Factors mediating this association may be increased burden of atherosclerosis in the aortic arch, plaque instability, or vessel tortuosity in elderly patients, which might increase the risk of procedure-related stroke in stenting.</P>
<P>There is insufficient evidence to answer the question whether comparative risks of endovascular treatment versus endarterectomy also depend on the sex of the patient (<LINK REF="REF-Brown-2011" TYPE="REFERENCE">Brown 2011</LINK>). Furthermore, other individual factors which may determine peri-procedural stroke risk, such as vascular anatomy or characteristics of the atherosclerotic plaque, could not be addressed in the present review.</P>
<P>The difference in the combined primary safety outcome was driven by a significant increase in risk of stroke with endovascular treatment occurring up to 30 days after the procedure. There was no significant difference in the occurrence of the combination of death, stroke leading to disability, or stroke which was otherwise classified as major, indicating that the increase in stroke risk associated with stenting was largely due to a difference in non-disabling strokes. However, excluding non-stroke deaths, there were more fatal, disabling or major strokes with endovascular treatment. This difference did not reach statistical significance (P = 0.06), but due to the small numbers of events leading to large confidence intervals, the current data cannot rule out an increase in strokes leading to death or disability in endovascular treatment compared with endarterectomy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Is endovascular treatment for carotid artery stenosis as effective as endarterectomy in preventing stroke in the long term?</HEADING>
<P>The evidence base to answer the second main research question of this review is less firm. The combination of death or any stroke between randomisation and 30 days after treatment or ipsilateral stroke during follow-up, as well as the combined outcome of death or any stroke between randomisation and end of follow-up favoured endarterectomy. However, there was no significant difference in the rate of stroke in any territory, or ipsilateral stroke, if events occurring up to 30 days after treatment were excluded, despite a higher incidence of severe restenosis following endovascular treatment. These findings demonstrate that the lower net benefit of endovascular treatment in preventing strokes is attributable to a higher peri-procedural stroke risk. However, to date only a single randomised trial published event rates beyond five years after treatment (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>). Little is therefore known on the long-term durability of endovascular treatment beyond four years, especially with respect to restenosis and recurrent stroke rates.</P>
<P>Long-term restenosis rates were reported in six trials. There was a highly significant increase in severe restenosis after endovascular treatment compared with endarterectomy in the <LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK> trial, in which mostly balloon-angioplasty without stenting was used. The combined results of two large (<LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>) and three small trials (<LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK>; <LINK REF="STD-Regensburg-2008" TYPE="STUDY">Regensburg 2008</LINK>; <LINK REF="STD-Beijing-2009" TYPE="STUDY">Beijing 2009</LINK>) showed no significant increase in severe restenosis after primary stenting compared with endarterectomy, albeit with a wide confidence interval surrounding the effect measure and evidence of substantial heterogeneity (I² = 58%). There was also substantial heterogeneity in the pooled analysis of all six trials reporting restenosis (I² = 55%), in which the increase in restenosis with endovascular treatment was significant. The <LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK> trial reported that patients who had severe restenosis in the first year after treatment were at increased risk for the combined outcome of ipsilateral stroke or TIA, but not for ipsilateral stroke alone. The authors of the <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK> trial stated that there were too few events occurring during follow-up for a proper analysis of stroke risk following restenosis; no information on clinical consequences is available from the <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK> trial. At present, the available evidence does not rule out the possibility of a small increase in restenosis rates among patients receiving stent treatment compared with endarterectomy. Whether restenosis increases the risk of recurrent stroke remains unknown.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Do the rates of cranial nerve palsy and other vascular complications differ between endovascular treatment and endarterectomy?</HEADING>
<P>There is strong evidence that endovascular treatment less often causes cranial nerve palsy and access site haematoma, and some evidence that it is associated with a lower risk of myocardial infarction (MI) compared with endarterectomy. However, combining MI with death or stroke occurring up to 30 days after treatment, the comparison again favoured surgery.</P>
<P>Because non-disabling stroke may recover completely while cranial neuropathy may have disabling consequences for the patient, e.g. dysphagia requiring tube feeding, we analysed a combined outcome of death or neurological complications (including stroke and cranial nerve palsy) within 30 days of procedure. Fewer of these combined outcomes occurred among patients treated endovascularly, but the difference was not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Does stenting with cerebral protection devices have a lower rate of treatment-related ischaemic events than stenting without cerebral protection devices?</HEADING>
<P>No evidence from large scale randomised trials comparing stenting with the use of cerebral protection devices versus unprotected stenting is available to answer the question whether these devices are effective in reducing the risk of peri-procedural stroke. Three trials of primary stenting versus endarterectomy for symptomatic carotid stenosis included in this review had available outcome data regarding the use of cerebral protection devices. Substantial heterogeneity between the effects of protected versus unprotected stenting was present (I² = 78%). Overall, rates of death or stroke occurring within 30 days of stenting did not differ significantly between patients treated with and those treated without protection devices.</P>
<P>This finding seemingly contradicts an earlier systematic review of observational studies which found that the use of protection devices was associated with a lower stroke risk (<LINK REF="REF-Kastrup-2003" TYPE="REFERENCE">Kastrup 2003</LINK>). However, the studies included in the mentioned review often compared outcomes with protected stenting with historical controls of patients treated without protection devices (and thus might have been confounded by a learning curve effect), or were subject to other types of bias due to their non-randomised design. It also has to be noted that the use of protection devices in the trials included in the present review was not subject to randomisation either, and selection bias may be operating as well.</P>
<P>Two small randomised studies reported increases in the rate of ischaemic brain lesions detectable on magnetic resonance imaging (MRI) following protected compared with unprotected stenting (<LINK REF="REF-Barbato-2008" TYPE="REFERENCE">Barbato 2008</LINK>; <LINK REF="REF-Macdonald-2010" TYPE="REFERENCE">Macdonald 2010</LINK>). An increase in risk of MRI lesions with the use of protection devices was also observed in an indirect comparison in a substudy of the <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK> trial. One possible explanation for the discrepancy between the observational studies and the MRI data is that protection devices could protect against embolism during stent deployment, but cause emboli during insertion of the device. The current evidence provides no final answer to the question whether overall, protection devices prevent strokes or whether they may in fact be harmful.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Is endovascular treatment safe and effective in asymptomatic stenosis?</HEADING>
<P>The total number of study participants with asymptomatic carotid stenosis randomly assigned to endovascular treatment or endarterectomy included in this review amounted to less than one-fourth of the combined trial populations of patients with symptomatic stenosis. There was no significant difference between treatments in the primary safety outcome measure of death or any stroke occurring between randomisation and 30 days after treatment in asymptomatic patients. However, the odds ratio of 1.71 was almost identical to the odds ratio of 1.72 for the same comparison in symptomatic patients; the confidence interval surrounding the effect measure was very wide and compatible with a small decrease or a substantial increase in peri-procedural death or stroke with endovascular treatment in asymptomatic stenosis. Combining the safety outcome with ipsilateral stroke during follow-up left the treatment effect virtually unchanged.</P>
<P>The existing evidence therefore does not allow any firm conclusions on the comparative safety and efficacy of endovascular treatment versus endarterectomy in patients with asymptomatic carotid stenosis. The data urge caution and the results of ongoing large scale trials in patients with asymptomatic disease must therefore be awaited to answer the question whether stenting may be a safe and effective alternative to surgery (<LINK REF="STD-ACST_x002d_2" TYPE="STUDY">ACST-2</LINK>; <LINK REF="STD-ACT-I" TYPE="STUDY">ACT I</LINK>; <LINK REF="STD-SPACE_x002d_2" TYPE="STUDY">SPACE-2</LINK>). The question of whether any form of revascularisation is beneficial for asymptomatic patients in comparison to optimised medical treatment using current regimens is also an important question that is being addressed by ongoing trials (<LINK REF="STD-ECST_x002d_2" TYPE="STUDY">ECST-2</LINK>; <LINK REF="STD-SPACE_x002d_2" TYPE="STUDY">SPACE-2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Is endovascular treatment safe and effective in patients considered at increased surgical risk?</HEADING>
<P>A single trial compared stenting with endarterectomy in patients who were perceived to be at increased risk with surgery, based on cardio-pulmonary comorbidity, stenosis following previous endarterectomy or irradiation, or contralateral carotid occlusion (<LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK>). The results of this trial showed non-inferiority of stenting in terms of the primary endpoint death, stroke or MI occurring up to 30 days after treatment, or death or ipsilateral stroke in the first year after treatment. It has to be noted that the definition of myocardial infarction used in the primary analysis was based solely on the basis of elevated cardiac enzymes. Moreover, the combined outcome of death or any stroke in the peri-procedural period was not reported, and peri-procedural outcome events were not provided according to symptom status. Fewer than 30% of study participants had symptomatic stenosis and the trial included a heterogeneous group of patients with various conditions thought to increase the risk of endarterectomy, which makes it difficult to form conclusions about the appropriateness of revascularisation using stenting (or endarterectomy) within the various groups included in the trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Is endovascular treatment safe and effective in patients unsuitable for surgery?</HEADING>
<P>Only two very small trials were identified comparing carotid stenting with best medical care in patients not well enough to undergo surgery. There was substantial heterogeneity in treatment effects between them (I² = 79%). Although presented here, these results do not justify any conclusion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Are the results of this review applicable to clinical practice?</HEADING>
<P>Centres which took part in the trials included in this review had a specific interest in secondary prevention of stroke and care must be taken when extrapolating the data into routine clinical practice in less specialised centres. However, contrary concerns, that the unfavourable stroke rates observed in some of the trials was the consequence of including centres with insufficient experience with the procedure, have also been voiced (<LINK REF="REF-Forsting-2007" TYPE="REFERENCE">Forsting 2007</LINK>; <LINK REF="REF-Roffi-2010" TYPE="REFERENCE">Roffi 2010</LINK>). We therefore included a comparison of the primary safety outcome according to the number of endovascular procedures in the carotid artery interventionalists needed to have performed before joining the trials. Indeed, point estimates of odds ratios favoured surgery more strongly among trials which required 10 or fewer pre-trial procedures than among those requiring more. However, the interaction between the number of pre-trial procedures and treatment effect was not significant. Importantly, point estimates of effect measures still favoured endarterectomy among the trials with higher experience.</P>
<P>Previous data on the role of experience from some of these trials has been somewhat conflicting. In the <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK> study, centre-specific peri-procedural stroke or death rates in the stenting arm decreased with increasing total number of patients enrolled at the centres. The investigators of the <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK> trial analysed outcomes after stenting on the level of individual interventionalists according to the number of procedures they had performed before the trial. Somewhat unexpectedly, the complication rate was lowest in the least experienced group, perhaps because these investigators chose to randomise 'easier' cases and were required to have their initial experience supervised by another, more experienced, investigator. A previously published pooled analysis of individual patient data from <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>, <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK> and <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK> showed that the excess stroke or death risk associated with stenting was higher among centres enrolling fewer than 50 patients into the trial than in the larger centres, but again the confidence intervals of the effect measures in higher and lower recruiting centres overlapped widely and the risk of stenting was still higher than endarterectomy in the larger centres (<LINK REF="REF-CSTC-2010" TYPE="REFERENCE">CSTC 2010</LINK>). Thus, while it stands to reason that the risks of stenting will decline with experience, the current evidence does not suggest that the higher stroke rates associated with endovascular treatment observed in clinical trials is mainly explained by lack of experience at the centres included in the trials. We therefore consider that for those research questions for which there was sufficient evidence, the findings of this review are applicable to routine clinical practice.</P>
<P>The results of the <LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK> trial, which enrolled patients at increased surgical risk, are difficult to extrapolate into clinical practice, mostly because outcomes were not provided according to symptom status and due to the heterogeneous indications for inclusion in the trial. Many physicians may opt in favour of conservative treatment in these patients if they have asymptomatic carotid stenosis. For this reason, we decided against pooling data from the <LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK> trial with data from other trials.</P>
</SUBSECTION>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2012-06-25 16:32:57 +0100" MODIFIED_BY="Martin M Brown">
<P>With regard to the comparison of the primary safety outcome, there was moderate heterogeneity between treatment effects observed in contributing trials (I² = 27%) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). There was less evidence of heterogeneity between trials within the two analysed age subgroups (younger than 70 years: I² = 0%; 70 years or older: I² = 18%) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). Some of the heterogeneity observed in the main comparison might therefore be accounted for by differences in population age.</P>
<P>However, there are several other possible reasons for the heterogeneity of data between trials which were not formally examined. Firstly, the endovascular technique used was not the same for all the trials. We have included in the meta-analysis results obtained at the early stage of development of carotid endovascular treatment using methods no longer in widespread use (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>) or acquired before standardisation of the stenting technique (<LINK REF="STD-Leicester-1998" TYPE="STUDY">Leicester 1998</LINK>; <LINK REF="STD-Kentucky-2001" TYPE="STUDY">Kentucky 2001</LINK>; <LINK REF="STD-Wallstent-2001" TYPE="STUDY">Wallstent 2001</LINK>).</P>
<P>Heterogeneity may also have been caused by differences in baseline characteristics of the patients in the trials other than age. Differences in symptom status were addressed by performing separate comparisons for patients with symptomatic or asymptomatic stenosis where this was possible. Data from the <LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK>, which specifically selected patients if they were at high surgical risk, where separated from the other trials. However, although the CAVATAS protocol did not specify high risk as an inclusion criterion, comparison of baseline characteristics suggests that CAVATAS also selected a higher proportion of patients at high surgical risk compared to ECST and NASCET (<LINK REF="REF-NASCET-1991" TYPE="REFERENCE">NASCET 1991</LINK>; <LINK REF="REF-ECST-1998" TYPE="REFERENCE">ECST 1998</LINK>; <LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>). Furthermore, history of cardiovascular disease was more common in the <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK> trial (also among the subgroup of symptomatic patients), than in the large European trials (<LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>; <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>).</P>
<P>Heterogeneity may have arisen because we included both completed trials and trials which stopped recruitment before reaching the planned sample size: three trials were terminated early because of concerns over the safety of stenting (<LINK REF="STD-Leicester-1998" TYPE="STUDY">Leicester 1998;</LINK> <LINK REF="STD-Wallstent-2001" TYPE="STUDY">Wallstent 2001;</LINK> <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>), while four trials were stopped for other reasons (<LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>; <LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK>; <LINK REF="STD-Regensburg-2008" TYPE="STUDY">Regensburg 2008</LINK>).</P>
<P>The <LINK REF="STD-Leicester-1998" TYPE="STUDY">Leicester 1998</LINK> trial, which planned to enrol 300 patients, was suspended after referral to the Data Monitoring Committee who invoked the stopping rule. A total of 23 patients were randomised, 17 of whom received their allocated treatment. Five of the seven patients undergoing endovascular treatment had strokes (three of which were disabling at 30 days) compared with 10 uncomplicated carotid endarterectomies (P = 0.0034). The investigators subsequently felt that the trial could not be restarted even in an amended form primarily because of difficulties with informed consent. The <LINK REF="STD-Wallstent-2001" TYPE="STUDY">Wallstent 2001</LINK> trial was stopped after a total of 219 patients had been enrolled (planned sample size 700 patients). The primary endpoint was the cumulative occurrence of ipsilateral stroke, procedure-related death or vascular death within one year. It was reported that the primary end-point rate after approximately one year was 12.1% in the stenting group and 3.6% in the endarterectomy group (P = 0.022) and that the 30-day peri-procedural stroke or death rate was 12.1% for stenting and 4.4% for endarterectomy (P = 0.049). The decision to terminate the study was based on the data and a futility analysis. However, it has been reported that at a meeting of the American Stroke Association, the trial was criticised firstly because it was stopped by the sponsor, rather than by the Data Safety and Monitoring Board, even though the outcome in all patients had not been validated, and secondly because the competence and experience of those undertaking stenting was questioned (<LINK REF="REF-American-Stroke-Association" TYPE="REFERENCE">American Stroke Association</LINK>). As we have not yet obtained detailed data for this study we can make no further assessment of its quality at this time. The (<LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>) trial was stopped by the Safety Committee after 527 patients had been randomised due to safety and futility concerns. The 30-day peri-procedural stroke or death rate was 9.6% in the stenting arm and 3.9% in the endarterectomy arm (P = 0.01). This non-inferiority trial originally planned to enrol 827 patients. However, based on the observed risks, 4000 patients would have been necessary to demonstrate non-inferiority of stenting with the predefined margin of a 2% absolute difference in 30-day stroke or death rates. The <LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK> trial did not specify a target sample size. Instead, it was planned to terminate the trial as soon as a non-inferiority margin of 3% absolute difference in either the 30-day death, stroke or MI rate (in all patients), or in the primary endpoint which also included ipsilateral stroke or death from neurological causes up to one year after treatment (in those patients followed-up for one year) could be demonstrated. However, randomisation was stopped after 334 patients in early 2002, citing an abrupt fall in the enrolment rate as the number of patients receiving stent treatment in non-randomised registries increased. The <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK> trial originally planned to include 1900 patients; the Steering Committee stopped the trial after two interim analyses (one at 950 patients and one at 1200 patients), which revealed that more than 2500 patients would have been necessary to demonstrate non-inferiority of stenting with the predefined margin of 2.5% absolute difference in the primary outcome measure (death or ipsilateral ischaemic stroke between randomisation and 30 days after treatment), also considering the lack of further funding. Two small single-centre studies were terminated when the large multicentre trials started recruitment: <LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK> was stopped after randomising 20 patients, when the centre joined <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>; the <LINK REF="STD-Regensburg-2008" TYPE="STUDY">Regensburg 2008</LINK> study ended randomisation after 87 of the 200 originally planned patients upon initiation of the <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK> trial.</P>
<P>Despite evidence of moderate heterogeneity in the comparison of the primary safety outcome and substantial heterogeneity in some of the secondary analyses, we feel that the quality of the evidence was sufficient to address the principal research questions of this review.</P>
</QUALITY_OF_EVIDENCE>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-06-25 16:32:58 +0100" MODIFIED_BY="Martin M Brown">
<IMPLICATIONS_PRACTICE MODIFIED="2012-03-16 13:11:25 +0000" MODIFIED_BY="Martin M Brown">
<P>Symptomatic carotid stenosis should not be routinely treated with carotid stenting in patients above the age of 70, provided the patients are fit and willing to undergo surgery, and endarterectomy can be performed at standard risk. Stenting may be offered as an alternative to endarterectomy to patients with symptomatic stenosis who are younger than 70 years at centres achieving peri-procedural stroke or death rates in this age group comparable to those with endarterectomy. Factors such as patients' preference, cardiovascular risk and vascular anatomy may also be taken into consideration in the choice between the two procedures.</P>
<P>Stenting may be considered in patients with symptomatic carotid stenosis deemed to require revascularisation in whom surgery is contraindicated, associated with a high risk of complications, or technically not feasible, so long as the risk of recurrent symptoms with optimised medical treatment alone is considered greater than the risk of the stenting procedure. However, in these patients randomised trial data are sparse and the optimal management is often unclear.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-06-25 16:32:58 +0100" MODIFIED_BY="Martin M Brown">
<P>There is insufficient data to justify stenting as an alternative to endarterectomy for asymptomatic carotid stenosis, but the existing data support the continuing inclusion of patients with asymptomatic carotid stenosis thought to require revascularisation in randomised clinical trials comparing stenting versus endarterectomy (<LINK REF="STD-ACST_x002d_2" TYPE="STUDY">ACST-2</LINK>; <LINK REF="STD-ACT-I" TYPE="STUDY">ACT I</LINK>).If the clinician is uncertain whether revascularisation provides benefit over optimised medical treatment alone, patients should be randomised in the <LINK REF="STD-SPACE_x002d_2" TYPE="STUDY">SPACE-2</LINK> trial comparing stenting versus endarterectomy versus best medical treatment alone, or in <LINK REF="STD-ECST_x002d_2" TYPE="STUDY">ECST-2</LINK> comparing revascularisation (by endarterectomy or stenting) versus best medical treatment alone for asymptomatic or low-to-intermediate risk symptomatic stenosis.</P>
<P>In addition, more data on long-term follow-up in patients with symptomatic or asymptomatic stenosis included in ongoing clinical trials are needed, particularly to assess whether the high rate of restenosis after endovascular treatment observed in <LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK> is representative of more modern techniques of stenting as well, and to answer the question whether restenosis increases the risk of late recurrent stroke.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-06-06 12:05:42 +0100" MODIFIED_BY="Martin M Brown">
<P>We would like to thank Mrs Hazel Fraser and Mrs Brenda Thomas at the Cochrane Stroke Group for searching the trials register and for help in defining the search strategy. We would like to acknowledge Dr Francesca Crawley and Dr Lucy Coward, the first authors of the first two versions of this review.</P>
<P>Dr Leo Bonati was supported in part by grants from the Swiss National Science Foundation (PBBSB-116873), the University of Basel, Switzerland, and The Stroke Association. Dr Jörg Ederle's and Dr Roland Featherstone's posts were funded by the Medical Research Council. Professor Martin Brown's Chair in Stroke Medicine is supported by The Reta Lila Weston Trust for Medical Research. Part of this work was undertaken at University College London Hospital/University College London, which received a proportion of funding from the Department of Health&#8217;s National Institute of Health Research Biomedical Research Centres funding scheme. This revision was funded in part by a Cochrane Review Incentive Scheme grant from NIHR.</P>
<P>If anyone is aware of completed or ongoing trials of carotid angioplasty and stenting not included in this review, please contact Professor Brown.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-07-23 14:43:30 +0100" MODIFIED_BY="Martin M Brown">
<P>The review authors are involved with two completed trials (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-CAVATAS_x002d_MED-2009" TYPE="STUDY">CAVATAS-MED 2009</LINK>) and two ongoing trials (<LINK REF="STD-ECST_x002d_2" TYPE="STUDY">ECST-2</LINK>; <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>) included in this systematic review. Leo H Bonati was a member of the ICSS writing committee. He contributed to the analysis of data in ICSS and CAVATAS, and is a member of the ECST-2 steering committee. Philippe Lyrer was involved as local principal investigator (PI) for the ICSS and CAVATAS trials. He was a member of the steering committee as well as PI in the BACASS trial. Jörg Ederle was also involved in the analysis and publication of ICSS. Roland Featherstone was the trial manager for ICSS and contributed to the analysis of data in ICSS and CAVATAS. He is also the Trial Manager and a member of the steering committee for ECST-2. Martin Brown was the chief investigator of two completed trials (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-CAVATAS_x002d_MED-2009" TYPE="STUDY">CAVATAS-MED 2009</LINK>) and two ongoing trials (<LINK REF="STD-ECST_x002d_2" TYPE="STUDY">ECST-2</LINK>; <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>).</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-10-30 22:13:04 +0000" MODIFIED_BY="Leo H Bonati">
<P>LHB and RF selected studies for inclusion in this review. LHB and PL extracted outcome data. LHB drafted the review. JE was the first author of the previous version of this review and critically reviewed the manuscript. MMB contributed to the critical revision of the review and gave final approval of the version to be published.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-06-06 12:07:15 +0100" MODIFIED_BY="Leo H Bonati">
<P>In the current update, outcome measures were separated into primary ones reflecting the main research questions as specified in the original version of this review (<LINK REF="REF-Crawley-1997" TYPE="REFERENCE">Crawley 1997</LINK>), and secondary ones reflecting additional research questions stated in the original version or added during previous updates (<LINK REF="REF-Coward-2004" TYPE="REFERENCE">Coward 2004</LINK>; <LINK REF="REF-Ederle-2007" TYPE="REFERENCE">Ederle 2007</LINK>). According to the original version of this review, the primary outcome measure to evaluate treatment safety was defined as death or any stroke occurring in the peri-procedural period. In order to allow an intention-to-treat approach, i.e. including outcomes in all patients who were randomised and subsequently followed in the contributing trials and comparing outcomes according to the randomly assigned treatment, we defined the peri-procedural period as the period between randomisation and 30 days after treatment (or 30 days after randomisation in patients not receiving treatment), in the current update. Hence, there were small differences in numbers of outcome events for some of the included trials between the current update and the previous version of this review. We defined the combined primary safety and long-term efficacy outcome measure as death or any stroke occurring in the peri-procedural period, or ipsilateral stroke thereafter, because this outcome could be extracted from all large trials included in this review. Myocardial infarction was added as a separate peri-procedural outcome measure.</P>
<P>The objectives of this review have been amended to include comparisons of outcomes according to age and sex. Individual patient data were extracted directly from the databases of five trials (<LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>; <LINK REF="STD-EVA_x002d_3S-2006" TYPE="STUDY">EVA-3S 2006</LINK>; <LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>; <LINK REF="STD-BACASS-2008" TYPE="STUDY">BACASS 2008</LINK>; <LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>) and from published results of one additional trial (<LINK REF="STD-Leicester-1998" TYPE="STUDY">Leicester 1998</LINK>), in order to perform subgroup analysis according to age. For subgroup analysis according to sex, data from these trials as well as published sex-specific summary data from <LINK REF="STD-CREST-2010" TYPE="STUDY">CREST 2010</LINK> were used.</P>
<P>In the previous update, the aim of investigating the presence of a learning curve effect (i.e. any change in event rates over time) was added. However, both at the time of the last and the current update, data on complication rates on the level of individual collaborators was insufficient to allow for a meta-analysis. Instead, we performed a comparison of the primary safety outcome according to the level of pre-trial experience in endovascular treatment required in the trials.</P>
<P>Data from one trial (<LINK REF="STD-SAPPHIRE-2004" TYPE="STUDY">SAPPHIRE 2004</LINK>) were separated from the other trials, because unlike all the other trials, this trial enrolled patients considered at increased risk for complications from surgery.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-06-25 16:34:56 +0100" MODIFIED_BY="Leo H Bonati">
<STUDIES MODIFIED="2012-06-25 16:34:23 +0100" MODIFIED_BY="Leo H Bonati">
<INCLUDED_STUDIES MODIFIED="2012-06-25 16:28:54 +0100" MODIFIED_BY="Leo H Bonati">
<STUDY DATA_SOURCE="PUB" ID="STD-BACASS-2008" MODIFIED="2012-06-17 11:54:15 +0100" MODIFIED_BY="Leo H Bonati" NAME="BACASS 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-06-17 11:54:15 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoffmann A, Engelter S, Taschner C, Mendelowitsch A, Merlo A, Radue EW, et al</AU>
<TI>Carotid artery stenting versus carotid endarterectomy - a prospective randomised controlled single-centre trial with long-term follow up (BACASS)</TI>
<SO>Schweizer Archiv für Neurologie und Psychiatrie</SO>
<YR>2008</YR>
<VL>159</VL>
<PG>84-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beijing-2003" MODIFIED="2012-06-06 14:09:49 +0100" MODIFIED_BY="Leo H Bonati" NAME="Beijing 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-06-06 14:09:49 +0100" MODIFIED_BY="Leo H Bonati" NOTES="&lt;p&gt;PT - Journal; Article&lt;/p&gt;" NOTES_MODIFIED="2012-06-06 14:09:49 +0100" NOTES_MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao XL, Jia JP, Ji XM, Peng M, Ling F</AU>
<TI>A follow-up: stroke in patients with bilateral severe carotid stenosis after intervention treatment</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2003</YR>
<VL>7</VL>
<NO>19</NO>
<PG>2714-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beijing-2009" MODIFIED="2012-06-06 14:10:07 +0100" MODIFIED_BY="Leo H Bonati" NAME="Beijing 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-06-06 14:10:07 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu CW, Liu B, Ye W, Wu WW, Li YJ, Zheng YH, et al</AU>
<TI>Carotid endarterectomy versus carotid stenting: a prospective randomized trial</TI>
<SO>Zhonghua Wai Ke Za Zhi</SO>
<YR>2009</YR>
<VL>47</VL>
<NO>4</NO>
<PG>267-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CAVATAS_x002d_CEA-2001" MODIFIED="2012-06-06 14:11:08 +0100" MODIFIED_BY="Leo H Bonati" NAME="CAVATAS-CEA 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-06-06 14:10:28 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonati LH, Ederle J, McCabe DJ, Dobson J, Featherstone RL, Gaines PA; CAVATAS Investigators</AU>
<TI>Long-term risk of carotid restenosis in patients randomly assigned to endovascular treatment or endarterectomy in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): long-term follow-up of a randomised trial</TI>
<SO>Lancet Neurology</SO>
<YR>2009</YR>
<VL>8</VL>
<NO>10</NO>
<PG>908-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-26 13:28:59 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown MM</AU>
<TI>Carotid And Vertebral Artery Transluminal Angioplasty Study</TI>
<SO>Stroke</SO>
<YR>1994</YR>
<VL>25</VL>
<PG>542</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-09-22 10:19:53 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>CAVATAS Investigators</AU>
<TI>CAVATAS - Carotid and Vertebral Artery Transluminal Angioplasty Study</TI>
<SO>Unpublished protocol</SO>
<YR>February 2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-26 13:30:50 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>CAVATAS Investigators</AU>
<TI>Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomised trial</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<NO>9270</NO>
<PG>1729-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-06 14:11:08 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ederle J, Bonati LH, Dobson J, Featherstone RL, Gaines PA, Beard JD; CAVATAS Investigators</AU>
<TI>Endovascular treatment with angioplasty or stenting versus endarterectomy in patients with carotid artery stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): long-term follow-up of a randomised trial</TI>
<SO>Lancet Neurology</SO>
<YR>2009</YR>
<VL>8</VL>
<NO>10</NO>
<PG>898-907</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CAVATAS_x002d_MED-2009" MODIFIED="2012-06-06 14:11:21 +0100" MODIFIED_BY="Leo H Bonati" NAME="CAVATAS-MED 2009" YEAR="2007">
<REFERENCE MODIFIED="2012-06-06 14:11:21 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ederle J, Featherstone RL, Brown MM; CAVATAS Collaborators</AU>
<TI>Long-term outcome of endovascular treatment versus medical care for carotid artery stenosis in patients not suitable for surgery and randomised in the Carotid and Vertebral Artery Transluminal Angioplasty study (CAVATAS)</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>1</NO>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CREST-2010" MODIFIED="2012-06-17 11:56:01 +0100" MODIFIED_BY="Leo H Bonati" NAME="CREST 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-06-06 14:12:02 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brott TG, Hobson RW, Howard G, Roubin GS, Clark WM, Brooks W; CREST Investigators</AU>
<TI>Stenting versus endarterectomy for treatment of carotid-artery stenosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2010</YR>
<VL>363</VL>
<NO>1</NO>
<PG>11-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-26 13:33:10 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hobson RW 2nd</AU>
<TI>CREST (Carotid Revascularization Endarterectomy versus Stent Trial): background, design, and current status</TI>
<SO>Seminars in Vascular Surgery</SO>
<YR>2000</YR>
<VL>13</VL>
<NO>2</NO>
<PG>139-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-02-15 14:04:18 +0000" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hobson RW</AU>
<TI>Update on the carotid revascularization endarterectomy versus stent trial (CREST) protocol</TI>
<SO>Journal of the American College of Surgeons</SO>
<YR>2002</YR>
<VL>194</VL>
<NO>S1</NO>
<PG>9-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-06 14:12:28 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Howard VJ, Lutsep HL, Mackey A, Demaerschalk BM, Sam AD 2nd, Gonzales NR; CREST investigators</AU>
<TI>Influence of sex on outcomes of stenting versus endarterectomy: a subgroup analysis of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST)</TI>
<SO>Lancet Neurology</SO>
<YR>2011</YR>
<VL>10</VL>
<NO>6</NO>
<PG>530-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-17 11:56:01 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sheffet AJ, Roubin G, Howard G, Howard V, Moore W, Meschia JF, et al</AU>
<TI>Design of the Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST)</TI>
<SO>International Journal of Stroke</SO>
<YR>2010</YR>
<VL>5</VL>
<NO>1</NO>
<PG>40-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-06 14:12:56 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silver FL, Mackey A, Clark WM, Brooks W, Timaran CH, Chiu D; CREST Investigators</AU>
<TI>Safety of stenting and endarterectomy by symptomatic status in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)</TI>
<SO>Stroke</SO>
<YR>2011</YR>
<VL>42</VL>
<NO>3</NO>
<PG>675-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EVA_x002d_3S-2006" MODIFIED="2012-06-06 14:14:27 +0100" MODIFIED_BY="Leo H Bonati" NAME="EVA-3S 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-06-06 14:13:09 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arquizan C, Trinquart L, Touboul PJ, Long A, Feasson S, Terriat B; EVA-3S Investigators</AU>
<TI>Restenosis is more frequent after carotid stenting than after endarterectomy: the EVA-3S study</TI>
<SO>Stroke</SO>
<YR>2011</YR>
<VL>42</VL>
<NO>4</NO>
<PG>1015-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-13 13:42:24 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>EVA-3S Investigators</AU>
<TI>Carotid angioplasty and stenting with and without cerebral protection: clinical alert from the Endarterectomy Versus Angioplasty in patients with Symptomatic Severe carotid Stenosis (EVA-3S) trial</TI>
<SO>Stroke</SO>
<YR>2004</YR>
<VL>35</VL>
<NO>1</NO>
<PG>e18-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-13 13:41:37 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>EVA-3S Investigators</AU>
<TI>Endarterectomy Versus Angioplasty in patients with Symptomatic Severe carotid Stenosis (EVA-3S) trial</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>1</NO>
<PG>62-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-06 14:13:43 +0100" MODIFIED_BY="Leo H Bonati" NOTES="&lt;p&gt;Cochrane ID: CN-00568452 PUBMED 17050890 Record Available: http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/452/CN-00568452/frame.html Journal Article Multicenter Study Randomized Controlled Trial UNIT: NEW&amp;#182;&lt;/p&gt;" NOTES_MODIFIED="2012-06-06 14:13:43 +0100" NOTES_MODIFIED_BY="Leo H Bonati" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mas JL, Chatellier G, Beyssen B, Branchereau A, Moulin T, Becquemin JP; EVA-3S Investigators</AU>
<TI>Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>355</VL>
<NO>16</NO>
<PG>1660-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-06 14:14:07 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mas JL, Chatellier G; EVA-3S Investigators</AU>
<TI>Endarterectomy versus stenting for carotid stenosis - authors' reply</TI>
<SO>New England Journal of Medicine</SO>
<YR>2007</YR>
<VL>356</VL>
<NO>3</NO>
<PG>306-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-06 14:14:27 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mas JL, Trinquart L, Leys D, Albucher JF, Rousseau H, Viguier A; EVA-3S Investigators</AU>
<TI>Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: results up to 4 years from a randomised, multicentre trial</TI>
<SO>Lancet Neurology</SO>
<YR>2008</YR>
<VL>7</VL>
<NO>10</NO>
<PG>885-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ICSS-2010" MODIFIED="2012-06-06 14:15:10 +0100" MODIFIED_BY="Leo H Bonati" NAME="ICSS 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-06-06 14:14:46 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonati LH, Jongen LM, Haller S, Flach HZ, Dobson J, Nederkoorn PJ; ICSS MRI study group</AU>
<TI>New ischaemic brain lesions on MRI after stenting or endarterectomy for symptomatic carotid stenosis: a substudy of the International Carotid Stenting Study (ICSS)</TI>
<SO>Lancet Neurology</SO>
<YR>2010</YR>
<VL>9</VL>
<NO>4</NO>
<PG>353-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-02-15 13:58:32 +0000" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Featherstone RL, Brown MM, Coward LJ; ICSS Investigators</AU>
<TI>International carotid stenting study: protocol for a randomised clinical trial comparing carotid stenting with endarterectomy in symptomatic carotid artery stenosis</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>1</NO>
<PG>69-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-06 14:15:03 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="OTHER">
<TI>ICSS - International Carotid Stenting Study; Protocol Version 3.2</TI>
<SO>http://www.ion.ucl.ac.uk/cavatas_icss/protocol.pdf</SO>
<YR>22 November 2007 (last accessed 15 April 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-06 14:15:10 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>International Carotid Stenting Study investigators</AU>
<TI>Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2010</YR>
<VL>375</VL>
<NO>9719</NO>
<PG>985-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kentucky-2001" MODIFIED="2012-06-25 16:28:54 +0100" MODIFIED_BY="Leo H Bonati" NAME="Kentucky 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-06-25 16:28:54 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brooks WH, McClure RR, Jones MR, Coleman TC, Breathitt L</AU>
<TI>Carotid angioplasty and stenting versus carotid endarterectomy: randomized trial in a community hospital</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2001</YR>
<VL>38</VL>
<NO>6</NO>
<PG>1589-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kentucky-2004" MODIFIED="2012-06-06 14:15:18 +0100" MODIFIED_BY="Leo H Bonati" NAME="Kentucky 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-06-06 14:15:18 +0100" MODIFIED_BY="Leo H Bonati" NOTES="&lt;p&gt;J English Article Brooks, WH, Neurosurg Associates, 1401 Harrodsburg Rd, Lexington, KY 40505 USA Neuromence@aol.com 61 22 LIPPINCOTT WILLIAMS &amp;amp; WILKINS PHILADELPHIA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA NEUROSURGERY FEB Discipline: Clinical Neurology; Surgery 771XE&amp;#182;&lt;/p&gt;" NOTES_MODIFIED="2012-06-06 14:15:18 +0100" NOTES_MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brooks WH, McClure RR, Jones MR, Coleman TL, Breathitt L</AU>
<TI>Carotid angioplasty and stenting versus carotid endarterectomy for treatment of asymptomatic carotid stenosis: a randomized trial in a community hospital</TI>
<SO>Neurosurgery</SO>
<YR>2004</YR>
<VL>54</VL>
<NO>2</NO>
<PG>318-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leicester-1998" MODIFIED="2012-04-26 13:36:25 +0100" MODIFIED_BY="Leo H Bonati" NAME="Leicester 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Naylor A, Bell P, Bolia A, Abbott R, Pye I, Robertson I, et al</AU>
<TI>A randomised controlled study to compare carotid endarterectomy with protected carotid angioplasty</TI>
<SO>Unpublished protocol</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-26 13:36:25 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Naylor AR, Bolia A, Abbott RJ, Pye IF, Smith J, Lennard N, et al</AU>
<TI>Randomized study of carotid angioplasty and stenting versus carotid endarterectomy: a stopped trial</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1998</YR>
<VL>28</VL>
<NO>2</NO>
<PG>326-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Regensburg-2008" MODIFIED="2012-06-06 14:16:05 +0100" MODIFIED_BY="Leo H Bonati" NAME="Regensburg 2008" YEAR="2000">
<REFERENCE MODIFIED="2012-04-21 23:06:24 +0100" MODIFIED_BY="Leo H Bonati" NOTES="&lt;p&gt;J German Article Link, J, Univ Klinikum Regensburg, Inst Rontgendiagnost, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany 26 8 SPRINGER-VERLAG NEW YORK 175 FIFTH AVE, NEW YORK, NY 10010 USA RADIOLOGE SEP Discipline: Radiology, Nuclear Medicine &amp;amp; Medical Imaging 359JD&amp;#182;&lt;/p&gt;" NOTES_MODIFIED="2012-04-21 23:06:24 +0100" NOTES_MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Link J, Manke C, Rosin L, Borisch I, Topel I, Horn M, et al</AU>
<TI>Carotid endarterectomy and carotid stenting. Pilot study of a prospective, randomized and controlled comparison</TI>
<TO>Karotisendarterektomie und Karotisstenting. Pilotstudie eines prospektiven, randomisierten und kontrollierten Vergleichs</TO>
<SO>Radiologe</SO>
<YR>2000</YR>
<VL>40</VL>
<NO>9</NO>
<PG>813-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-06 14:16:05 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Steinbauer MG, Pfister K, Greindl M, Schlachetzki F, Borisch I, Schuirer G, et al.</AU>
<TI>Alert for increased long-term follow-up after carotid artery stenting: results of a prospective, randomized, single-center trial of carotid artery stenting vs carotid endarterectomy</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2008</YR>
<VL>48</VL>
<NO>1</NO>
<PG>93-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SAPPHIRE-2004" MODIFIED="2012-06-06 14:17:16 +0100" MODIFIED_BY="Leo H Bonati" NAME="SAPPHIRE 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-06-06 14:16:32 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gurm HS, Yadav JS, Fayad P, Katzen BT, Mishkel GJ, Bajwa TK; SAPPHIRE Investigators</AU>
<TI>Long-term results of carotid stenting versus endarterectomy in high-risk patients</TI>
<SO>New England Journal of Medicine</SO>
<YR>2008</YR>
<VL>358</VL>
<NO>15</NO>
<PG>1572-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-06 14:16:52 +0100" MODIFIED_BY="Hazel Fraser" NOTES="&lt;p&gt;J English Article Yadav, JS, Cleveland Clin Fdn, Desk F25,9500 Euclid Ave, Cleveland, OH 44195 USA yadavj@ccf.org 32 285 MASSACHUSETTS MEDICAL SOC WALTHAM WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA N ENGL J MED OCT 7 Discipline: Medicine, General &amp;amp; Internal 859UP&amp;#182;&lt;/p&gt;" NOTES_MODIFIED="2012-06-06 14:16:52 +0100" NOTES_MODIFIED_BY="Hazel Fraser" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yadav JS, Wholey MH, Kuntz RE, Fayad P, Katzen BT, Mishkel GJ; Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy Investigators</AU>
<TI>Protected carotid-artery stenting versus endarterectomy in high-risk patients</TI>
<SO>New England Journal of Medicine</SO>
<YR>2004</YR>
<VL>351</VL>
<NO>15</NO>
<PG>1493-501</PG>
<IDENTIFIERS MODIFIED="2008-09-22 14:30:25 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-06 14:17:16 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yadav JS</AU>
<TI>Carotid stenting in high-risk patients: design and rationale of the SAPPHIRE trial</TI>
<SO>Cleveland Clinical Journal of Medicine</SO>
<YR>2004</YR>
<VL>71 Suppl 1</VL>
<PG>S45-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Yadav, J</AU>
<TI>SAPPHIRE</TI>
<SO>American Heart Association Scientific Session</SO>
<YR>November 2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SPACE-2006" MODIFIED="2012-06-17 11:59:56 +0100" MODIFIED_BY="Leo H Bonati" NAME="SPACE 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-06-17 11:59:56 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eckstein HH, Ringleb P, Allenberg JR, Berger J, Fraedrich G, Hacke W, et al</AU>
<TI>Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial</TI>
<SO>Lancet Neurology</SO>
<YR>October 2008</YR>
<VL>7</VL>
<NO>10</NO>
<PG>893-902</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-19 14:01:57 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fiehler J, Jansen O, Berger J, Eckstein HH, Ringleb PA, Stingele R</AU>
<TI>Differences in complication rates among the centres in the SPACE study</TI>
<SO>Neuroradiology</SO>
<YR>2008</YR>
<VL>50</VL>
<NO>12</NO>
<PG>1049-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-06 14:18:17 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ringleb PA, Kunze A, Allenberg JR, Hennerici MG, Jansen O, Maurer PC; Steering Committee of the SPACE Study</AU>
<TI>The Stent-Supported Percutaneous Angioplasty of the Carotid Artery vs. Endarterectomy Trial</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>1</NO>
<PG>66-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-26 13:39:21 +0100" MODIFIED_BY="Leo H Bonati" NOTES="&lt;p&gt;J English Article Hacke, W, Univ Heidelberg, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany Neurologie@med.uni-heidelberg.de 27 2 LANCET LTD LONDON 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND LANCET OCT 7 Discipline: Medicine, General &amp;amp; Internal 091WF&amp;#182;&lt;/p&gt;" NOTES_MODIFIED="2012-04-26 13:39:21 +0100" NOTES_MODIFIED_BY="Leo H Bonati" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>SPACE Collaborative Group</AU>
<TI>30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>368</VL>
<NO>9543</NO>
<PG>1239-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TESCAS_x002d_C-2006" MODIFIED="2012-04-26 13:39:48 +0100" MODIFIED_BY="Leo H Bonati" NAME="TESCAS-C 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-04-26 13:39:48 +0100" MODIFIED_BY="Leo H Bonati" NOTES="&lt;p&gt;2006067256 Chinese Journal: Article 200608&amp;#182;&lt;/p&gt;" NOTES_MODIFIED="2012-04-26 13:39:48 +0100" NOTES_MODIFIED_BY="Leo H Bonati" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ling F, Jiao LQ</AU>
<TI>Preliminary report of trial of endarterectomy versus stenting for the treatment of carotid atherosclerotic stenosis in China (TESCAS-C)</TI>
<SO>Chinese Journal of Cerebrovascular Diseases</SO>
<YR>2006</YR>
<VL>3</VL>
<NO>1</NO>
<PG>4-8</PG>
<IDENTIFIERS MODIFIED="2008-09-22 14:30:43 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<REFERENCE MODIFIED="2011-09-22 10:29:33 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="OTHER">
<TI>TESCAS-C (Ling) study, 2006</TI>
<SO>http://www.trialresultscenter.org/study8539-TESCAS-C-</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Wallstent-2001" MODIFIED="2012-06-06 14:18:57 +0100" MODIFIED_BY="Leo H Bonati" NAME="Wallstent 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-06-06 14:18:57 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alberts MJ, McCann R, Smith TP, Stack R, Roubin G, Schneck M; Schneider WALLSTENT Endoprosthesis Clinical Investigators</AU>
<TI>A randomized trial of carotid stenting versus endarterectomy in patients with symptomatic carotid stenosis: study design</TI>
<SO>Journal of Neurovascular Disease</SO>
<YR>1997</YR>
<VL>2</VL>
<NO>6</NO>
<PG>228-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-26 13:41:48 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alberts MJ</AU>
<TI>Results of a multicentre prospective randomized trial of carotid artery stenting vs carotid endarterectomy</TI>
<SO>Stroke</SO>
<YR>2001</YR>
<VL>32</VL>
<PG>325</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-29 11:13:35 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="OTHER">
<TI>WALLSTENT</TI>
<SO>http://controlled-trials.com/mrct/trial/WALLSTENT/1026/5243.html</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2012-06-25 16:34:23 +0100" MODIFIED_BY="Leo H Bonati">
<STUDY DATA_SOURCE="PUB" ID="STD-ACST_x002d_2" MODIFIED="2012-06-06 14:20:19 +0100" MODIFIED_BY="Leo H Bonati" NAME="ACST-2" YEAR="2006">
<REFERENCE MODIFIED="2012-04-30 10:14:27 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="OTHER">
<TI>Asymptomatic CarotidSurgery Trial (ACST-2) - A large, simple randomised trial to compare carotid endarterectomy versus carotid artery stenting to prevent stroke (complete trial protocol)</TI>
<SO>www.acst.org.uk</SO>
<YR>(last accessed July 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-06 14:20:19 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="OTHER">
<TI>Carotid endarterectomy versus carotid artery stenting in asymptomatic patients (ACST-2)</TI>
<SO>www.clinicaltrials.gov</SO>
<YR>(last accessed 12 April 2011, last updated 4 April 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-06 14:19:42 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rudarakanchana N, Dialynas M, Halliday A</AU>
<TI>Asymptomatic Carotid Surgery Trial-2 (ACST-2): rationale for a randomised clinical trial comparing carotid endarterectomy with carotid artery stenting in patients with asymptomatic carotid artery stenosis</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>2</NO>
<PG>239-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-ACT-I" MODIFIED="2012-06-06 14:21:02 +0100" MODIFIED_BY="Leo H Bonati" NAME="ACT I" YEAR="">
<REFERENCE MODIFIED="2012-06-06 14:20:34 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="YES" TYPE="OTHER">
<TI>Asymptomatic Carotid Trial 1 (ACT1)</TI>
<SO>www.act1trial.com</SO>
<YR>(last accessed 12 April 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-06 14:21:02 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="OTHER">
<TI>Carotid stenting vs surgery of severe carotid artery disease and stroke prevention in asymptomatic patients (ACT I)</TI>
<SO>www.clinicaltrials.gov</SO>
<YR>(last accessed 12 April 2011, last updated 18 October 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Agostoni" MODIFIED="2012-04-26 13:44:12 +0100" MODIFIED_BY="Leo H Bonati" NAME="Agostoni" YEAR="2005">
<REFERENCE MODIFIED="2012-04-26 13:44:12 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Agostoni E, Beghi E, Pappada G, Marina R, Ferrarese C</AU>
<TI>Early invasive treatment (endarterectomy vs stenting) of moderate-to-severe carotid stenosis in patients with transient ischaemic attack or minor stroke</TI>
<SO>Neurological Sciences</SO>
<YR>2005</YR>
<VL>26 Suppl 1</VL>
<PG>S31-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-AMTEC" MODIFIED="2011-09-22 10:31:34 +0100" MODIFIED_BY="Leo H Bonati" NAME="AMTEC" YEAR="2009">
<REFERENCE MODIFIED="2011-09-22 10:31:34 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="OTHER">
<TI>Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis (AMTEC)</TI>
<SO>www.clinicaltrials.gov</SO>
<YR>(last accessed 12 April 2011, last updated February 24, 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carmel-Medical-Center" MODIFIED="2012-06-06 14:21:41 +0100" MODIFIED_BY="Leo H Bonati" NAME="Carmel Medical Center" YEAR="2009">
<REFERENCE MODIFIED="2012-06-06 14:21:41 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="OTHER">
<TI>Comparing carotid stenting with endarterectomy in severe asymptomatic carotid stenosis</TI>
<SO>www.clinicaltrials.gov</SO>
<YR>(last accessed 12 April 2011, last updated 31 October 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ECST_x002d_2" MODIFIED="2011-09-22 10:31:56 +0100" MODIFIED_BY="Leo H Bonati" NAME="ECST-2" YEAR="2011">
<REFERENCE MODIFIED="2011-09-22 10:31:56 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="OTHER">
<TI>The 2nd European Carotid Surgery Trial (ECST-2); protocol summary</TI>
<SO>www.ion.ucl.ac.uk/cavatas_icss/ECST2/index2.htm</SO>
<YR>(last accessed 13 April 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SPACE_x002d_2" MODIFIED="2012-06-25 16:34:23 +0100" MODIFIED_BY="Leo H Bonati" NAME="SPACE-2" YEAR="2009">
<REFERENCE MODIFIED="2012-06-25 16:34:23 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Reiff T, Stingele R, Eckstein HH, Fraedrich G, Jansen O, Mudra H, et al; SPACE2-Study Group</AU>
<TI>Stent-protected angioplasty in asymptomatic carotid artery stenosis vs endarterectomy: SPACE2 - a three-arm randomised-controlled clinical trial</TI>
<SO>International Journal of Stroke</SO>
<YR>2009</YR>
<VL>4</VL>
<NO>4</NO>
<PG>294-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-06 14:23:11 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="OTHER">
<TI>SPACE-2: Stent-Protected angioplasty in Asymptomatic Carotid artery stenosis vs Endarterectomy - a three-arm clinical trial (clinical trial protocol)</TI>
<SO>www.space-2.de</SO>
<YR>(last accessed 12 April 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vienna-General-Hospital" MODIFIED="2012-06-06 14:23:37 +0100" MODIFIED_BY="Leo H Bonati" NAME="Vienna General Hospital" YEAR="2005">
<REFERENCE MODIFIED="2012-06-06 14:23:37 +0100" MODIFIED_BY="Leo H Bonati" PRIMARY="NO" TYPE="OTHER">
<TI>Stenting versus best medical treatment of asymptomatic high grade carotid artery stenosis</TI>
<SO>www.clinicaltrials.gov</SO>
<YR>(last accessed 13 April 2011; last updated July 11 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-06-25 16:34:56 +0100" MODIFIED_BY="Leo H Bonati">
<ADDITIONAL_REFERENCES MODIFIED="2012-06-25 16:34:56 +0100" MODIFIED_BY="Leo H Bonati">
<REFERENCE ID="REF-ACAS-1995" MODIFIED="2012-04-26 13:45:48 +0100" MODIFIED_BY="Leo H Bonati" NAME="ACAS 1995" TYPE="JOURNAL_ARTICLE">
<AU>Executive Committee for the Asymptomatic Carotid Atherosclerosis Study</AU>
<TI>Endarterectomy for Asymptomatic Carotid Artery Stenosis</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>18</NO>
<PG>1421-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ACST-2010" MODIFIED="2012-06-06 14:24:07 +0100" MODIFIED_BY="Leo H Bonati" NAME="ACST 2010" TYPE="JOURNAL_ARTICLE">
<AU>Halliday A, Harrison M, Hayter E, Kong X, Mansfield A, Marro J; Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group</AU>
<TI>10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial</TI>
<SO>Lancet</SO>
<YR>2010</YR>
<VL>376</VL>
<NO>9746</NO>
<PG>1074&#8211;84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-American-Stroke-Association" MODIFIED="2012-06-06 14:24:29 +0100" MODIFIED_BY="Hazel Fraser" NAME="American Stroke Association" TYPE="OTHER">
<TI>WALLSTENT</TI>
<SO>http://controlled-trials.com/mrct/trial/WALLSTENT/1026/5243.html</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bamford-1989" MODIFIED="2012-04-26 13:47:33 +0100" MODIFIED_BY="Leo H Bonati" NAME="Bamford 1989" TYPE="JOURNAL_ARTICLE">
<AU>Bamford JM, Sandercock PA, Warlow CP, Slattery J</AU>
<TI>Interobserver agreement for the assessment of handicap in stroke patients</TI>
<SO>Stroke</SO>
<YR>1989</YR>
<VL>20</VL>
<NO>6</NO>
<PG>828</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barbato-2008" MODIFIED="2012-06-06 14:24:58 +0100" MODIFIED_BY="Leo H Bonati" NAME="Barbato 2008" TYPE="JOURNAL_ARTICLE">
<AU>Barbato JE, Dillavou E, Horowitz MB, Jovin TG, Kanal E, David S, et al</AU>
<TI>A randomized trial of carotid artery stenting with and without cerebral protection</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2008</YR>
<VL>47</VL>
<NO>4</NO>
<PG>760-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bonaldi-2002" NAME="Bonaldi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Bonaldi G</AU>
<TI>Angioplasty and stenting of the cervical carotid bifurcation: report of a 4 year series</TI>
<SO>Neuroradiology</SO>
<YR>2002</YR>
<VL>44</VL>
<NO>2</NO>
<PG>164-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bond-2002" MODIFIED="2012-06-06 14:25:23 +0100" MODIFIED_BY="Leo H Bonati" NAME="Bond 2002" TYPE="JOURNAL_ARTICLE">
<AU>Bond R, Narayan SK, Rothwell PM, Warlow CP</AU>
<TI>Clinical and radiographic risk factors for operative stroke and death in the European carotid surgery trial</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>2</NO>
<PG>108-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bond-2005" MODIFIED="2012-06-25 16:34:56 +0100" MODIFIED_BY="Leo H Bonati" NAME="Bond 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bond R, Rerkasem K, Cuffe R, Rothwell PM</AU>
<TI>A systematic review of the associations between age and sex and the operative risks of carotid endarterectomy</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>2</NO>
<PG>69&#8211;77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-2011" MODIFIED="2012-06-06 14:25:33 +0100" MODIFIED_BY="Leo H Bonati" NAME="Brown 2011" TYPE="JOURNAL_ARTICLE">
<AU>Brown MM, Raine R</AU>
<TI>Should sex influence the choice between carotid stenting and carotid endarterectomy?</TI>
<SO>Lancet Neurology</SO>
<YR>2011</YR>
<VL>10</VL>
<NO>6</NO>
<PG>494-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bush-2005" MODIFIED="2008-09-22 14:31:17 +0100" MODIFIED_BY="Hazel Fraser" NAME="Bush 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bush RL, Kougias P, Guerrero MA, Lubbe DF, Zhou W, Lumsden AB, et al</AU>
<TI>A comparison of carotid artery stenting with neuroprotection versus carotid endarterectomy under local anesthesia</TI>
<SO>American Journal of Surgery</SO>
<YR>2005</YR>
<VL>190</VL>
<NO>5</NO>
<PG>696-700</PG>
<IDENTIFIERS MODIFIED="2008-09-22 14:31:17 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<REFERENCE ID="REF-CAPTURE-2007" MODIFIED="2012-06-06 14:27:08 +0100" MODIFIED_BY="Leo H Bonati" NAME="CAPTURE 2007" TYPE="JOURNAL_ARTICLE">
<AU>Gray WA, Yadav JS, Verta P, Scicli A, Fairman R, Wholey M; CAPTURE Trial Collaborators</AU>
<TI>The CAPTURE Registry: predictors of outcomes in carotid artery stenting with embolic protection for high surgical risk patients in the early post-approval setting</TI>
<SO>Catheterization and Cardiovascular Interventions</SO>
<YR>2007</YR>
<VL>70</VL>
<NO>7</NO>
<PG>1025-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CSTC-2010" MODIFIED="2012-06-06 14:27:43 +0100" MODIFIED_BY="Leo H Bonati" NAME="CSTC 2010" TYPE="JOURNAL_ARTICLE">
<AU>Bonati LH, Dobson J, Algra A, Branchereau A, Chatellier G, Fraedrich G; Carotid Stenting Trialists' Collaboration</AU>
<TI>Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data</TI>
<SO>Lancet</SO>
<YR>2010</YR>
<VL>376</VL>
<NO>9746</NO>
<PG>1062-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Weerd-2010" MODIFIED="2012-06-06 14:27:51 +0100" MODIFIED_BY="Leo H Bonati" NAME="De Weerd 2010" TYPE="JOURNAL_ARTICLE">
<AU>De Weerd M, Greving JP, Hedblad B, Lorenz MW, Mathiesen EB, O'Leary DH, et al</AU>
<TI>Prevalence of asymptomatic carotid artery stenosis in the general population: an individual participant data meta-analysis</TI>
<SO>Stroke</SO>
<YR>2010</YR>
<VL>41</VL>
<NO>6</NO>
<PG>1294-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dietrich-1996" MODIFIED="2012-04-26 13:53:03 +0100" MODIFIED_BY="Leo H Bonati" NAME="Dietrich 1996" TYPE="JOURNAL_ARTICLE">
<AU>Diethrich EB, Ndiaye M, Reid DB</AU>
<TI>Stenting in the carotid artery. Initial experience in 110 patients</TI>
<SO>Journal of Endovascular Surgery</SO>
<YR>1996</YR>
<VL>3</VL>
<NO>1</NO>
<PG>42-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ECST-1998" MODIFIED="2012-04-26 13:53:30 +0100" MODIFIED_BY="Leo H Bonati" NAME="ECST 1998" TYPE="JOURNAL_ARTICLE">
<AU>European Carotid Surgery Trialists Collaboration Group</AU>
<TI>Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST)</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>351</VL>
<NO>9113</NO>
<PG>1379-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fischman-1994" MODIFIED="2012-06-06 14:28:16 +0100" MODIFIED_BY="Leo H Bonati" NAME="Fischman 1994" TYPE="JOURNAL_ARTICLE">
<AU>Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I; Stent Restenosis Study Investigators</AU>
<TI>A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>331</VL>
<NO>8</NO>
<PG>496-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Forsting-2007" MODIFIED="2012-06-06 14:28:25 +0100" MODIFIED_BY="Leo H Bonati" NAME="Forsting 2007" TYPE="JOURNAL_ARTICLE">
<AU>Forsting M</AU>
<TI>Shortcomings and promises of recent carotid-stenting trials</TI>
<SO>Lancet Neurology</SO>
<YR>2007</YR>
<VL>6</VL>
<NO>2</NO>
<PG>101-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gray-2006" MODIFIED="2012-06-06 14:28:43 +0100" MODIFIED_BY="Hazel Fraser" NAME="Gray 2006" TYPE="JOURNAL_ARTICLE">
<AU>Gray WA, Hopkins LN, Yadav S, Davis T, Wholey M, Atkinson R; ARCHeR Trial Collaborators</AU>
<TI>Protected carotid stenting in high-surgical-risk patients: the ARCHeR results</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2006</YR>
<VL>44</VL>
<NO>2</NO>
<PG>258-68</PG>
<IDENTIFIERS MODIFIED="2008-09-22 14:32:02 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<REFERENCE ID="REF-Guimaraens-2002" MODIFIED="2012-04-26 14:11:37 +0100" MODIFIED_BY="Leo H Bonati" NAME="Guimaraens 2002" TYPE="JOURNAL_ARTICLE">
<AU>Guimaraens L, Sola MT, Matali A, Arbelaez A, Delgado M, Soler L, et al</AU>
<TI>Carotid angioplasty with cerebral protection and stenting: report of 164 patients (194 carotid percutaneous transluminal angioplasties)</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>2</NO>
<PG>114-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-06-01 10:40:41 +0100" MODIFIED_BY="Leo H Bonati" NAME="Higgins 2011" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Assessing risk of bias in included studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0</SO>
<YR>updated March 2011</YR>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kastrup-2003" NAME="Kastrup 2003" TYPE="JOURNAL_ARTICLE">
<AU>Kastrup A, Groschel K, Krapf H, Brehm BR, Dichgans J, Schulz JB</AU>
<TI>Early outcome of carotid angioplasty and stenting with or without cerebral protection devices. A systematic review of the literature</TI>
<SO>Stroke</SO>
<YR>2003</YR>
<VL>34</VL>
<NO>3</NO>
<PG>813-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Macdonald-2010" MODIFIED="2012-06-06 14:29:18 +0100" MODIFIED_BY="Leo H Bonati" NAME="Macdonald 2010" TYPE="JOURNAL_ARTICLE">
<AU>Macdonald S, Evans DH, Griffiths PD, McKevitt FM, Venables GS, Cleveland TJ, et al</AU>
<TI>Filter-protected versus unprotected carotid artery stenting: a randomised trial</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2010</YR>
<VL>29</VL>
<NO>3</NO>
<PG>282-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McBride-1988" MODIFIED="2012-04-26 13:58:05 +0100" MODIFIED_BY="Leo H Bonati" NAME="McBride 1988" TYPE="JOURNAL_ARTICLE">
<AU>McBride W, Lange R, Hillis L</AU>
<TI>Restenosis after successful angioplasty, pathophysiology and prevention</TI>
<SO>New England Journal of Medicine</SO>
<YR>1988</YR>
<VL>318</VL>
<NO>26</NO>
<PG>1734-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NASCET-1991" MODIFIED="2012-06-06 14:29:31 +0100" MODIFIED_BY="Leo H Bonati" NAME="NASCET 1991" TYPE="JOURNAL_ARTICLE">
<AU>North American Symptomatic Carotid Endarterectomy Trial Collaborative Group</AU>
<TI>Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1991</YR>
<VL>325</VL>
<NO>7</NO>
<PG>445-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NASCET-1998" MODIFIED="2012-06-06 14:29:53 +0100" MODIFIED_BY="Leo H Bonati" NAME="NASCET 1998" TYPE="JOURNAL_ARTICLE">
<AU>Barnett HJ, Taylor DW, Eliasziw M, Fox AJ, Ferguson GG, Haynes RB; North American Symptomatic Carotid Endarterectomy Trial Collaborators</AU>
<TI>Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>339</VL>
<NO>20</NO>
<PG>1415-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pro_x002d_CAS-2008" MODIFIED="2012-06-06 14:30:06 +0100" MODIFIED_BY="Leo H Bonati" NAME="Pro-CAS 2008" TYPE="JOURNAL_ARTICLE">
<AU>Theiss W, Hermanek P, Mathias K, Brückmann H, Dembski J, Hoffmann FJ; German Society of Angiology/Vascular Medicine; German Society of Radiology</AU>
<TI>Predictors of death and stroke after carotid angioplasty and stenting: a subgroup analysis of the Pro-CAS data</TI>
<SO>Stroke</SO>
<YR>2008</YR>
<VL>39</VL>
<NO>8</NO>
<PG>2325-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reimers-2001" MODIFIED="2012-04-26 14:00:13 +0100" MODIFIED_BY="Leo H Bonati" NAME="Reimers 2001" TYPE="JOURNAL_ARTICLE">
<AU>Reimers B, Corvaja N, Moshari S, Sacca S, Albiero R, Di Mario C, et al</AU>
<TI>Cerebral protection with filter devices during carotid artery stenting</TI>
<SO>Circulation</SO>
<YR>2001</YR>
<VL>104</VL>
<NO>1</NO>
<PG>12-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reimers-2004" MODIFIED="2008-09-22 14:32:47 +0100" MODIFIED_BY="Hazel Fraser" NAME="Reimers 2004" TYPE="JOURNAL_ARTICLE">
<AU>Reimers B, Schluter M, Castriota F, Tubler T, Corvaja N, Cernetti C, et al</AU>
<TI>Routine use of cerebral protection during carotid artery stenting: Results of a multicenter registry of 753 patients</TI>
<SO>American Journal of Medicine</SO>
<YR>2004</YR>
<VL>116</VL>
<NO>4</NO>
<PG>217-22</PG>
<IDENTIFIERS MODIFIED="2008-09-22 14:32:47 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<REFERENCE ID="REF-Roffi-2010" MODIFIED="2012-06-06 14:30:30 +0100" MODIFIED_BY="Leo H Bonati" NAME="Roffi 2010" TYPE="JOURNAL_ARTICLE">
<AU>Roffi M, Sievert H, Gray WA, White CJ, Torsello G, Cao P, et al</AU>
<TI>Carotid artery stenting versus surgery: adequate comparisons?</TI>
<SO>Lancet Neurology</SO>
<YR>2010</YR>
<VL>9</VL>
<NO>4</NO>
<PG>339-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rothwell-2004" MODIFIED="2012-04-26 14:02:23 +0100" MODIFIED_BY="Leo H Bonati" NAME="Rothwell 2004" TYPE="JOURNAL_ARTICLE">
<AU>Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJ; Carotid Endarterectomy Trialists Collaboration</AU>
<TI>Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>363</VL>
<NO>9413</NO>
<PG>915&#8211;24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roubin-2001" MODIFIED="2012-04-26 14:02:48 +0100" MODIFIED_BY="Leo H Bonati" NAME="Roubin 2001" TYPE="JOURNAL_ARTICLE">
<AU>Roubin GS, New G, Iyer SS, Vitek JJ, Al-Mubarak N, Liu MW, et al</AU>
<TI>Immediate and late clinical outcomes of carotid artery stenting in patients with symptomatic and asymptomatic carotid artery stenosis: a 5-year prospective analysis</TI>
<SO>Circulation</SO>
<YR>2001</YR>
<VL>103</VL>
<NO>4</NO>
<PG>532-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Safian-2006" MODIFIED="2008-09-22 14:32:53 +0100" MODIFIED_BY="Hazel Fraser" NAME="Safian 2006" TYPE="JOURNAL_ARTICLE">
<AU>Safian RD, Bresnahan JF, Jaff MR, Foster M, Bacharach JM, Maini B, et al</AU>
<TI>Protected carotid stenting in high-risk patients with severe carotid artery stenosis</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2006</YR>
<VL>47</VL>
<NO>12</NO>
<PG>2384-9</PG>
<IDENTIFIERS MODIFIED="2008-09-22 14:32:53 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<REFERENCE ID="REF-Schnaudigel-2008" MODIFIED="2012-06-06 14:31:00 +0100" MODIFIED_BY="Leo H Bonati" NAME="Schnaudigel 2008" TYPE="JOURNAL_ARTICLE">
<AU>Schnaudigel S, Gröschel K, Pilgram SM, Kastrup A</AU>
<TI>New brain lesions after carotid stenting versus carotid endarterectomy: a systematic review of the literature</TI>
<SO>Stroke</SO>
<YR>2008</YR>
<VL>39</VL>
<NO>6</NO>
<PG>1911-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Serruys-1996" MODIFIED="2012-06-06 14:31:11 +0100" MODIFIED_BY="Leo H Bonati" NAME="Serruys 1996" TYPE="JOURNAL_ARTICLE">
<AU>Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G; Benestent Study Group</AU>
<TI>A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>331</VL>
<NO>8</NO>
<PG>489-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Theron-1996" MODIFIED="2012-04-26 14:08:14 +0100" MODIFIED_BY="Leo H Bonati" NAME="Theron 1996" TYPE="JOURNAL_ARTICLE">
<AU>Theron J, Payelle GG, Coskun O, Huet HF, Guimaraens L</AU>
<TI>Carotid artery stenosis: treatment with protected balloon angioplasty and stent placement</TI>
<SO>Neuroradiology</SO>
<YR>1996</YR>
<VL>201</VL>
<NO>3</NO>
<PG>627-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Touz_x00e9_-2009" MODIFIED="2012-04-26 14:08:57 +0100" MODIFIED_BY="Leo H Bonati" NAME="Touzé 2009" TYPE="JOURNAL_ARTICLE">
<AU>Touze E, Trinquart L, Chatellier G, Mas JL</AU>
<TI>Systematic review of the perioperative risks of stroke or death after carotid angioplasty and stenting</TI>
<SO>Stroke</SO>
<YR>2009</YR>
<VL>40</VL>
<NO>12</NO>
<PG>e683&#8211;93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Swieten-1988" MODIFIED="2012-06-06 14:31:36 +0100" MODIFIED_BY="Leo H Bonati" NAME="Van Swieten 1988" TYPE="JOURNAL_ARTICLE">
<AU>Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, Van Gijn J</AU>
<TI>Interobserver agreement for the assessment of handicap in stroke patients</TI>
<SO>Stroke</SO>
<YR>1998</YR>
<VL>19</VL>
<NO>5</NO>
<PG>604-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-White-2006" MODIFIED="2012-04-26 14:10:18 +0100" MODIFIED_BY="Hazel Fraser" NAME="White 2006" TYPE="JOURNAL_ARTICLE">
<AU>White CJ, Iyer SS, Hopkins LN, Katzen BT, Russell ME; BEACH Trial Investigators</AU>
<TI>Carotid stenting with distal protection in high surgical risk patients: The BEACH trial 30 day results</TI>
<SO>Catheterization and Cardiovascular Interventions</SO>
<YR>2006</YR>
<VL>67</VL>
<NO>4</NO>
<PG>503-12</PG>
<IDENTIFIERS MODIFIED="2008-09-22 14:33:29 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-06-17 11:52:05 +0100" MODIFIED_BY="Leo H Bonati">
<REFERENCE ID="REF-Coward-2004" MODIFIED="2012-06-17 11:52:05 +0100" MODIFIED_BY="Leo H Bonati" NAME="Coward 2004" TYPE="COCHRANE_REVIEW">
<AU>Coward LJ, Featherstone RL, Brown MM</AU>
<TI>Percutaneous transluminal angioplasty and stenting for carotid artery stenosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-04-30 10:14:50 +0100" MODIFIED_BY="Leo H Bonati">
<IDENTIFIER MODIFIED="2012-04-30 10:14:50 +0100" MODIFIED_BY="Leo H Bonati" TYPE="DOI" VALUE="10.1002/14651858.CD000515.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Crawley-1997" MODIFIED="2012-04-30 10:15:17 +0100" MODIFIED_BY="Leo H Bonati" NAME="Crawley 1997" TYPE="COCHRANE_REVIEW">
<AU>Crawley F and Brown MM</AU>
<TI>Percutaneous transluminal angioplasty and stenting for carotid artery stenosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004 (first published online 21 July 1997)</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-04-30 10:15:17 +0100" MODIFIED_BY="Leo H Bonati">
<IDENTIFIER MODIFIED="2012-04-30 10:15:17 +0100" MODIFIED_BY="Leo H Bonati" TYPE="DOI" VALUE="10.1002/14651858.CD000515.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ederle-2007" MODIFIED="2012-04-30 10:15:04 +0100" MODIFIED_BY="Leo H Bonati" NAME="Ederle 2007" TYPE="COCHRANE_REVIEW">
<AU>Ederle J, Featherstone R, Brown MM</AU>
<TI>Percutaneous transluminal angioplasty and stenting for carotid artery stenosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-04-30 10:15:04 +0100" MODIFIED_BY="Leo H Bonati">
<IDENTIFIER MODIFIED="2012-04-30 10:15:04 +0100" MODIFIED_BY="Leo H Bonati" TYPE="DOI" VALUE="10.1002/14651858.CD000515.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2012-04-03 16:55:36 +0100" MODIFIED_BY="Leo H Bonati"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-06-25 16:33:59 +0100" MODIFIED_BY="Martin M Brown">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-06-25 16:33:59 +0100" MODIFIED_BY="Martin M Brown" SORT_BY="USER" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Follow-up" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Funding" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="Trial registration number">
<INCLUDED_CHAR MODIFIED="2012-06-25 16:33:03 +0100" MODIFIED_BY="Leo H Bonati" ORDER="1" STUDY_ID="STD-Leicester-1998">
<CHAR_METHODS MODIFIED="2012-06-25 16:33:03 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Single-centre randomised trial (Leicester Royal Infirmary, UK)</LI>
<LI>Planned sample size 300 patients; 23 patients randomly assigned to endovascular treatment (n = 11) or endarterectomy (n = 12) between June and September 1996</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-06 12:09:11 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Inclusion criteria: symptomatic carotid stenosis of &#8805; 70% measured with duplex ultrasound (no restrictions as of time of most recent event reported; events dated back to 10 months prior to randomisation among included patients)</LI>
<LI>Exclusion criteria: asymptomatic stenosis, symptomatic 0% to 69% stenosis, crescendo TIA or stroke in evolution, and vertebrobasilar or non-hemispheric symptoms</LI>
<LI>Mean age of study participants was 67 years, 53% were male (of those receiving the randomly allocated treatment)</LI>
<LI>Mean degree of stenosis was 82%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 12:09:55 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Endovascular treatment consisted of pre-dilation with balloon-angioplasty where necessary, insertion of a stent (<I>Wallstent, </I>Schneider, USA), and post-dilation in all cases. No protection devices were available at the time the trial was conducted. A consultant radiologist with personal experience of more than 4000 angioplasties to peripheral arteries, who had also done 8 successful procedures in the carotid artery before the trial, performed the procedures</LI>
<LI>Endarterectomy was performed under general anaesthesia, with routine use of shunting and patching. 1 consultant surgeon or 1 supervised trainee performed the procedures</LI>
<LI>Aspirin therapy was "not stopped" before treatment</LI>
<LI>All patients received intravenous heparin at the time of the procedure</LI>
<LI>All patients were monitored with transcranial Doppler and received an intravenous infusion of dextran in case of sustained microembolisation</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 12:10:10 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Primary method of comparison: per-protocol, including only patients receiving the allocated treatment</LI>
<LI>Primary outcome: death or any stroke within 30 days of treatment</LI>
<LI>Secondary outcomes relevant for this review included separate reporting of primary outcome components, disabling and non-disabling strokes, as well as cranial nerve palsies</LI>
<LI>Disabling stroke was defined as a stroke leading to a score of 3-6 on the Oxfordshire Handicap Stroke scale 30 days after treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-06-06 12:10:12 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>24 hours and 30 days after treatment</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2012-06-06 12:10:14 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>The Stroke Association, UK</LI>
<LI>Stents were provided at cost price by Schneider UK Ltd</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2012-06-06 12:10:15 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>No registration found</LI>
</UL>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2012-06-06 12:10:17 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Terminated early by recommendation of the data monitoring committee due to safety concerns</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-25 16:33:05 +0100" MODIFIED_BY="Martin M Brown" ORDER="2" STUDY_ID="STD-Wallstent-2001">
<CHAR_METHODS MODIFIED="2012-06-06 13:37:02 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Multicentre randomised trial conducted in the USA</LI>
<LI>Planned sample size 700 patients; 219 patients randomly assigned to endovascular treatment (n = 107) or endarterectomy (n = 112)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-06 13:37:46 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Inclusion criteria: symptomatic carotid stenosis of &#8805; 60% documented by intra-arterial angiography (most recent event in the last 120 days), age &gt; 18 years, medically stable, life expectancy at least 2 years</LI>
<LI>Exclusion criteria: ipsilateral arterial stenosis greater than the target lesion (i.e. tandem stenosis), NIHSS score &#8805; 15, Rankin score &gt; 2, Barthel score &#8804; 60, atrial fibrillation, left ventricular thrombus, endocarditis, heparin sensitivity, not suitable for surgery, moderate or severe dementia, bleeding diathesis or coagulopathy, history of intracranial haemorrhage</LI>
<LI>Mean age of study participants was 68 years, 64% were male</LI>
<LI>Mean degree of stenosis was 76%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-25 16:33:05 +0100" MODIFIED_BY="Martin M Brown">
<UL>
<LI>Endovascular treatment consisted of insertion of the <I>Wallstent </I>endoprosthesis (Schneider, USA), performed within 2 weeks of randomisation. Pre-dilation and post-dilation was done routinely. No protection devices were used. Patients received aspirin 325 mg bd and ticlopidine 250 mg bd for 3 days prior to treatment and heparin during treatment. Following treatment all patients received aspirin and ticlopidine for 4 weeks and then aspirin only (325 mg bd). Interventionalists had to have performed at least 10 stent procedures in the carotid artery using the <I>Wallstent </I>endoprosthesis with 30-day complication rates of &#8804; 10%</LI>
<LI>Endarterectomy must be performed within 2 weeks of randomisation. Surgical technique and type of anaesthesia were not specified. Patients were treated with aspirin 325 mg bd following the procedure for the duration of the study. Use of ticlopidine was optional. Surgeons had to have performed at least 30 carotid endarterectomies in the previous 2 years with 30-day death or stroke rates of &#8804; 6%</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 13:38:40 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Primary method of comparison: unknown</LI>
<LI>Primary outcome: any death within 30 days of treatment, or ipsilateral stroke or vascular death within 1 year of treatment</LI>
<LI>Secondary outcomes relevant for this review included any death, major stroke, MI, and target vessel patency during follow-up</LI>
<LI>Disabling stroke was defined as a stroke leading to a Barthel score of &lt; 90, an NIHSS score of &#8805; 5, or a Rankin score of &gt; 2</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-06-06 13:38:49 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>24 hours, and 1, 6, and 12 months after treatment and then annually, clinically</LI>
<LI>1, 6, and 12 months after treatment and the annually by carotid ultrasound</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-10-22 23:29:56 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Schneider, USA</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2012-06-06 13:38:52 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>No registration found</LI>
</UL>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2012-06-06 13:38:54 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Terminated early by the sponsor after randomisation due to safety and futility concerns</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-25 16:33:07 +0100" MODIFIED_BY="Martin M Brown" ORDER="3" STUDY_ID="STD-CAVATAS_x002d_CEA-2001">
<CHAR_METHODS MODIFIED="2012-06-06 13:39:33 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>International randomised multicentre trial (22 centres in Europe, Australia, and Canada)</LI>
<LI>505 patients randomly assigned to endovascular treatment (n = 252) or endarterectomy (n = 253) between March 1992 and July 1997</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-25 16:33:06 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Inclusion criteria: symptomatic or asymptomatic carotid artery stenosis of &#8805; 30% according to the common carotid artery method, documented by intra-arterial angiography or consistent findings of at least 2 non-invasive imaging methods, considered to require revascularisation and suitable for surgery and endovascular treatment</LI>
<LI>Exclusion criteria: patients unsuitable for surgery because of medical or surgical risk factors, unwillingness or inability to give informed consent, unwillingness to undergo either procedure, thrombus present on preliminary angiography, intracranial stenosis beyond the skull base, major stroke with no useful recovery of function within the region supplied by the treatable artery</LI>
<LI>90% of patients (n = 452) had ischaemic symptoms in the territory of the relevant carotid artery in the previous 6 months before randomisation</LI>
<LI>Mean age of study participants was 68 years, 70% were male</LI>
<LI>Mean degree of carotid stenosis was 86% (common carotid artery method)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-25 16:33:07 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Endovascular treatment consisted of balloon angioplasty with or without stent insertion. Stents were used in 55 patients (26% of successful endovascular procedures) and included <I>Wallstent </I>(Schneider, USA), <I>Streker</I> (Medi-Tech, USA), and <I>Palmaz</I> (Johnson and Johnson, USA). No protection devices were available at the time the trial was conducted. Patients received a minimum of 150 mg aspirin daily or an alternative antiplatelet agent for at least 24 hours prior to the procedure and throughout the trial, as well as heparin during the procedure and for the following 24 hours. Prior expertise in endovascular treatment was required, albeit not in the carotid artery, as this was considered an entirely new treatment for carotid stenosis in most participating centres at the time, and not defined by a minimum number of procedures</LI>
<LI>Endarterectomy was done by the technique routinely used by the collaborating surgeon (no specification on type of anaesthesia, shunting or patching, heparin or antiplatelet therapy during the procedure). Surgical expertise in carotid endarterectomy was requested but not defined by a minimum number of procedures</LI>
<LI>All patients received best medical treatment throughout the study which was specified to include antiplatelet therapy (or anticoagulant, as appropriate), and control of hypertension, diabetes and hypercholesterolaemia</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 13:40:47 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Primary method of comparison: intention-to-treat</LI>
<LI>Primary safety outcome: disabling stroke or death within 30 days of treatment</LI>
<LI>Secondary safety outcomes relevant for this review included the following events occurring within 30 days of treatment: death, disabling stroke, any stroke, MI, cranial nerve palsy, haematoma requiring surgery or extending hospital stay</LI>
<LI>Primary efficacy outcome: disabling stroke or death between randomisation and end of follow-up</LI>
<LI>Secondary efficacy outcomes relevant for this review included any stroke, ipsilateral stroke, and restenosis measured on ultrasound, occurring during follow-up</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-06-06 13:40:54 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>1 and 6 months after treatment, then 1 year after randomisation and annually thereafter, clinically and with carotid ultrasound</LI>
<LI>No predefined maximum length of follow-up; centres were encouraged to follow patients up for as long as the centre and individual patients were willing to do so</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-10-31 09:10:47 +0000" MODIFIED_BY="Martin M Brown">
<UL>
<LI>British Heart Foundation</LI>
<LI>National Health Service Management Executive, UK</LI>
<LI>The Stroke Association, UK</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2012-04-01 06:33:22 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>ISRCTN 01425573</LI>
</UL>
</CHAR_USER_DEF_3>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-25 16:33:09 +0100" MODIFIED_BY="Martin M Brown" ORDER="4" STUDY_ID="STD-CAVATAS_x002d_MED-2009">
<CHAR_METHODS MODIFIED="2012-06-06 13:41:34 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>International randomised multicentre trial (12 centres in Europe, Australia, and Canada)</LI>
<LI>40 patients randomly assigned to endovascular treatment in combination with best medical treatment (n = 20) or best medical treatment alone (n = 20) between April 1992 and May 1997</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-25 16:33:09 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Inclusion criteria: symptomatic or asymptomatic carotid stenosis warranting treatment (see <LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>), unsuitable for surgery because of surgical or medical contraindications</LI>
<LI>Exclusion criteria: see <LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>
</LI>
<LI>62.5% of patients (n = 25) had cerebrovascular symptoms in the previous 6 months before randomisation</LI>
<LI>Mean age of study participants was 69 years, 78% were male</LI>
<LI>Mean degree of carotid stenosis was 86% (common carotid artery method)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 13:42:13 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Endovascular treatment: see <LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>
</LI>
<LI>Medical treatment and management of vascular risk factors were not specified but left to the discretion of the individual centres</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 13:42:16 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Primary method of comparison: intention-to-treat</LI>
<LI>Primary outcome measure: stroke or death during follow-up</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-06-06 13:42:46 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Identical to <LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>. The first follow-up visit in the medical arm was done 1 month after randomisation</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2012-06-06 13:42:44 +0100" MODIFIED_BY="Martin M Brown">
<UL>
<LI>See <LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>
</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2012-04-03 22:43:22 +0100" MODIFIED_BY="Martin M Brown">
<UL>
<LI>ISRCTN 01425573</LI>
</UL>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2011-03-31 11:15:08 +0100" MODIFIED_BY="Leo H Bonati"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-25 16:33:18 +0100" MODIFIED_BY="Martin M Brown" ORDER="5" STUDY_ID="STD-Kentucky-2001">
<CHAR_METHODS MODIFIED="2012-06-25 16:33:10 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Single-centre randomised trial (Central Baptist Hospital, Lexington, Kentucky, USA)</LI>
<LI>104 patients randomised to endovascular treatment (n = 53) or endarterectomy (n = 51)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-25 16:33:18 +0100" MODIFIED_BY="Martin M Brown">
<UL>
<LI>Inclusion criteria: symptomatic carotid stenosis of &gt; 70% according to NASCET criteria documented by intra-arterial angiography (most recent event in the previous 3 months), anticipated life expectancy of 5 years, willingness to complete treatment within 2 weeks</LI>
<LI>Exclusion criteria: NIHSS &gt; 4, cardiac arrhythmia, allergy/sensitivity to aspirin, other antiplatelets or heparin, coagulopathy, recent intracranial haemorrhage, vertebrobasilar insufficiency, intracranial occlusive disease</LI>
<LI>Mean age of study participants was 68 years, no information on sex distribution of participants was provided</LI>
<LI>Mean degree of stenosis was 85%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 13:43:54 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Endovascular treatment consisted of stent insertion (<I>Wallstent, </I>Boston Scientific, USA) with routine pre- and post-dilation by balloon-angioplasty. No distal protection devices were used</LI>
<LI>Endarterectomy was performed under general anaesthesia with standard operative techniques, using intra-operative EEG monitoring (no further details provided</LI>
<LI>No information on prior experience of interventionalists or surgeons provided</LI>
<LI>Patients in both arms received 325 mg aspirin and 75 mg clopidogrel before the procedure, and patients in the endovascular group received heparin at the time of the procedure</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 13:43:56 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>No primary outcome was defined. Reported outcome events relevant for this review included death, stroke, cranial nerve palsy, and haematoma requiring treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-06-06 13:43:58 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>24 hours, and 1, 3, 6, 12 and 24 months after treatment, clinically and with carotid ultrasound</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2012-06-06 13:43:59 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Stents were provided by Boston Scientific, USA</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2012-06-06 13:44:00 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>No registration found</LI>
</UL>
</CHAR_USER_DEF_3>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-25 16:33:21 +0100" MODIFIED_BY="Martin M Brown" ORDER="6" STUDY_ID="STD-Kentucky-2004">
<CHAR_METHODS MODIFIED="2012-06-06 13:44:25 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Single-centre randomised trial (Central Baptist Hospital, Lexington, Kentucky, USA)</LI>
<LI>85 patients randomised to endovascular treatment (n = 43) or endarterectomy (n = 42) within 1 year</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-25 16:33:21 +0100" MODIFIED_BY="Martin M Brown">
<UL>
<LI>Inclusion criteria: asymptomatic carotid stenosis of &gt; 80% according to NASCET criteria documented by intra-arterial angiography, anticipated life expectancy of 5 years, willingness to complete treatment within 1 month</LI>
<LI>Exclusion criteria: any symptoms of cerebrovascular ischaemia</LI>
<LI>Mean age of study participants was 68 years, no information on sex distribution of participants was provided</LI>
<LI>Mean degree of stenosis was 86%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 13:44:51 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Identical to <LINK REF="STD-Kentucky-2001" TYPE="STUDY">Kentucky 2001</LINK> trial</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 13:44:58 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>See <LINK REF="STD-Kentucky-2001" TYPE="STUDY">Kentucky 2001</LINK> trial</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-06-06 13:45:00 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>24 hours, and 1, 3, 6, 12, 24, and 48 months after treatment, clinically and with carotid ultrasound</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2012-06-06 13:45:01 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>No financial support</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2012-06-06 13:45:02 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>No registration found</LI>
</UL>
</CHAR_USER_DEF_3>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-25 16:33:23 +0100" MODIFIED_BY="Leo H Bonati" ORDER="7" STUDY_ID="STD-Beijing-2003">
<CHAR_METHODS MODIFIED="2012-06-25 16:33:23 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Single-centre randomised trial (Xuanwu Hospital, Capital Medical University, Beijing, China)</LI>
<LI>21 patients randomised to endovascular treatment (n = 8) or medical care alone (n = 13) between 2001 and 2003</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-25 16:33:23 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Inclusion criteria: carotid stenosis of &gt; 70% and contralateral carotid occlusion, demonstrated on duplex ultrasound or intra-arterial angiography</LI>
<LI>Exclusion criteria: cardiorespiratory dysfunction or plasma glucose &gt; 8 mmol/L despite medication</LI>
<LI>Mean age 69 years, 71% male. All patients in the study were described as having had symptoms of TIA or stroke before randomisation but no maximum time between last symptoms and randomisation was specified</LI>
<LI>Mean degree of stenosis was 83%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 14:36:37 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Endovascular treatment consisted of stent insertion (<I>Smart</I> or <I>Wallstent</I>). No information on use of protection devices was provided. Patients received iv heparin during treatment, and ticlopidine 250 mg daily for 6 weeks and aspirin 300 mg daily for 6 months after treatment, followed by aspirin 100 mg daily for life</LI>
<LI>Medical care consisted of individual risk factor targeting</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 13:45:56 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>No primary method of comparison defined</LI>
<LI>No primary outcome was specified. Numbers of patients with death, stroke or TIA during follow-up were reported</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-06-06 13:45:58 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>A single follow-up at 1.5 years after treatment was specified, assessing recurrent events, and carotid stenosis on duplex ultrasound</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2012-06-06 13:46:00 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>No information available</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2012-06-06 13:46:00 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>No registration found</LI>
</UL>
</CHAR_USER_DEF_3>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-06 13:47:22 +0100" MODIFIED_BY="Leo H Bonati" ORDER="8" STUDY_ID="STD-SAPPHIRE-2004">
<CHAR_METHODS MODIFIED="2012-06-06 13:46:24 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Multicentre randomised non-inferiority trial conducted in the USA (29 centres)</LI>
<LI>No predefined sample size; recruitment was planned to stop if non-inferiority of stenting was demonstrated at repeated interim analyses. 334 patients randomly assigned to endovascular treatment or endarterectomy (n = 167 in each arm) between August 2000 and July 2002</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-06 13:46:42 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Inclusion criteria: age &#8805; 18 years, symptomatic stenosis of &#8805; 50% or asymptomatic stenosis of &#8805; 80% according to NASCET criteria documented by duplex ultrasound; high surgical risk defined by at least one of the following criteria: significant cardiopulmonary disease, contralateral carotid occlusion, contralateral laryngeal nerve palsy, previous radical neck surgery or radiation therapy to the neck, recurrent stenosis after endarterectomy, age &gt; 80 years</LI>
<LI>Exclusion criteria: ischaemic stroke within the previous 48 hours, intraluminal thrombus, vascular disease precluding endovascular treatment, intracranial aneurysm, need for more than 2 stents, history of bleeding disorder, planned percutaneous or surgical intervention, life expectancy &lt;1 year, ostial lesion in the common carotid or brachiocephalic artery</LI>
<LI>Mean age 72.5 years, 67% male. 71% had asymptomatic carotid stenosis</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 13:47:03 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Endovascular treatment consisted of insertion of a stent (<I>Smart</I> or <I>Precise</I>, Cordis, Johnson &amp; Johnson, USA) with routine use of a distal protection device (<I>Angioguard</I> or <I>Angioguard XP</I>, Cordis, Johnson &amp; Johnson, USA). Patients received 81 or 325 mg aspirin daily starting at least 72 hours before stenting and indefinitely thereafter, as well as 75 mg clopidogrel daily starting 24 hours before stenting until 2 to 4 weeks after treatment. Interventionalists had performed a median of 64 carotid stent procedures before joining the trial (range 20 to 700)</LI>
<LI>Endarterectomy was performed according to customary techniques. Patients received 81 or 325 mg aspirin daily starting at least 72 hours before endarterectomy and indefinitely thereafter. Surgeons had median annual volumes of 30 carotid endarterectomies (range 15 to 100) and had to demonstrate peri-procedural stroke or death rates of &lt; 6% prior to joining the trial</LI>
<LI>All patients were given heparin during the procedure</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 13:47:17 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Method of comparison: intention-to-treat and per-protocol</LI>
<LI>Non-inferiority margin (primary safety outcome or its 30-day components): 95% confidence interval of risk difference below 3.0% (type 1 error probability one sided 2.5%)</LI>
<LI>Primary outcome: death, any stroke, or MI within 30 days after treatment or death or ipsilateral stroke between 31 days and 1 year after treatment</LI>
<LI>Secondary outcomes relevant for this review included components of the primary outcome, major and minor stroke, cranial nerve palsy, and death or any stroke within 30 days after treatment or ipsilateral stroke or death from neurologic causes up to 3 years after treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-06-06 13:47:20 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>24 hours, 30 days, 6 and 12 months after treatment, and annually thereafter for 3 years, clinically</LI>
<LI>Duplex ultrasound before discharge and at each visit except 30 days after treatment</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-10-19 22:28:34 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Cordis, Johnson &amp; Johnson, USA</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2011-10-19 22:28:38 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>NCT00231270</LI>
</UL>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2012-06-06 13:47:22 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Terminated early due to a drop in the randomisation rate</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-25 16:33:25 +0100" MODIFIED_BY="Leo H Bonati" ORDER="9" STUDY_ID="STD-TESCAS_x002d_C-2006">
<CHAR_METHODS MODIFIED="2012-06-06 13:48:06 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Multicentre, randomised trial conducted in China</LI>
<LI>166 patients randomly assigned to endovascular treatment (n = 82) or endarterectomy (n = 84)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-25 16:33:25 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Inclusion criteria: symptomatic carotid stenosis &gt; 50% or asymptomatic carotid stenosis &gt; 70%</LI>
<LI>Mean age was 63 years, no information on sex distribution of participants available</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 13:48:13 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Endovascular treatment consisted of stent insertion with routine use of protection devices</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 13:48:17 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Primary outcome: death, stroke or MI at 30 within days after treatment, or death or ipsilateral stroke between 31 days and 6 months after treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-06-06 13:48:18 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>1 and 6 months after treatment</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2012-06-06 13:48:19 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>No information available</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2012-06-06 13:48:20 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>No registration found</LI>
</UL>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2012-06-06 13:48:35 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Publication in Chinese with English abstract only. Data presented in review taken from abstract and the following web site: <A HREF="http://www.trialresultscenter.org/study8539-TESCAS-C-">http://www.trialresultscenter.org/study8539-TESCAS-C-</A>
</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-25 16:33:28 +0100" MODIFIED_BY="Martin M Brown" ORDER="10" STUDY_ID="STD-EVA_x002d_3S-2006">
<CHAR_METHODS MODIFIED="2012-06-06 13:49:05 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Multicentre randomised non-inferiority trial (30 centres in France)</LI>
<LI>Planned sample size 872 patients; 527 patients randomly assigned to endovascular treatment (n = 265) or endarterectomy (n = 262) between November 2000 and September 2005</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-06 13:49:32 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Inclusion criteria: age &#8805; 18 years, symptomatic carotid stenosis of 60% to 99% according to NASCET criteria documented by intra-arterial angiography or a combination of duplex ultrasound and magnetic resonance angiography (most recent event in the last 120 days before randomisation)</LI>
<LI>Exclusion criteria: modified Rankin score &#8805; 3; non-atherosclerotic carotid disease; severe tandem lesion; previous revascularisation of the relevant carotid artery; history of bleeding disorder; uncontrolled hypertension or diabetes; unstable angina; contraindication to heparin, ticlopidine, or clopidogrel; life expectancy of less than 2 years; or percutaneous or surgical intervention within 30 days before or after the study procedure</LI>
<LI>Mean age 70 years, 75% male</LI>
<LI>93% of patients had &#8805; 70% degree of stenosis</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 13:49:47 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Endovascular treatment consisted of stent insertion. Use of protection devices became mandatory in the stenting group during the course of the study. Interventionalists had to have performed at least 12 carotid stenting procedures or at least 35 stenting procedures in the supra-aortic trunks, of which at least 5 were in the carotid artery</LI>
<LI>Vascular surgeons performed endarterectomies by their routinely used techniques. Surgeons had to have performed at least 25 endarterectomies in the year before enrolment</LI>
<LI>It was recommended to use between 100 mg and 300 mg of aspirin daily in all patients, and 75 mg clopidogrel or 500 mg ticlopidine daily for 3 days before and 30 days after stenting</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-25 16:33:28 +0100" MODIFIED_BY="Martin M Brown">
<UL>
<LI>Primary method of comparison: modified intention-to-treat analysis for peri-procedural outcomes, including only randomised patients who underwent carotid revascularisation, analysed by the randomly assigned treatment. Regular intention-to-treat analysis for long-term outcomes</LI>
<LI>Non-inferiority margin (primary safety outcome): 90% confidence interval of risk difference below 2.0% (type 1 error probability one-sided 5%)</LI>
<LI>Primary safety outcome: any stroke or death within 30 days after treatment</LI>
<LI>Secondary safety outcomes relevant to this review included primary outcome components, disabling stroke, MI, cranial nerve palsy, and access site haematoma</LI>
<LI>Primary efficacy outcome: any stroke or death within 30 days of treatment or ipsilateral stroke up to 4 years after treatment</LI>
<LI>Secondary efficacy outcomes relevant to this review included any stroke, and death or any stroke up to 4 years after treatment, and carotid restenosis up to 3 years after treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-06-06 13:50:12 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>48 hours, 1 month and then every 6 months after treatment for 2-4 years, clinically</LI>
<LI>1, 6, 12, 18, 24, and 36 months after randomisation with duplex ultrasound</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-10-19 22:39:44 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>French Ministry of Health</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2011-10-19 22:39:50 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>NCT00190398</LI>
</UL>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2012-06-06 13:50:16 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Terminated early by recommendation of the safety committee due to safety and futility concerns</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-25 16:33:29 +0100" MODIFIED_BY="Leo H Bonati" ORDER="11" STUDY_ID="STD-SPACE-2006">
<CHAR_METHODS MODIFIED="2012-06-06 13:50:53 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Multicentre, randomised non-inferiority trial (35 centres in Germany, Austria and Switzerland)</LI>
<LI>Planned sample size 1900 patients, revised upwards to 2500 after interim analysis; 1214 patients randomly assigned to endovascular treatment (n = 613) or endarterectomy (n = 601) between March 2001 and February 2006</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-25 16:33:29 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Inclusion criteria: symptomatic carotid stenosis of &#8805; 50% according to NASCET criteria or &#8805; 70% according to ECST criteria, documented by duplex ultrasound (most recent event in the last 180 days before randomisation), age &gt; 50 years, modified Rankin score &#8804; 3</LI>
<LI>Exclusion criteria: intracranial bleeding in the previous 90 days, uncontrolled hypertension, intracranial arteriovenous malformation or aneurysm, life expectancy &lt; 2 years, coagulation abnormality, contraindications for heparin, aspirin, or clopidogrel, planned surgery, stenosis due to dissection, irradiation, or occurring after previous revascularisation, floating thrombus, intracranial tandem stenosis of higher degree</LI>
<LI>Mean age 69 years, 72% male</LI>
<LI>62% of patients had &#8805; 70% degree of stenosis</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 13:51:27 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Endovascular treatment consisted of stent insertion. Choice of balloon size, pre-dilation, and use of protection devices were at the discretion of the interventionalist. Used stents and protection devices had to be CE-certified and approved for use in the study by a separate committee. Patients had to be given 100 mg aspirin plus 75 mg clopidogrel daily for 3 days before and 30 days after treatment. Interventionalists had to show proof of at least 25 consecutive successful angioplasty or stent procedures in the carotid artery</LI>
<LI>Carotid endarterectomies were performed by vascular surgeons who needed to have 25 consecutive procedures completed. Surgeons used their routine techniques without specifications on type of anaesthesia or shunt use. Patients had to be given at least 100 mg aspirin before, during, and after surgery</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 13:51:40 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Primary method of comparison: intention-to-treat</LI>
<LI>Non-inferiority margin (primary safety outcome): 90% confidence interval of risk difference below 2.5% (type 1 error probability one-sided 5%)</LI>
<LI>Primary safety outcome: death or ipsilateral stroke between randomisation and 30 days after treatment</LI>
<LI>Secondary safety outcomes relevant for this review included death or any stroke, death or disabling stroke, death, and any stroke between randomisation and 30 days after treatment</LI>
<LI>Primary efficacy outcome: death or any stroke between randomisation and 30 days after treatment, or ipsilateral stroke up to 2 years after randomisation</LI>
<LI>Secondary efficacy outcomes relevant for this review included death or any stroke, and carotid restenosis within 2 years after randomisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-06-06 13:51:42 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>1, 7 and 30 days after treatment, and 6, 12, and 24 months after randomisation clinically and with duplex ultrasound</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-10-31 09:15:22 +0000" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Federal Ministry of Education and Research</LI>
<LI>German Research Foundation</LI>
<LI>German Society of Neurology</LI>
<LI>German Society of Neuroradiology</LI>
<LI>German Radiological Society</LI>
<LI>Boston Scientific, USA</LI>
<LI>Guidant, USA</LI>
<LI>Sanofi-Aventis, France</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2011-10-20 10:12:47 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>ISRCTN57874028</LI>
</UL>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2012-06-06 13:51:48 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Terminated early by the steering committee due to futility concerns and lack of funding</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-25 16:33:37 +0100" MODIFIED_BY="Leo H Bonati" ORDER="12" STUDY_ID="STD-BACASS-2008">
<CHAR_METHODS MODIFIED="2012-06-25 16:33:30 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Single-centre randomised trial (University Hospital Basel, Switzerland)</LI>
<LI>No sample size was calculated; 20 patients were randomly assigned to endovascular treatment (n = 10) or endarterectomy (n = 10) between November 1998 and February 2002</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-25 16:33:36 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Inclusion criteria: symptomatic carotid stenosis of &#8805; 70% according to NASCET criteria, documented by concordant findings on duplex ultrasound and magnetic resonance angiography, or by intra-arterial angiography (all included patients had their most recent event in the last 3 months before randomisation)</LI>
<LI>Exclusion criteria: unavailable for at least 2 years for follow-up, carotid occlusion or free-floating thrombus, carotid stenosis occurring after prior revascularisation or neck irradiation, intracranial haemorrhage within 2 months prior to treatment, intracranial mass lesions or vascular malformations, life expectancy &lt; 2 years</LI>
<LI>Mean age 70 years, 85% male</LI>
<LI>Mean degree of stenosis was 83%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-25 16:33:37 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Endovascular treatment consisted of stent insertion (<I>Wallstent</I>, Boston scientific) without pre-dilation, with routine use of a protection device (<I>FilterWire</I>, Boston Scientific, USA; and <I>Angioguard RX</I>, Cordis, USA) and routine post-dilation. Dual antiplatelet therapy with aspirin and clopidogrel was started prior to, or immediately after, the procedure and continued for 1 month thereafter</LI>
<LI>Endarterectomy was performed under general anaesthesia with intra-operative EEG monitoring or local anaesthesia, with or without patch use, with selective shunting, and under single antiplatelet therapy</LI>
<LI>Previous centre experience included approximately 50 carotid endarterectomies and 15 carotid stent procedures annually</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 13:53:55 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>3 separate primary safety outcomes were defined: stroke, death, and MI within 30 days after treatment</LI>
<LI>Secondary outcomes relevant for this review included major stroke (defined by an increase in NIHSS by &#8805; 4 points, or symptoms including aphasia or hemianopia lasting for &gt; 24 hours), access site haematoma and cranial nerve palsy occurring within 30 days after treatment, and ipsilateral stroke and restenosis during follow-up</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-06-06 13:53:57 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>1 day and 1, 6, and 12 months after treatment and yearly thereafter, clinically and with ultrasound</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2012-06-06 13:53:58 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>No financial support</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2012-06-06 13:53:58 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>No registration found</LI>
</UL>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2012-06-06 13:54:24 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Recruitment was stopped when the centre joined the International Carotid Stenting Study (<LINK REF="STD-ICSS-2010" TYPE="STUDY">ICSS 2010</LINK>)</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-25 16:33:41 +0100" MODIFIED_BY="Leo H Bonati" ORDER="13" STUDY_ID="STD-Regensburg-2008">
<CHAR_METHODS MODIFIED="2012-06-25 16:33:39 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Single-centre randomised trial (University Hospital Regensburg, Germany)</LI>
<LI>Planned sample size 200 patients; 87 patients randomised to endovascular treatment (n = 43) or endarterectomy (n = 44) between August 1999 and April 2002</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-25 16:33:41 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Inclusion criteria: age 40 to 80 years, symptomatic carotid stenosis &#8805; 70% according to NASCET criteria documented by intra-arterial angiography</LI>
<LI>Exclusion criteria: contralateral carotid stenosis &#8805; 70% (symptomatic) or &#8805; 90% (asymptomatic), tandem stenosis, cerebral ischaemia within the previous 4 weeks, floating thrombus, dissection, near-occlusion, fibromuscular dysplasia, previous endarterectomy in the relevant artery</LI>
<LI>Mean age 69 years, no sex distribution provided</LI>
<LI>Mean degree of stenosis was 85%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 13:55:30 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Endovascular treatment consisted of insertion of a single type of stent (<I>Wallstent</I>, Boston Scientific, USA), with routine post-dilatation and no use of protection devices</LI>
<LI>A single experienced radiologist performed the procedures (number of pre-trial procedures not provided)</LI>
<LI>Endarterectomy was performed in regional anaesthesia with eversion technique and selective shunting</LI>
<LI>Patients in both arms received 300 mg clopidogrel and 100 mg aspirin on the day before treatment and heparin during treatment, followed by 75 mg clopidogrel and 100 mg aspirin daily for 30 days, and 300 mg aspirin daily thereafter. In addition, patients in the stenting group received 500 mg aspirin iv before treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 13:55:35 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Primary outcome specified in the protocol: cerebral ischaemia (including stroke or TIA), myocardial infarct or death within 30 days of treatment</LI>
<LI>Prespecified secondary outcomes relevant for this review included ipsilateral cerebral ischaemia or death, and severe carotid restenosis or occlusion during follow-up</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-06-06 13:55:43 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>The prospectively defined follow-up 12 months included clinical examinations and carotid ultrasound 3 to 5 days, 30 days, 6 and 12 months after treatment</LI>
<LI>Long-term follow-up assessed retrospectively up to a median of 66 months in the endovascular and 64 months in the surgical arm</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-10-31 09:19:42 +0000" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Bristol Meyer Squibb, USA</LI>
<LI>Boston Scientific, USA</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2012-06-06 13:55:45 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>No registration found</LI>
</UL>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2012-06-06 13:56:07 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Recruitment was stopped after the Stent-Protected Angioplasty Versus Carotid Endarterectomy (<LINK REF="STD-SPACE-2006" TYPE="STUDY">SPACE 2006</LINK>) trial was initiated</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-25 16:33:42 +0100" MODIFIED_BY="Leo H Bonati" ORDER="14" STUDY_ID="STD-Beijing-2009">
<CHAR_METHODS MODIFIED="2012-06-25 16:33:42 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Single-centre randomised trial (Peking Union Medical College Hospital, Beijing, China)</LI>
<LI>40 patients were randomised to stenting (23 procedures) or endarterectomy (23 procedures; 3 patients in each arm were treated bilaterally) between May 2004 and December 2006</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-06 13:56:48 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Inclusion criteria: symptomatic carotid stenosis of &#8805; 50% or asymptomatic carotid stenosis of &#8805; 70%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 13:56:52 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Endovascular treatment consisted of stent insertion. Protection devices were used in 21 of 23 procedures</LI>
<LI>Shunts were used in 9 and patches in 12 of 23 endarterectomies</LI>
<LI>No further information available</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 13:56:57 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Primary outcome specified in the abstract: any stroke or death within 30 days after treatment</LI>
<LI>Secondary outcomes relevant to this review included peri-procedural MI, wound haematoma; and ipsilateral stroke and carotid restenosis occurring up to 18 months after treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-06-06 13:56:58 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>1 and 18 months after treatment</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2012-06-06 13:56:59 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>No information available</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2012-06-06 13:57:00 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>No registration found</LI>
</UL>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2012-06-06 13:57:01 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Publication in Chinese with English abstract only. Results were taken from abstract</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-25 16:33:43 +0100" MODIFIED_BY="Leo H Bonati" ORDER="15" STUDY_ID="STD-ICSS-2010">
<CHAR_METHODS MODIFIED="2012-06-06 13:57:23 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Multicentre randomised trial conducted at 50 academic centres in Europe, Australia, New Zealand, and Canada</LI>
<LI>Planned sample size of 1500 patients enrolled at experienced centres; 1713 patients randomly assigned to endovascular treatment (n = 855) or endarterectomy (n = 858) between May 2001 and October 2008, 1511 of whom at experienced centres</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-25 16:33:43 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Inclusion criteria: symptomatic atheromatous carotid stenosis of &#8805; 50% according to NASCET criteria documented by non-invasive imaging (including duplex ultrasound) or intra-arterial angiography (most recent event in the previous 12 months), age &gt; 40 years</LI>
<LI>Exclusion criteria: major stroke without useful recovery of function, previous endarterectomy or stenting in the relevant carotid artery, planned major surgery</LI>
<LI>Mean age 70 years, 70% male</LI>
<LI>90% of patients had &#8805; 70% degree of stenosis</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 13:57:54 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Endovascular treatment consisted of insertion of CE-certified stents. Use of protection devices was recommended but not mandatory. A combination of aspirin and clopidogrel to cover stent procedures was recommended, the use of heparin mandatory</LI>
<LI>Endarterectomy technique, type of anaesthesia, and use of shunts and patches were left to the discretion of the surgeons</LI>
<LI>Centres were enrolled by a credentialing committee based on previous experience and classified as experienced (requiring a surgeon who had done at least 50 carotid endarterectomies and an interventionalist who had done at least 50 stent procedures, 10 of which in the carotid artery) or supervised (in centres with less experience, procedures were proctored by an outside surgeon, or interventionalist)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 13:58:02 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Primary method of comparison: intention-to-treat</LI>
<LI>Primary safety outcome: death, any stroke or MI occurring within 120 days after randomisation</LI>
<LI>Secondary safety outcomes relevant to this review included components of the primary outcome, disabling stroke (defined by a score on the modified Rankin scale of 3 or more, 30 days after stroke onset), cranial nerve palsy, and access site haematoma requiring surgery or prolonging hospital stay</LI>
<LI>Primary efficacy outcome specified in the protocol: long-term rate of fatal or disabling stroke in any territory</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-06-06 13:58:06 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>30 days after treatment, 6 and 12 months after randomisation, and annually thereafter, clinically and with ultrasound</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-10-31 09:20:15 +0000" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Medical Research Council</LI>
<LI>The Stroke Association</LI>
<LI>European Union</LI>
<LI>Sanofi-Synthélabo, France</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2011-10-20 20:49:59 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>ISRCTN2533747</LI>
</UL>
</CHAR_USER_DEF_3>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-25 16:33:44 +0100" MODIFIED_BY="Leo H Bonati" ORDER="16" STUDY_ID="STD-CREST-2010">
<CHAR_METHODS MODIFIED="2012-06-06 13:58:42 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Multicentre randomised trial (108 centres in the USA and 9 centres in Canada)</LI>
<LI>Both superiority and non-inferiority analyses were specified in the protocol</LI>
<LI>Calculated sample size 2500 patients; 2522 patients with symptomatic or asymptomatic carotid stenosis randomly assigned to endovascular treatment (n = 1271) or endarterectomy (n = 1251) between December 2000 and July 2008</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-25 16:33:44 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Inclusion criteria: age &#8805;18 years, symptomatic carotid stenosis of &#8805; 50% on intra-arterial angiography or &#8805; 70% on duplex ultrasound or non-invasive angiography (most recent event within 180 days before randomisation); or asymptomatic carotid stenosis of 60% to 99% on intra-arterial angiography, 70% to 99% on duplex ultrasound, or 80% to 99% on non-invasive angiography</LI>
<LI>Exclusion criteria: major or evolving stroke, atrial fibrillation, MI in the previous 30 days, unstable angina, bleeding history, dementia, increased surgical risk, post-irradiation or post-endarterectomy stenosis</LI>
<LI>Mean age 69 years, 65% male</LI>
<LI>86% of patients had &#8805; 70% degree of stenosis</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 13:59:48 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Endovascular treatment consisted of insertion of the <I>RX Acculink</I> stent and, whenever feasible, use of the <I>RX Accunet</I> protection device (Abbott Vascular Solutions, USA). Patients received 650 mg of aspirin plus 150 mg clopidogrel daily at least 48 hours before treatment, or 650 mg aspirin plus 450 mg clopidogrel 4 or more hours before treatment, and 325 to 650 mg aspirin daily plus either 75 mg clopidogrel or 500 mg ticlopidine daily for 28 to 30 days after treatment. Interventionists with fewer than 30 carotid stent procedures were required to complete a specific training program. All Interventionists were certified to participate based on evaluation of their performance during an average of 20 procedures in a lead-in phase</LI>
<LI>Endarterectomy technique was not specified. Patients received 325 mg aspirin daily at least 48 hours before treatment. Surgeons had to show performance of more than 12 procedures annually with rates of complications or death below 3% in asymptomatic and below 5% in symptomatic patients</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 13:59:59 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Primary method of comparison: intention-to-treat</LI>
<LI>Primary outcome: death, stroke, or myocardial infarction between randomisation and 30 days after treatment, or ipsilateral stroke up to 4 years after randomisation</LI>
<LI>Secondary outcomes relevant for this review included peri-procedural components of the primary outcome, major stroke defined "on the basis of clinical data or if the NIHSS score was 9 or higher 90 days after the procedure", cranial nerve palsy not resolving for at least 1 month, access site haematoma requiring treatment, and degree of stenosis of the relevant carotid artery 6 and 12 months after treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-06-06 14:00:14 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>18 to 54 hours and 1 month after treatment, and every 6 months thereafter up to 4 years clinically, and by telephone interviews between visits</LI>
<LI>Functional assessment at each visit included the NIH Stroke Scale and the modified Rankin scale</LI>
<LI>Carotid ultrasound was performed 1, 6 and 12 months after treatment and annually thereafter</LI>
<LI>Cardiac enzyme levels were measured before and 6 to 8 hours after treatment</LI>
<LI>ECG was performed before stenting or endarterectomy, as well as 6 to 48 hours and 1 month thereafter</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-10-31 09:21:57 +0000" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>National Institute of Neurological Disorders and Stroke</LI>
<LI>National Institutes of Health</LI>
<LI>Abbott Vascular (formerly Guidant), USA</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2011-10-20 21:07:41 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>NCT00004732</LI>
</UL>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2012-06-06 14:00:17 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Inclusion criteria were changed in 2005 to include patients with asymptomatic stenosis, as well</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AF: atrial fibrillation<BR/>bd: twice daily<BR/>ECG: electrocardiography<BR/>ECST: European Carotid Surgery Trial<BR/>EEG: electroencephalography<BR/>ICA: internal carotid artery<BR/>iv: intravenous<BR/>MI: myocardial infarction<BR/>NASCET: North American Symptomatic Carotid Endarterectomy Trial<BR/>NIHSS: National Institutes of Health Stroke Scale<BR/>TIA: transient ischaemic attack</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2012-06-06 14:09:24 +0100" MODIFIED_BY="Martin M Brown" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Follow-up" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Trial registration number" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="Funding">
<ONGOING_CHAR MODIFIED="2012-06-06 14:04:07 +0100" MODIFIED_BY="Martin M Brown" STUDY_ID="STD-ACST_x002d_2">
<CHAR_STUDY_NAME MODIFIED="2012-04-30 00:42:05 +0100" MODIFIED_BY="Leo H Bonati">
<P>Asymptomatic Carotid Surgery Trial-2 (ACST-2)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-06-06 14:04:07 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Multicentre trial, 1:1 randomisation between endovascular treatment or endarterectomy</LI>
<LI>Planned sample size: 5000 patients</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-06 14:03:07 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Inclusion criteria: &#8805; 18 years, carotid artery stenosis considered to require treatment, without ipsilateral carotid territory symptoms "for some months"; patients fit and willing to be followed-up for at least 5 years</LI>
<LI>Exclusion criteria: small likelihood of benefit from revascularisation, previous revascularisation in the relevant artery, unsuitable for either procedure</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 14:03:13 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Endovascular treatment consists of stent insertion without further specifications. The use of protection devices is optional</LI>
<LI>No specifications on endarterectomy are made</LI>
<LI>Interventionalists and surgeons must have performed at least 25 procedures in the carotid artery to participate in the trial</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 14:03:29 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Primary objectives are to compare the following between treatment groups:</LI>
</UL>
<OL>
<LI>peri-procedural risks of stroke, MI, and death, within the first month after procedure</LI>
<LI>long-term prevention of stroke in subsequent years</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-10-20 21:44:29 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>January 2008</LI>
</UL>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-06 14:03:55 +0100" MODIFIED_BY="Martin M Brown">
<P>Principal Investigator: Alison Halliday, ACST Office, Nuffield Department of Surgical Sciences, Level 6, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU,<BR/>UK (acst@nds.ox.ac.uk)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2012-06-06 14:03:59 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>1 month after treatment clinically, and then annually up to 5 years after treatment by questionnaires</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-10-20 21:43:16 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>NCT00883402</LI>
<LI>ISRCTN21144362</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2012-04-30 00:44:12 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>National Institute of Health Research (NIHR) Health Technology Assessment programme, UK</LI>
<LI>BUPA Foundation, UK</LI>
</UL>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2011-10-20 21:55:58 +0100" MODIFIED_BY="Leo H Bonati"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-06 14:04:35 +0100" MODIFIED_BY="Leo H Bonati" STUDY_ID="STD-ACT-I">
<CHAR_STUDY_NAME MODIFIED="2012-04-30 00:43:15 +0100" MODIFIED_BY="Leo H Bonati">
<P>Asymptomatic Carotid Trial-1 (ACT 1)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-06-06 14:04:13 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Multicentre trial in the USA, 3:1 randomisation between endovascular treatment or endarterectomy</LI>
<LI>Planned sample size: 2058 patients</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-06 14:04:23 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Inclusion criteria: severe carotid stenosis considered to require treatment, without related symptoms in the previous 6 months</LI>
<LI>Exclusion criteria: high surgical risk</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 14:04:24 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Endovascular treatment consists of stent insertion with routine use of filter protection devices</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 14:04:27 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Primary outcomes: occurrence of major adverse events within 30 days after treatment; ipsilateral stroke between 31 and 365 days after treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-10-20 21:52:19 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>April 2005</LI>
</UL>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-09-22 09:52:05 +0100" MODIFIED_BY="Leo H Bonati">
<P>Principal Investigators: Jon Matsumura, MD, university of Wisconsin, Madison; Kenneth Rosenfeld, MD, Massachusetts General Hospital</P>
<P>Contact: Sandy Lee (Sandy.Lee@av.abbott.com) </P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2012-06-06 14:04:35 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>30 days, 6 and 12 months after treatment, then annually up to 5 years</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-10-20 22:01:38 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>NCT00106938</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2011-10-31 09:21:48 +0000" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Abbott Vascular, USA</LI>
</UL>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2011-10-20 22:01:23 +0100" MODIFIED_BY="Leo H Bonati"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-06 14:05:10 +0100" MODIFIED_BY="Leo H Bonati" STUDY_ID="STD-Agostoni">
<CHAR_STUDY_NAME MODIFIED="2012-06-06 14:04:46 +0100" MODIFIED_BY="Leo H Bonati">
<P>Early invasive treatment (endarterectomy versus stenting) of moderate to severe carotid stenosis in patients with transient ischaemic attack or minor stroke</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-06-06 14:04:50 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Multicentre trial, randomisation between endovascular treatment or endarterectomy</LI>
<LI>Planned sample size: 400 patients</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-06 14:04:57 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Inclusion criteria: &#8805; 18 years, 5% to 95% carotid stenosis with ipsilateral TIA or stroke in the previous month</LI>
<LI>Exclusion criteria: TIA or stroke in the previous 48 hours, endoluminal thrombus, tandem stenosis, restenosis after previous endarterectomy, severe cardiopulmonary disease, life expectancy &lt;1 year.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-10-20 22:02:55 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Endovascular treatment consists of stent insertion. No further specifications of study procedures are provided.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 14:05:06 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Primary outcome: cumulative incidence of TIA, stroke, or death at 2 years, or MI at 1 month</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-10-20 22:03:10 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Unknown</LI>
</UL>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-10-20 22:36:50 +0100" MODIFIED_BY="Leo H Bonati">
<P>Principal Investigator: E. Agostoni, Stroke Unit, Clinica Neurologica, Universita Milano-Bicocca, Milan, Italy<BR/>(e.agostoni@libero.it)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2012-06-06 14:05:10 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>30 days, 6, 12 and 24 months after treatment</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-10-20 22:03:49 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>No registration found</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2011-10-20 22:03:57 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>No information available</LI>
</UL>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2011-10-20 22:04:13 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Recruitment status unknown</LI>
</UL>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-06 14:05:49 +0100" MODIFIED_BY="Leo H Bonati" STUDY_ID="STD-AMTEC">
<CHAR_STUDY_NAME MODIFIED="2011-09-22 09:52:05 +0100" MODIFIED_BY="Leo H Bonati">
<P>Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis (AMTEC) </P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-06-06 14:05:21 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Randomised trial, 1:1 randomisation between endarterectomy plus best medical treatment (BMT) or BMT alone</LI>
<LI>Planned sample size: 150 patients</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-06 14:05:30 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Inclusion criteria: age 40 to 80 years, asymptomatic carotid stenosis of 70% to 79% without associated symptoms in the previous 6 months</LI>
<LI>Exclusion criteria: previous revascularisation of the relevant artery, high surgical risk, life expectancy &lt; 6 months</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 14:05:38 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>BMT includes 10 mg atorvastatin or higher, 100 mg aspirin, and 50 mg losartan/5 mg amlodipine or higher, and cardiovascular risk factor management</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 14:05:39 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Primary outcome measure: death, stroke, or MI up to 24 months after treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-10-20 22:10:58 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>April 2009</LI>
</UL>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-06 14:05:49 +0100" MODIFIED_BY="Leo H Bonati">
<P>Study Chair: Evgeny Chazov, MD; Contact: Igor Kolos, PhD (docsn173@yandex.ru) and Sergey Boytsov, MD (prof-boytsov@mail.ru)</P>
<P>Russian Cardiology Research and Production Center, Moscow, Russian Federation, 121552</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2011-10-20 22:11:03 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>2 years</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-10-20 22:11:07 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>NCT00805311</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2011-10-20 22:11:15 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>No information available</LI>
</UL>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2011-04-12 15:53:07 +0100" MODIFIED_BY="Leo H Bonati"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-06 14:06:56 +0100" MODIFIED_BY="Leo H Bonati" STUDY_ID="STD-Carmel-Medical-Center">
<CHAR_STUDY_NAME MODIFIED="2012-06-06 14:06:33 +0100" MODIFIED_BY="Leo H Bonati">
<P>A randomized evaluation of short term and long term outcome after endovascular repair by stenting of carotid artery stenosis in patients with severe asymptomatic carotid stenosis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-06-06 14:06:36 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Randomised trial of stenting or endarterectomy (ratio of randomisation unknown)</LI>
<LI>Planned sample size: 500 patients</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-06 14:06:43 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Inclusion criteria: age 18 to 80 years, asymptomatic severe carotid stenosis (70% to 99%), without associated symptoms in the previous 4 months</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 14:06:46 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Endovascular treatment consists of insertion of the <I>Rapid-Exchange</I> balloon-mounted stent with routine use of the <I>Angioguard</I> protection device (both: Cordis, Johnson&amp;Johnson, USA)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 14:06:52 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>The primary aim is to compare cardiovascular and neurological mortality and morbidity between the 2 procedures (no definitions of endpoints)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-10-20 22:17:24 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>January 2009</LI>
</UL>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-06 14:06:56 +0100" MODIFIED_BY="Leo H Bonati">
<P>Dr Dallit Mannheim, Carmel Medical Center, Haifa, Israel, 34362</P>
<P>(<A HREF="mailto:dalitma%40clalit.org.il?subject=NCT00772278,%20cas%20vs%20cea-001-carmel,%20Comparing%20Carotid%20Stenting%20With%20Endarterectomy%20in%20Severe%20Asymptomatic%20Carotid%20Stenosis">dalitma@clalit.org.il</A>)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2011-10-20 22:17:27 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>2 Years</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-10-20 22:17:30 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>NCT00772278</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2012-04-30 00:46:34 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>No information available</LI>
</UL>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2011-04-12 15:31:29 +0100" MODIFIED_BY="Leo H Bonati"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-06 14:07:43 +0100" MODIFIED_BY="Martin M Brown" STUDY_ID="STD-ECST_x002d_2">
<CHAR_STUDY_NAME MODIFIED="2011-09-22 09:52:05 +0100" MODIFIED_BY="Martin M Brown">
<P>The 2nd European Carotid Surgery Trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-06-06 14:07:08 +0100" MODIFIED_BY="Martin M Brown">
<UL>
<LI>Multicentre randomised trial, 1:1 assignment between carotid revascularisation plus optimised medical treatment (OMT) versus OMT alone</LI>
<LI>Planned sample size: 320 patients in pilot phase, 2000 patients in full trial</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-06 14:07:10 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Inclusion criteria: asymptomatic or low-to-intermediate risk symptomatic carotid stenosis based on a 5-year carotid artery risk score</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 14:07:29 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Carotid revascularisation can be done with endarterectomy or stenting, which is specified by the centre before randomisation</LI>
<LI>OMT includes all 3 of optimal antiplatelet, high-dose statin, and blood pressure dependent antihypertensive therapy, as well as risk factor modification</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 14:07:31 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Long-term survival free of any stroke, peri-procedural MI or peri-procedural death</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-10-20 22:19:48 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Planned in 2011</LI>
</UL>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-10-20 22:37:13 +0100" MODIFIED_BY="Martin M Brown">
<P>Prof Martin M Brown, UCL Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK Email: Email: (martin.brown@ucl.ac.uk)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2012-06-06 14:07:41 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>48 hours and 30 days after treatment, 6 and 12 months after randomisation, and then annually for at least 5 years</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2012-06-06 14:07:42 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Not registered yet</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2012-06-06 14:07:43 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>National Institute of Health Research (NIHR) Health Technology Assessment programme, UK</LI>
</UL>
</CHAR_USER_DEF_3>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-06 14:08:24 +0100" MODIFIED_BY="Leo H Bonati" STUDY_ID="STD-SPACE_x002d_2">
<CHAR_STUDY_NAME MODIFIED="2011-09-22 09:52:05 +0100" MODIFIED_BY="Leo H Bonati">
<P>Stent-protected angioplasty in asymptomatic carotid artery stenosis (SPACE-2)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-06-06 14:07:52 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Multicentre trial, 3:3:1 randomisation between endovascular treatment plus best medical treatment (BMT), endarterectomy plus BMT, or BMT alone</LI>
<LI>Planned sample size: 3640 patients</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-06 14:08:05 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Inclusion criteria: age 50 to 85 years, asymptomatic carotid stenosis of 70% to 99% (no associated symptoms in the previous 180 days)</LI>
<LI>Exclusion criteria: non-atherosclerotic stenosis, post-irradiation stenosis, previous revascularisation in the relevant artery, tandem stenosis, pre-existing disability, life expectancy &lt; 5 years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 14:08:14 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Endovascular treatment consists of stent insertion, with or without protection devices</LI>
<LI>Technical aspects of endarterectomy are not specified</LI>
<LI>Participating interventionists and surgeons must have performed at least 40 procedures in the previous 2 years or 20 procedures in the SPACE-1 trial with a complication rate &lt; 6%</LI>
<LI>BMT consists of lipid-lowering and antiplatelet treatment, as well as risk factor management</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 14:08:18 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Primary safety outcome: death or any stroke within 30 days after treatment</LI>
<LI>Primary efficacy outcome: death or any stroke within 30 days after treatment, or ipsilateral ischaemic stroke up to 5 years</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-10-20 22:32:41 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>March 2009</LI>
</UL>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-10-20 22:37:24 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Prof Werner Hacke, Department of Neurology, University of Heidelberg, Heidelberg, Germany (neurology@med.uni-heidelberg.de)</LI>
</UL>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2012-06-06 14:08:22 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>30 days and 12 months after treatment and then annually up to 5 years, clinically and with ultrasound</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-10-20 22:31:54 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>ISRCTN78592017</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2012-06-06 14:08:24 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Joint funding by Federal Ministry of Education and Research and DRG (German Research Society), Germany</LI>
</UL>
</CHAR_USER_DEF_3>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-06 14:09:24 +0100" MODIFIED_BY="Leo H Bonati" STUDY_ID="STD-Vienna-General-Hospital">
<CHAR_STUDY_NAME MODIFIED="2012-06-06 14:08:57 +0100" MODIFIED_BY="Leo H Bonati">
<P>Stenting versus best medical treatment of asymptomatic high grade carotid artery stenosis - a randomized controlled trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-06-06 14:09:01 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Randomised trial, 1:1 assignment to endovascular treatment plus BMT (best medical treatment) versus BMT alone</LI>
<LI>Planned sample size: 300 patients</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-06 14:09:11 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Inclusion criteria: asymptomatic 80% to 99% carotid stenosis</LI>
<LI>Exclusion criteria: non-atherosclerotic stenosis, prior revascularisation in the relevant carotid artery, severe cardiovascular comorbidity, life expectancy &lt; 6 months</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 14:09:16 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Endovascular treatment consists of stent insertion with routine use of filter-type protection devices</LI>
<LI>BMT includes 40 mg simvastatin or higher and 75 mg clopidogrel daily), and risk factor management</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 14:09:19 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Neurological events (ipsilateral and contralateral), composite of myocardial infarction, stroke and cardiovascular death; and any death within 24 months</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-10-20 22:36:03 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>March 2004</LI>
</UL>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-09-22 09:52:05 +0100" MODIFIED_BY="Leo H Bonati">
<P>Prof Martin Schillinger (Principal Investigator), Vienna General Hospital, Vienna, Austria (martin.schillinger@meduniwien.ac.at)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2012-06-06 14:09:24 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>1, 1.5, 3, 5 and 10 years post randomisation</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-10-20 22:38:22 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>NCT00497094</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2011-10-20 22:38:29 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>No information available</LI>
</UL>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2011-10-20 22:38:32 +0100" MODIFIED_BY="Leo H Bonati">
<UL>
<LI>Recruitment status unknown</LI>
</UL>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>MI: myocardial infarction<BR/>TIA: transient ischaemic attack</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-06-06 14:00:48 +0100" MODIFIED_BY="Martin M Brown">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-06-06 14:00:23 +0100" MODIFIED_BY="Martin M Brown" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:54:38 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-BACASS-2008">
<DESCRIPTION>
<UL>
<LI>Quote: "As randomisation procedure sealed envelopes were used for treatment allocation". 50 envelopes were prepared</LI>
<LI>Comment: adequate</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:46:04 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Beijing-2003">
<DESCRIPTION>
<UL>
<LI>Quote: "Patients were allocated to two groups by random number table"</LI>
<LI>Comment: adequate</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:57:06 +0100" MODIFIED_BY="Leo H Bonati" RESULT="UNKNOWN" STUDY_ID="STD-Beijing-2009">
<DESCRIPTION>
<UL>
<LI>Quote: "A prospective randomised single-center clinical trial [...]"</LI>
<LI>Comment: the method of randomisation is unknown</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:41:04 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-CAVATAS_x002d_CEA-2001">
<DESCRIPTION>
<UL>
<LI>Quote: "patients were randomly assigned to a treatment group, in equal proportions, by telephone call or fax to the randomisation centre at the Clinical Trial Service Unit in Oxford, UK., [...] We randomly assigned patients by computer with a minimisation algorithm, which took account of centre and timing of symptoms, [...]"</LI>
<LI>Comment: adequate</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:43:01 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-CAVATAS_x002d_MED-2009">
<DESCRIPTION>
<UL>
<LI>Quote: see <LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>
</LI>
<LI>Comment: adequate</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 14:00:23 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-CREST-2010">
<DESCRIPTION>
<UL>
<LI>Quote: "Eligible patients were randomly assigned, with the use of a Web-based system, to undergo either carotid-artery stenting or carotid endarterectomy. Randomization was based on a permuted-block design (with random block sizes of 2, 4, or 6), was stratified according to center and symptomatic status [...]"</LI>
<LI>Comment: adequate</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:50:22 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-EVA_x002d_3S-2006">
<DESCRIPTION>
<UL>
<LI>Quote: "Randomization was carried out centrally by means of a computer-generated sequence, involving randomized blocks of two, four, or six patients that were stratified according to study center and degree of stenosis [...]"</LI>
<LI>Comment: adequate</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:58:10 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-ICSS-2010">
<DESCRIPTION>
<UL>
<LI>Quote: "Eligible patients were randomly assigned in a 1:1 ratio to receive carotid artery stenting or carotid endarterectomy by use of a computerised service provided by Oxford Clinical Trials Service Unit staff who were not involved in other parts of the trial. [...]. Randomisation was stratified by centre with minimisation for sex, age, contralateral occlusion, and side of the randomised artery."</LI>
<LI>Comment: adequate</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:44:05 +0100" MODIFIED_BY="Martin M Brown" RESULT="UNKNOWN" STUDY_ID="STD-Kentucky-2001">
<DESCRIPTION>
<UL>
<LI>Quote: "[...] two-arm randomized clinical trial [...]". "[...] were selected randomly for CEA or carotid stenting [...]"</LI>
<LI>Comment: No information on method of randomisation provided</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:45:06 +0100" MODIFIED_BY="Martin M Brown" RESULT="UNKNOWN" STUDY_ID="STD-Kentucky-2004">
<DESCRIPTION>
<UL>
<LI>Quotes: "[...] two-arm randomized clinical trial [...]". "[...] were selected randomly to undergo CEA [...] or CAS [...]"</LI>
<LI>Comment: No information on method of randomisation provided</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 12:10:34 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Leicester-1998">
<DESCRIPTION>
<UL>
<LI>Quote: "Three hundred random treatment methods were numbered and sealed in opaque envelopes and allocated on a consecutive basis [...]"</LI>
<LI>Comment: adequate</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:56:16 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Regensburg-2008">
<DESCRIPTION>
<UL>
<LI>Quote [<I>translation from German:</I> "200 patients will be randomised using a random key, half into the surgical arm and half into the interventional arm. Stratification will be done according to age [...], degree of stenosis [...], and presence of coronary heart disease]"</LI>
<LI>Comment: adequate</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:47:28 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-SAPPHIRE-2004">
<DESCRIPTION>
<UL>
<LI>Quote: "Randomization was performed with the use of a pseudo random-number generator, and the numbers were distributed by an automated, centralized telephone response system"</LI>
<LI>Comment: adequate</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:51:52 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-SPACE-2006">
<DESCRIPTION>
<UL>
<LI>Quote: "The random allocation schedule was generated using a computer program. This was done by members of the data and statistic centre, who also obtained and analysed the data."</LI>
<LI>Comment: adequate</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:48:50 +0100" MODIFIED_BY="Leo H Bonati" RESULT="UNKNOWN" STUDY_ID="STD-TESCAS_x002d_C-2006">
<DESCRIPTION>
<UL>
<LI>Quote: "[...] a multicentre randomized controlled trial [...]"</LI>
<LI>Comment: method of randomisation not known</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-30 15:40:33 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Wallstent-2001">
<DESCRIPTION>
<UL>
<LI>Quote: "Randomization of patients is performed using a computerized random number generator. Assignment is provided in sequentially numbered, sealed envelopes."</LI>
<LI>Comment: adequate</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-06-06 14:00:24 +0100" MODIFIED_BY="Leo H Bonati" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:54:39 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-BACASS-2008">
<DESCRIPTION>
<UL>
<LI>Quote: see above</LI>
<LI>Comment: adequate</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 21:37:26 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Beijing-2003">
<DESCRIPTION>
<UL>
<LI>Quote: see above</LI>
<LI>Comment: adequate</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:57:06 +0100" MODIFIED_BY="Leo H Bonati" RESULT="UNKNOWN" STUDY_ID="STD-Beijing-2009">
<DESCRIPTION>
<UL>
<LI>Quote and comment: see above</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:41:05 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-CAVATAS_x002d_CEA-2001">
<DESCRIPTION>
<UL>
<LI>See quote above</LI>
<LI>Comment: adequate</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:43:02 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-CAVATAS_x002d_MED-2009">
<DESCRIPTION>
<UL>
<LI>Quote: see <LINK REF="STD-CAVATAS_x002d_CEA-2001" TYPE="STUDY">CAVATAS-CEA 2001</LINK>
</LI>
<LI>Comment: adequate</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 14:00:24 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-CREST-2010">
<DESCRIPTION>
<UL>
<LI>Quote: see above</LI>
<LI>Comment: adequate</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:50:23 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-EVA_x002d_3S-2006">
<DESCRIPTION>
<UL>
<LI>Quote: see above</LI>
<LI>Comment: adequate</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:58:11 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-ICSS-2010">
<DESCRIPTION>
<UL>
<LI>Quote: see above</LI>
<LI>Comment: adequate</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:44:06 +0100" MODIFIED_BY="Leo H Bonati" RESULT="UNKNOWN" STUDY_ID="STD-Kentucky-2001">
<DESCRIPTION>
<UL>
<LI>Comment: no information provided</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:45:07 +0100" MODIFIED_BY="Leo H Bonati" RESULT="UNKNOWN" STUDY_ID="STD-Kentucky-2004">
<DESCRIPTION>
<UL>
<LI>Comment: no information provided</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 12:10:36 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Leicester-1998">
<DESCRIPTION>
<UL>
<LI>Quote: see above</LI>
<LI>Comment: adequate</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:56:17 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Regensburg-2008">
<DESCRIPTION>
<UL>
<LI>Quote: see above</LI>
<LI>Comment: adequate</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:47:30 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-SAPPHIRE-2004">
<DESCRIPTION>
<UL>
<LI>Quote: see above</LI>
<LI>Comment: adequate</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:51:53 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-SPACE-2006">
<DESCRIPTION>
<UL>
<LI>Quote: see above</LI>
<LI>Comment: adequate</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:48:51 +0100" MODIFIED_BY="Leo H Bonati" RESULT="UNKNOWN" STUDY_ID="STD-TESCAS_x002d_C-2006">
<DESCRIPTION>
<UL>
<LI>Comment: see above</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:38:59 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Wallstent-2001">
<DESCRIPTION>
<UL>
<LI>See above</LI>
<LI>Comment: adequate</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-03-29 10:11:00 +0100" MODIFIED_BY="Leo H Bonati" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2012-06-06 14:00:26 +0100" MODIFIED_BY="Leo H Bonati" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-06 13:54:41 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-BACASS-2008">
<DESCRIPTION>
<UL>
<LI>Comment: blinding not possible, but the outcome is not likely to have been influenced</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-06 13:46:08 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Beijing-2003">
<DESCRIPTION>
<UL>
<LI>Comment: blinding not possible, but the outcome is not likely to have been influenced</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-06 13:57:07 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Beijing-2009">
<DESCRIPTION>
<UL>
<LI>Comment: blinding not possible, but the outcome is not likely to have been influenced</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-06 13:41:07 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-CAVATAS_x002d_CEA-2001">
<DESCRIPTION>
<UL>
<LI>Comment: blinding not possible, but the outcome is not likely to have been influenced</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-06 13:43:04 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-CAVATAS_x002d_MED-2009">
<DESCRIPTION>
<UL>
<LI>Comment: blinding not possible, but the outcome is not likely to have been influenced</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-06 14:00:26 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-CREST-2010">
<DESCRIPTION>
<UL>
<LI>Comment: blinding not possible, but the outcome is not likely to have been influenced</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-06 13:50:24 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-EVA_x002d_3S-2006">
<DESCRIPTION>
<UL>
<LI>Comment: blinding not possible, but the outcome is not likely to have been influenced</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-06 13:58:12 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-ICSS-2010">
<DESCRIPTION>
<UL>
<LI>Comment: blinding not possible, but the outcome is not likely to have been influenced</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-06 13:44:07 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Kentucky-2001">
<DESCRIPTION>
<UL>
<LI>Comment: blinding not possible, but the outcome is not likely to have been influenced</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-06 13:45:08 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Kentucky-2004">
<DESCRIPTION>
<UL>
<LI>Comment: blinding not possible, but the outcome is not likely to have been influenced</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-06 12:10:37 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Leicester-1998">
<DESCRIPTION>
<UL>
<LI>Comment: blinding not possible, but the outcome is not likely to have been influenced</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-06 13:56:18 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Regensburg-2008">
<DESCRIPTION>
<UL>
<LI>Comment: blinding not possible, but the outcome is not likely to have been influenced</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-06 13:47:31 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-SAPPHIRE-2004">
<DESCRIPTION>
<UL>
<LI>Comment: blinding not possible, but the outcome is not likely to have been influenced</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-06 13:51:54 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-SPACE-2006">
<DESCRIPTION>
<UL>
<LI>Comment: blinding not possible, but the outcome is not likely to have been influenced</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-06 13:48:52 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-TESCAS_x002d_C-2006">
<DESCRIPTION>
<UL>
<LI>Comment: blinding not possible, but the outcome is not likely to have been influenced</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-06 13:39:00 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Wallstent-2001">
<DESCRIPTION>
<UL>
<LI>Comment: blinding not possible, but the outcome is not likely to have been influenced</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-06-06 14:00:30 +0100" MODIFIED_BY="Leo H Bonati" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-06 13:54:44 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-BACASS-2008">
<DESCRIPTION>
<UL>
<LI>Outcome assessment was not blinded but done by neurologists who were not involved in the procedures</LI>
<LI>Comment: influence on outcome judged unlikely</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-19 21:49:28 +0100" MODIFIED_BY="Leo H Bonati" RESULT="UNKNOWN" STUDY_ID="STD-Beijing-2003">
<DESCRIPTION>
<UL>
<LI>Comment: no information available</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-06 13:57:08 +0100" MODIFIED_BY="Leo H Bonati" RESULT="UNKNOWN" STUDY_ID="STD-Beijing-2009">
<DESCRIPTION>
<UL>
<LI>Comment: no information available</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-06 13:41:15 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-CAVATAS_x002d_CEA-2001">
<DESCRIPTION>
<UL>
<LI>Outcome assessment was not blinded but done by neurologists or clinicians who were not involved in the procedures. Outcome events were centrally adjudicated blinded to treatment</LI>
<LI>Comment: influence on outcome judged unlikely</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-06 13:43:07 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-CAVATAS_x002d_MED-2009">
<DESCRIPTION>
<UL>
<LI>Outcome assessment was not blinded but done by neurologists who were not involved in the procedures. Outcome events were centrally adjudicated blinded to treatment</LI>
<LI>Comment: influence on outcome judged unlikely</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-06 14:00:30 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-CREST-2010">
<DESCRIPTION>
<UL>
<LI>Outcome assessment was not blinded but done by clinicians who were not involved in the procedures. Outcome events were adjudicated centrally, blinded to treatment</LI>
<LI>Comment: influence on outcome judged unlikely</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-06 13:50:26 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-EVA_x002d_3S-2006">
<DESCRIPTION>
<UL>
<LI>Outcome assessment was not blinded but done by neurologists who were not involved in the procedures. Outcome events were centrally adjudicated blinded to treatment</LI>
<LI>Comment: influence on outcome judged unlikely</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-06 13:58:18 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-ICSS-2010">
<DESCRIPTION>
<UL>
<LI>Outcome assessment was not blinded but done by clinicians who were not involved in the procedures. Outcome events were adjudicated centrally, as well as by an independent external adjudicator, blinded to treatment</LI>
<LI>Comment: influence on outcome judged unlikely</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-06 13:44:10 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Kentucky-2001">
<DESCRIPTION>
<UL>
<LI>Outcome assessment was not blinded but done by a neurologist who was not involved in the procedures</LI>
<LI>Comment: influence on outcome judged unlikely</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-06 13:45:12 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Kentucky-2004">
<DESCRIPTION>
<UL>
<LI>Outcome assessment was not blinded but done by a neurologist who was not involved in the procedures</LI>
<LI>Comment: influence on outcome judged unlikely</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-06 12:10:39 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Leicester-1998">
<DESCRIPTION>
<UL>
<LI>Outcome assessment was not blinded but done by a neurologist who was not involved in the procedures</LI>
<LI>Comment: Influence on outcome judged unlikely</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-06 13:56:20 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Regensburg-2008">
<DESCRIPTION>
<UL>
<LI>Outcome assessment was not blinded but done by neurologists who were not involved in the procedures</LI>
<LI>Comment: influence on outcome judged unlikely</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-06 13:47:36 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-SAPPHIRE-2004">
<DESCRIPTION>
<UL>
<LI>Outcome assessment was not blinded but done by neurologists who were not involved in the procedures. Outcome events were centrally adjudicated blinded to treatment</LI>
<LI>Comment: influence on outcome judged unlikely</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-06 13:51:56 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-SPACE-2006">
<DESCRIPTION>
<UL>
<LI>Outcome assessment was not blinded but done by neurologists who were not involved in the procedures. Outcome events were centrally adjudicated blinded to treatment</LI>
<LI>Comment: influence on outcome judged unlikely</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-06 13:48:53 +0100" MODIFIED_BY="Leo H Bonati" RESULT="UNKNOWN" STUDY_ID="STD-TESCAS_x002d_C-2006">
<DESCRIPTION>
<UL>
<LI>Comment: no information available</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-06 13:39:03 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Wallstent-2001">
<DESCRIPTION>
<UL>
<LI>Outcome assessment was not blinded but done by study neurologists who were not involved in the procedures</LI>
<LI>Comment: Influence on outcome judged unlikely</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-06-06 14:00:47 +0100" MODIFIED_BY="Leo H Bonati" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-06 13:54:45 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-BACASS-2008">
<DESCRIPTION>
<UL>
<LI>Comment: Numbers of patients at risk during follow-up and reasons for loss of follow-up provided</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-06 13:46:10 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Beijing-2003">
<DESCRIPTION>
<UL>
<LI>Comment: Outcome events for all patients are provided</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-06 13:57:08 +0100" MODIFIED_BY="Leo H Bonati" RESULT="UNKNOWN" STUDY_ID="STD-Beijing-2009">
<DESCRIPTION>
<UL>
<LI>Comment: no information available</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-06 13:41:19 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-CAVATAS_x002d_CEA-2001">
<DESCRIPTION>
<UL>
<LI>1 patient with carotid occlusion assigned endovascular treatment was randomised in error and excluded from the analysis. Numbers of patients at risk during follow-up provided</LI>
<LI>Comment: censoring assumed to be non-informative</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-06 13:43:08 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-CAVATAS_x002d_MED-2009">
<DESCRIPTION>
<UL>
<LI>Numbers of patients at risk during follow-up provided</LI>
<LI>Comment: censoring assumed to be non-informative</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-06 14:00:47 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-CREST-2010">
<DESCRIPTION>
<UL>
<LI>9 Patients in the endovascular group and 11 patients in the endarterectomy group enrolled at a single centre were excluded from the analysis due to scientific misconduct. 33 and 47 patients in the 2 arms, respectively, who were included in the analysis were lost to follow-up during the trial. Numbers of patients at risk during follow-up provided</LI>
<LI>Comment: No information on clinical outcome is available from excluded patients; however, the numbers are small and the risk of bias is considered low. Numbers of patients lost to follow-up are considered low. Censoring was assumed to be non-informative</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-06 13:50:35 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-EVA_x002d_3S-2006">
<DESCRIPTION>
<UL>
<LI>All but 3 patients were followed up to death or end of study. Numbers of patients at risk during follow-up provided</LI>
<LI>Comment: censoring assumed to be non-informative</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-06 13:58:24 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-ICSS-2010">
<DESCRIPTION>
<UL>
<LI>2 and 1 patients in the endovascular and surgical arms, respectively, immediately withdrew consent after randomisation</LI>
<LI>Comment: No information on clinical outcome is available from these patients, who were excluded from the analysis in the trial; however, the numbers are small and the risk of bias is considered low. Numbers of patients at risk during follow-up are provided; censoring assumed to be non-informative</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-06 13:44:11 +0100" MODIFIED_BY="Leo H Bonati" RESULT="UNKNOWN" STUDY_ID="STD-Kentucky-2001">
<DESCRIPTION>
<UL>
<LI>Numbers of patients at risk during follow-up not provided</LI>
<LI>Comment: bias possible</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-06 13:45:13 +0100" MODIFIED_BY="Leo H Bonati" RESULT="UNKNOWN" STUDY_ID="STD-Kentucky-2004">
<DESCRIPTION>
<UL>
<LI>Numbers of patients at risk during follow-up not provided</LI>
<LI>Comment: bias possible</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-06 12:11:13 +0100" MODIFIED_BY="Leo H Bonati" RESULT="UNKNOWN" STUDY_ID="STD-Leicester-1998">
<DESCRIPTION>
<UL>
<LI>4 patients randomised to endovascular treatment (1 patient refusing the allocated treatment after admission and 3 patients waiting for admission when the trial was suspended) and 2 patients randomised to surgery (1 patient refusing the allocated treatment and one patient occluding the relevant ICA) did not receive their allocated treatment and were excluded from analysis in this trial</LI>
<LI>Comment: outcome events occurring after randomisation were not systematically reported for these patients. In particular, it is unclear whether the patients refusing the allocated treatment crossed-over to receive the alternative treatment</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-06 13:56:28 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Regensburg-2008">
<DESCRIPTION>
<UL>
<LI>3 patients (1 in the endovascular group and 2 in the endarterectomy group) were lost to follow-up</LI>
<LI>Comment: risk of attrition bias considered low</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-06 13:47:41 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-SAPPHIRE-2004">
<DESCRIPTION>
<UL>
<LI>143 of 167 patients (86%) in the endovascular arm and 117 of 167 patients (70%) in the surgical arm had available follow-up at 3 years</LI>
<LI>Numbers of patients at risk during follow-up provided</LI>
<LI>Comment: censoring assumed to be non-informative</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-06 13:52:06 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-SPACE-2006">
<DESCRIPTION>
<UL>
<LI>6 and 12 patients in the endovascular and surgical arms, respectively, immediately withdrew consent after randomisation</LI>
<LI>541 (89%) patients in the endovascular arm and 522 (89%) patients in the surgical arm had follow-up data available at 2 years. Reasons for attrition provided. Numbers of patients at risk during follow-up provided</LI>
<LI>Comment: No information on clinical outcome is available from patients who withdrew consent and were excluded from the analysis in the trial; however, the numbers are small and the risk of bias is considered low. Censoring assumed to be non-informative</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-06 13:48:54 +0100" MODIFIED_BY="Leo H Bonati" RESULT="UNKNOWN" STUDY_ID="STD-TESCAS_x002d_C-2006">
<DESCRIPTION>
<UL>
<LI>Comment: no information available</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-06 13:39:10 +0100" MODIFIED_BY="Leo H Bonati" RESULT="UNKNOWN" STUDY_ID="STD-Wallstent-2001">
<DESCRIPTION>
<UL>
<LI>Trial results presented at conference (2001 International Stroke Conference) and published in abstract form. No peer-reviewed publication of the results has appeared so far</LI>
<LI>Numbers of patients excluded from analysis or lost during follow-up not provided</LI>
<LI>Comment: bias possible</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-06-06 14:00:48 +0100" MODIFIED_BY="Martin M Brown" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:54:47 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-BACASS-2008">
<DESCRIPTION>
<UL>
<LI>Comment: No reference to a study protocol is made but the generally expected major outcome events are reported</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:46:10 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Beijing-2003">
<DESCRIPTION>
<UL>
<LI>Comment: No reference to a study protocol is made but the generally expected major outcome events are reported</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:57:09 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Beijing-2009">
<DESCRIPTION>
<UL>
<LI>Comment: No reference to a study protocol is made but the generally expected major outcome events are reported</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:41:20 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-CAVATAS_x002d_CEA-2001">
<DESCRIPTION>
<UL>
<LI>Comment: the primary analysis prespecified in the protocol was reported</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:43:10 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-CAVATAS_x002d_MED-2009">
<DESCRIPTION>
<UL>
<LI>Comment: the primary analysis prespecified in the protocol was reported</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 14:00:48 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-CREST-2010">
<DESCRIPTION>
<UL>
<LI>Comment: the primary analysis prespecified in the protocol was reported</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:50:38 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-EVA_x002d_3S-2006">
<DESCRIPTION>
<UL>
<LI>Comment: the primary analysis prespecified in the protocol was reported</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:58:27 +0100" MODIFIED_BY="Martin M Brown" RESULT="YES" STUDY_ID="STD-ICSS-2010">
<DESCRIPTION>
<UL>
<LI>Comment: the primary analysis prespecified in the protocol for the comparison of long-term outcome has not been performed at the time of writing, but secondary short-term analyses specified in the protocol have been reported</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:44:12 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Kentucky-2001">
<DESCRIPTION>
<UL>
<LI>Comment: No reference to a study protocol is made but the generally expected major outcome events are reported</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:45:16 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Kentucky-2004">
<DESCRIPTION>
<UL>
<LI>Comment: No reference to a study protocol is made but the generally expected major outcome events are reported</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 12:11:27 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Leicester-1998">
<DESCRIPTION>
<UL>
<LI>Comment: no reference to a study protocol is made, but the generally expected major outcome events are reported</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:56:33 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Regensburg-2008">
<DESCRIPTION>
<UL>
<LI>Comment: the primary outcome pre-specified in the protocol (see above) was not available in the final publication because it was not specified if events occurred within 30 days of treatment or not</LI>
<LI>However, all pre-specified outcome events occurring during the prospective follow-up period up to 1 year after treatment were provided. Therefore, the risk of reporting bias is considered low</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:47:53 +0100" MODIFIED_BY="Martin M Brown" RESULT="UNKNOWN" STUDY_ID="STD-SAPPHIRE-2004">
<DESCRIPTION>
<UL>
<LI>Protocol was published only a few months before the initial results of the trial</LI>
<LI>Expected major outcome events were reported, but not for symptomatic and asymptomatic patients separately</LI>
<LI>Concern has been expressed about the fact that the Chief Investigator of SAPPHIRE received undeclared royalties from sales of the protection device used in the trial</LI>
<LI>Comment: bias possible</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:52:07 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-SPACE-2006">
<DESCRIPTION>
<UL>
<LI>Comment: the primary analysis prespecified in the protocol was reported</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:48:54 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-TESCAS_x002d_C-2006">
<DESCRIPTION>
<UL>
<LI>Comment: no reference to a study protocol is made but the generally expected major outcome events are reported</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 13:39:11 +0100" MODIFIED_BY="Leo H Bonati" RESULT="YES" STUDY_ID="STD-Wallstent-2001">
<DESCRIPTION>
<UL>
<LI>Comment: the primary analysis prespecified in the protocol was reported</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-06-06 14:33:16 +0100" MODIFIED_BY="Leo H Bonati">
<COMPARISON ID="CMP-001" MODIFIED="2012-06-06 14:33:16 +0100" MODIFIED_BY="Leo H Bonati" NO="1">
<NAME>Endovascular treatment or endarterectomy for symptomatic carotid stenosis</NAME>
<DICH_OUTCOME CHI2="13.732183951807409" CI_END="2.30832026211718" CI_START="1.2859973198432408" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="OR" EFFECT_SIZE="1.7229317079973139" ESTIMABLE="YES" EVENTS_1="237" EVENTS_2="144" I2="27.178371371264546" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.3632960637649307" LOG_CI_START="0.10924006347272577" LOG_EFFECT_SIZE="0.23626806361882824" METHOD="MH" MODIFIED="2012-04-26 12:27:08 +0100" MODIFIED_BY="Leo H Bonati" NO="1" P_CHI2="0.18556179467571476" P_Q="1.0" P_Z="2.669024754979959E-4" Q="0.0" RANDOM="YES" SCALE="137.32" SORT_BY="USER" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.05680806269986446" TOTALS="YES" TOTAL_1="2896" TOTAL_2="2882" WEIGHT="100.0" Z="3.645471036758112">
<NAME>Death or any stroke between randomisation and 30 days after treatment</NAME>
<GROUP_LABEL_1>Endovascular</GROUP_LABEL_1>
<GROUP_LABEL_2>Endarterectomy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours endovascular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours endarterectomy</GRAPH_LABEL_2>
<DICH_DATA CI_END="1141.1781485259646" CI_START="1.870382816878338" EFFECT_SIZE="46.2" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="3.0573534471197634" LOG_CI_START="0.27193050399248764" LOG_EFFECT_SIZE="1.6646419755561255" MODIFIED="2011-04-07 05:35:54 +0100" MODIFIED_BY="Leo H Bonati" ORDER="141" O_E="0.0" SE="1.6361712248589013" STUDY_ID="STD-Leicester-1998" TOTAL_1="7" TOTAL_2="10" VAR="2.6770562770562774" WEIGHT="0.8146239176031064"/>
<DICH_DATA CI_END="8.610771955301907" CI_START="1.017223667936998" EFFECT_SIZE="2.9595744680851066" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.9350420876789284" LOG_CI_START="0.007416456433729546" LOG_EFFECT_SIZE="0.471229272056329" MODIFIED="2012-04-26 12:27:08 +0100" MODIFIED_BY="Leo H Bonati" ORDER="143" O_E="0.0" SE="0.5448918876143604" STUDY_ID="STD-Wallstent-2001" TOTAL_1="107" TOTAL_2="112" VAR="0.29690716918794074" WEIGHT="6.296226675796598">
<FOOTNOTE>Number of outcome events derived from percentages in abstract</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.5511624133453887" CI_START="0.8883884817831615" EFFECT_SIZE="1.505464480874317" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="28" LOG_CI_END="0.4067381077569552" LOG_CI_START="-0.05139708084220649" LOG_EFFECT_SIZE="0.1776705134573744" MODIFIED="2011-04-07 05:35:56 +0100" MODIFIED_BY="Leo H Bonati" ORDER="144" O_E="0.0" SE="0.2691108775889059" STUDY_ID="STD-CAVATAS_x002d_CEA-2001" TOTAL_1="221" TOTAL_2="231" VAR="0.07242066443667108" WEIGHT="17.233561979563447"/>
<DICH_DATA CI_END="7.903493981362571" CI_START="0.012526033124823309" EFFECT_SIZE="0.3146417445482866" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8978191269063819" LOG_CI_START="-1.902186444150841" LOG_EFFECT_SIZE="-0.5021836586222296" MODIFIED="2012-04-22 22:27:57 +0100" MODIFIED_BY="Leo H Bonati" ORDER="168" O_E="0.0" SE="1.6447371326901248" STUDY_ID="STD-Kentucky-2001" TOTAL_1="53" TOTAL_2="51" VAR="2.705160235649733" WEIGHT="0.8063348446027984"/>
<DICH_DATA CI_END="4.148006694258992" CI_START="0.10984191530611638" EFFECT_SIZE="0.675" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6178394486035498" LOG_CI_START="-0.9592319029415" LOG_EFFECT_SIZE="-0.17069622716897506" MODIFIED="2012-04-22 22:27:58 +0100" MODIFIED_BY="Leo H Bonati" ORDER="11109" O_E="0.0" SE="0.926379518526656" STUDY_ID="STD-TESCAS_x002d_C-2006" TOTAL_1="82" TOTAL_2="84" VAR="0.858179012345679" WEIGHT="2.433992063261359">
<FOOTNOTE>Includes data from patients with symptomatic and asymptomatic carotid stenosis</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="5.334916366746794" CI_START="1.256053307016904" EFFECT_SIZE="2.588617265087853" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="11" LOG_CI_END="0.7271276155608508" LOG_CI_START="0.09900807128972597" LOG_EFFECT_SIZE="0.4130678434252884" MODIFIED="2012-04-22 22:28:09 +0100" MODIFIED_BY="Leo H Bonati" ORDER="11110" O_E="0.0" SE="0.36896052954674813" STUDY_ID="STD-EVA_x002d_3S-2006" TOTAL_1="265" TOTAL_2="262" VAR="0.13613187236341678" WEIGHT="11.542821748733015"/>
<DICH_DATA CI_END="1.761445054099918" CI_START="0.7239014738576496" EFFECT_SIZE="1.1292088694223925" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="39" LOG_CI_END="0.24586910049859123" LOG_CI_START="-0.1403205391505368" LOG_EFFECT_SIZE="0.052774280674027216" MODIFIED="2012-04-22 22:28:09 +0100" MODIFIED_BY="Leo H Bonati" ORDER="11111" O_E="0.0" SE="0.22684970599944507" STUDY_ID="STD-SPACE-2006" TOTAL_1="607" TOTAL_2="589" VAR="0.051460789112034666" WEIGHT="20.56982448208447"/>
<DICH_DATA CI_END="8.33159693509127" CI_START="0.010916862780006007" EFFECT_SIZE="0.30158730158730157" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9207282515421643" LOG_CI_START="-1.9619021485436698" LOG_EFFECT_SIZE="-0.5205869485007528" MODIFIED="2012-04-22 22:28:10 +0100" MODIFIED_BY="Leo H Bonati" ORDER="11112" O_E="0.0" SE="1.693271366261031" STUDY_ID="STD-BACASS-2008" TOTAL_1="10" TOTAL_2="10" VAR="2.8671679197994986" WEIGHT="0.7616585402811404"/>
<DICH_DATA CI_END="24.865351153969893" CI_START="0.17655180691208816" EFFECT_SIZE="2.0952380952380953" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3955945968139534" LOG_CI_START="-0.753127833309417" LOG_EFFECT_SIZE="0.3212333817522682" MODIFIED="2012-04-22 22:29:22 +0100" MODIFIED_BY="Leo H Bonati" ORDER="11114" O_E="0.0" SE="1.2621701918020378" STUDY_ID="STD-Beijing-2009" TOTAL_1="23" TOTAL_2="23" VAR="1.593073593073593" WEIGHT="1.3498369842796614">
<FOOTNOTE>Includes data from patients with symptomatic and asymptomatic carotid stenosis</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.0576936022033623" CI_START="1.303833544191394" EFFECT_SIZE="1.9966781128695132" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="34" LOG_CI_END="0.48539396454943984" LOG_CI_START="0.11522215009719003" LOG_EFFECT_SIZE="0.30030805732331495" MODIFIED="2011-02-17 21:04:15 +0000" MODIFIED_BY="Leo H Bonati" ORDER="11115" O_E="0.0" SE="0.21744075618928535" STUDY_ID="STD-ICSS-2010" TOTAL_1="853" TOTAL_2="857" VAR="0.04728048245216824" WEIGHT="21.395930506999566"/>
<DICH_DATA CI_END="3.2880580036929823" CI_START="1.1175238282244249" EFFECT_SIZE="1.9168941461935092" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="21" LOG_CI_END="0.5169394702006163" LOG_CI_START="0.04825679207784766" LOG_EFFECT_SIZE="0.282598131139232" MODIFIED="2011-02-17 13:48:36 +0000" MODIFIED_BY="Leo H Bonati" ORDER="11116" O_E="0.0" SE="0.2753065251459877" STUDY_ID="STD-CREST-2010" TOTAL_1="668" TOTAL_2="653" VAR="0.07579368278795835" WEIGHT="16.79518825679483"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.170165979176222" CI_END="2.3484117078224904" CI_START="1.170646068507439" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="OR" EFFECT_SIZE="1.658058784542707" ESTIMABLE="YES" EVENTS_1="180" EVENTS_2="113" I2="38.15771580280685" I2_Q="80.95920862848443" ID="CMP-001.02" LOG_CI_END="0.3707742368521207" LOG_CI_START="0.06842561093217746" LOG_EFFECT_SIZE="0.2195999238921491" METHOD="MH" MODIFIED="2012-06-06 14:32:33 +0100" MODIFIED_BY="Leo H Bonati" NO="2" P_CHI2="0.09486375497227284" P_Q="0.02192309247054558" P_Z="0.004411990845034556" Q="5.251882553032793" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.11688961638036649" TOTALS="YES" TOTAL_1="1963" TOTAL_2="1959" WEIGHT="99.99999999999997" Z="2.847097059077185">
<NAME>Death or any stroke between randomisation and 30 days after treatment according to age</NAME>
<GROUP_LABEL_1>Endovascular</GROUP_LABEL_1>
<GROUP_LABEL_2>Endarterectomy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours endovascular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours endarterectomy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.9929177243229503" CI_END="1.6747439404864695" CI_START="0.7977142963292108" DF="4" EFFECT_SIZE="1.1558404665077155" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="57" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.22394841511335437" LOG_CI_START="-0.0981526246201365" LOG_EFFECT_SIZE="0.06289789524660892" MODIFIED="2012-06-06 14:32:33 +0100" MODIFIED_BY="Leo H Bonati" NO="1" P_CHI2="0.4069653833076957" P_Z="0.44399813214076256" STUDIES="6" TAU2="0.0" TOTAL_1="1006" TOTAL_2="988" WEIGHT="47.9227430276761" Z="0.7654592452649487">
<NAME>Age &lt; 70 years</NAME>
<DICH_DATA CI_END="299.8597123071941" CI_START="0.2701263179930581" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.4769181199842394" LOG_CI_START="-0.5684331011055893" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2011-04-14 07:44:02 +0100" MODIFIED_BY="Leo H Bonati" ORDER="155" O_E="0.0" SE="1.7888543819998317" STUDY_ID="STD-Leicester-1998" TOTAL_1="3" TOTAL_2="7" VAR="3.1999999999999997" WEIGHT="0.9509554761544726"/>
<DICH_DATA CI_END="2.695089711085943" CI_START="0.6236256381013398" EFFECT_SIZE="1.2964285714285715" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.43057322606492376" LOG_CI_START="-0.20507603867713717" LOG_EFFECT_SIZE="0.11274859369389331" MODIFIED="2011-03-30 10:07:38 +0100" MODIFIED_BY="Leo H Bonati" ORDER="156" O_E="0.0" SE="0.3733835246240934" STUDY_ID="STD-CAVATAS_x002d_CEA-2001" TOTAL_1="130" TOTAL_2="136" VAR="0.13941525646071098" WEIGHT="12.306493862302009"/>
<DICH_DATA CI_END="4.05742477828077" CI_START="0.5001212392818313" EFFECT_SIZE="1.4245014245014245" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6082504770674863" LOG_CI_START="-0.30092470132709664" LOG_EFFECT_SIZE="0.15366288787019472" MODIFIED="2011-03-30 10:07:38 +0100" MODIFIED_BY="Leo H Bonati" ORDER="157" O_E="0.0" SE="0.534054000278694" STUDY_ID="STD-EVA_x002d_3S-2006" TOTAL_1="127" TOTAL_2="106" VAR="0.28521367521367524" WEIGHT="7.844288794535089"/>
<DICH_DATA CI_END="1.397190676897558" CI_START="0.3795680951468401" EFFECT_SIZE="0.728236914600551" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="22" LOG_CI_END="0.1452556790372856" LOG_CI_START="-0.42071029962725015" LOG_EFFECT_SIZE="-0.13772731029498228" MODIFIED="2011-03-30 10:07:37 +0100" MODIFIED_BY="Leo H Bonati" ORDER="158" O_E="0.0" SE="0.33245121744432593" STUDY_ID="STD-SPACE-2006" TOTAL_1="347" TOTAL_2="333" VAR="0.11052381198021446" WEIGHT="13.869956436765795"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-04-14 13:43:14 +0100" MODIFIED_BY="Leo H Bonati" ORDER="196" O_E="0.0" SE="0.0" STUDY_ID="STD-BACASS-2008" TOTAL_1="4" TOTAL_2="2" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.9844986581597523" CI_START="0.7396039307106155" EFFECT_SIZE="1.4857142857142858" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="14" LOG_CI_END="0.4748713879675336" LOG_CI_START="-0.13100078939848653" LOG_EFFECT_SIZE="0.17193529928452353" MODIFIED="2011-03-30 10:07:42 +0100" MODIFIED_BY="Leo H Bonati" ORDER="197" O_E="0.0" SE="0.35589231610044725" STUDY_ID="STD-ICSS-2010" TOTAL_1="395" TOTAL_2="404" VAR="0.12665934065934065" WEIGHT="12.951048457918743"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.123839065141002" CI_END="3.29467667013468" CI_START="1.4650196843848535" DF="5" EFFECT_SIZE="2.196990253831557" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="56" I2="18.35187132101953" ID="CMP-001.02.02" LOG_CI_END="0.5178128006397893" LOG_CI_START="0.16584346002274888" LOG_EFFECT_SIZE="0.34182813033126913" MODIFIED="2011-09-22 10:52:19 +0100" MODIFIED_BY="Leo H Bonati" NO="2" P_CHI2="0.29435477275482025" P_Z="1.4067184166681592E-4" STUDIES="6" TAU2="0.04702792311317391" TOTAL_1="957" TOTAL_2="971" WEIGHT="52.07725697232387" Z="3.8069840013759135">
<NAME>Age &gt;/= 70 years</NAME>
<DICH_DATA CI_END="4042.0650708662793" CI_START="0.9819238261667526" EFFECT_SIZE="63.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="3.606603300691083" LOG_CI_START="-0.007922201783919221" LOG_EFFECT_SIZE="1.7993405494535817" MODIFIED="2011-04-14 07:43:44 +0100" MODIFIED_BY="Leo H Bonati" ORDER="160" O_E="0.0" SE="2.1231901723436146" STUDY_ID="STD-Leicester-1998" TOTAL_1="4" TOTAL_2="3" VAR="4.507936507936508" WEIGHT="0.6820179309903722"/>
<DICH_DATA CI_END="3.826590077600343" CI_START="0.8250349624419756" EFFECT_SIZE="1.7768147345612135" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" LOG_CI_END="0.582811941040442" LOG_CI_START="-0.08352764699687028" LOG_EFFECT_SIZE="0.24964214702178586" MODIFIED="2011-03-30 10:07:19 +0100" MODIFIED_BY="Leo H Bonati" ORDER="161" O_E="0.0" SE="0.3914111724472744" STUDY_ID="STD-CAVATAS_x002d_CEA-2001" TOTAL_1="91" TOTAL_2="95" VAR="0.15320270591654997" WEIGHT="11.678282143204878"/>
<DICH_DATA CI_END="11.83032246845201" CI_START="1.521753836544081" EFFECT_SIZE="4.24297520661157" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="5" LOG_CI_END="1.0729965826972967" LOG_CI_START="0.18234440534065216" LOG_EFFECT_SIZE="0.6276704940189745" MODIFIED="2011-03-30 10:07:19 +0100" MODIFIED_BY="Leo H Bonati" ORDER="162" O_E="0.0" SE="0.5231734977786752" STUDY_ID="STD-EVA_x002d_3S-2006" TOTAL_1="138" TOTAL_2="156" VAR="0.2737105087779734" WEIGHT="8.075302953930631"/>
<DICH_DATA CI_END="3.183047603126448" CI_START="0.9044715659511692" EFFECT_SIZE="1.6967545638945234" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="17" LOG_CI_END="0.5028431336321708" LOG_CI_START="-0.043605081589804154" LOG_EFFECT_SIZE="0.2296190260211833" MODIFIED="2011-03-30 10:07:18 +0100" MODIFIED_BY="Leo H Bonati" ORDER="163" O_E="0.0" SE="0.32098638658367845" STUDY_ID="STD-SPACE-2006" TOTAL_1="260" TOTAL_2="256" VAR="0.10303226037204667" WEIGHT="14.342431008115733"/>
<DICH_DATA CI_END="11.167759639734198" CI_START="0.013246076102544148" EFFECT_SIZE="0.38461538461538464" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.047966058192728" LOG_CI_START="-1.877912754134364" LOG_EFFECT_SIZE="-0.4149733479708179" MODIFIED="2011-04-14 13:43:26 +0100" MODIFIED_BY="Leo H Bonati" ORDER="194" O_E="0.0" SE="1.718675697694639" STUDY_ID="STD-BACASS-2008" TOTAL_1="6" TOTAL_2="8" VAR="2.9538461538461536" WEIGHT="1.027185202673475"/>
<DICH_DATA CI_END="4.0630026479478465" CI_START="1.3695995992311565" EFFECT_SIZE="2.358958837772397" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="20" LOG_CI_END="0.6088471053657332" LOG_CI_START="0.13659362025092064" LOG_EFFECT_SIZE="0.37272036280832693" MODIFIED="2011-03-30 10:07:27 +0100" MODIFIED_BY="Leo H Bonati" ORDER="195" O_E="0.0" SE="0.277404034848894" STUDY_ID="STD-ICSS-2010" TOTAL_1="458" TOTAL_2="453" VAR="0.07695299855044639" WEIGHT="16.272037733408787"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.123215525943813" CI_END="2.290331987444661" CI_START="1.2724132017663308" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="OR" EFFECT_SIZE="1.7071170602077366" ESTIMABLE="YES" EVENTS_1="220" EVENTS_2="133" I2="29.919704731751466" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.359898438612894" LOG_CI_START="0.1046281664275651" LOG_EFFECT_SIZE="0.23226330252022956" METHOD="MH" MODIFIED="2012-03-30 15:43:58 +0100" MODIFIED_BY="Leo H Bonati" NO="3" P_CHI2="0.14502096127393438" P_Q="0.5242005650878487" P_Z="3.615971172959307E-4" Q="0.40562094474157895" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.07882155213572292" TOTALS="YES" TOTAL_1="2631" TOTAL_2="2612" WEIGHT="100.00000000000001" Z="3.566633152954693">
<NAME>Death or any stroke between randomisation and 30 days after treatment according to sex</NAME>
<GROUP_LABEL_1>Endovascular</GROUP_LABEL_1>
<GROUP_LABEL_2>Endarterectomy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours endovascular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours endarterectomy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.24156904855576" CI_END="2.913664197010407" CI_START="1.191746022271838" DF="5" EFFECT_SIZE="1.8634236547342153" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="90" I2="55.522223113130586" ID="CMP-001.03.01" LOG_CI_END="0.46443949740342116" LOG_CI_START="0.07618371104315404" LOG_EFFECT_SIZE="0.27031160422328754" MODIFIED="2011-10-21 22:23:31 +0100" MODIFIED_BY="Leo H Bonati" NO="1" P_CHI2="0.046795321780794596" P_Z="0.006350091929316788" STUDIES="7" TAU2="0.15763079233860283" TOTAL_1="1827" TOTAL_2="1830" WEIGHT="62.07631627646586" Z="2.7291338725305194">
<NAME>Male</NAME>
<DICH_DATA CI_END="856.5291809361639" CI_START="0.851109356488266" EFFECT_SIZE="27.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.932742163452926" LOG_CI_START="-0.07001463513495126" LOG_EFFECT_SIZE="1.4313637641589874" MODIFIED="2011-04-14 07:47:16 +0100" MODIFIED_BY="Leo H Bonati" ORDER="191" O_E="0.0" SE="1.7638342073763937" STUDY_ID="STD-Leicester-1998" TOTAL_1="5" TOTAL_2="4" VAR="3.111111111111111" WEIGHT="0.704845889467898"/>
<DICH_DATA CI_END="2.8526301406777317" CI_START="0.8457821153132972" EFFECT_SIZE="1.5532879818594105" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="21" LOG_CI_END="0.45524546661836685" LOG_CI_START="-0.0727415025691927" LOG_EFFECT_SIZE="0.19125198202458707" MODIFIED="2011-03-30 10:08:18 +0100" MODIFIED_BY="Leo H Bonati" ORDER="192" O_E="0.0" SE="0.3101421592784212" STUDY_ID="STD-CAVATAS_x002d_CEA-2001" TOTAL_1="156" TOTAL_2="158" VAR="0.09618815896188158" WEIGHT="12.847349505736606"/>
<DICH_DATA CI_END="8.279916938120683" CI_START="1.4259099116941196" EFFECT_SIZE="3.436046511627907" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="7" LOG_CI_END="0.9180259800823702" LOG_CI_START="0.15409208786504267" LOG_EFFECT_SIZE="0.5360590339737065" MODIFIED="2011-03-30 10:08:18 +0100" MODIFIED_BY="Leo H Bonati" ORDER="193" O_E="0.0" SE="0.44873854982221245" STUDY_ID="STD-EVA_x002d_3S-2006" TOTAL_1="193" TOTAL_2="204" VAR="0.20136628609654225" WEIGHT="8.02465567226036"/>
<DICH_DATA CI_END="1.7535284678236593" CI_START="0.6136060391591398" EFFECT_SIZE="1.0372924648786719" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="29" LOG_CI_END="0.24391282086957095" LOG_CI_START="-0.2121103746774214" LOG_EFFECT_SIZE="0.015901223096074783" MODIFIED="2011-03-30 10:08:18 +0100" MODIFIED_BY="Leo H Bonati" ORDER="194" O_E="0.0" SE="0.2678702824155273" STUDY_ID="STD-SPACE-2006" TOTAL_1="436" TOTAL_2="422" VAR="0.07175448820137434" WEIGHT="14.932063031644063"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-04-14 13:45:17 +0100" MODIFIED_BY="Leo H Bonati" ORDER="198" O_E="0.0" SE="0.0" STUDY_ID="STD-BACASS-2008" TOTAL_1="8" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.726311798283009" CI_START="1.5510184719240487" EFFECT_SIZE="2.7075075075075077" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="18" LOG_CI_END="0.6745223689694471" LOG_CI_START="0.19061697009401346" LOG_EFFECT_SIZE="0.43256966953173026" MODIFIED="2011-03-30 10:08:22 +0100" MODIFIED_BY="Leo H Bonati" ORDER="199" O_E="0.0" SE="0.28424842666978617" STUDY_ID="STD-ICSS-2010" TOTAL_1="601" TOTAL_2="606" VAR="0.0807971680642488" WEIGHT="14.086135526911168"/>
<DICH_DATA CI_END="2.9098632253655916" CI_START="0.7612593371536214" EFFECT_SIZE="1.4883415435139573" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="15" LOG_CI_END="0.46387257597388326" LOG_CI_START="-0.11846736752895226" LOG_EFFECT_SIZE="0.17270260422246547" MODIFIED="2011-10-21 22:23:31 +0100" MODIFIED_BY="Leo H Bonati" ORDER="219" O_E="0.0" SE="0.34206936544277633" STUDY_ID="STD-CREST-2010" TOTAL_1="428" TOTAL_2="427" VAR="0.11701145077442365" WEIGHT="11.48126665044577"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.624326789158419" CI_END="2.2936498220843196" CI_START="1.0236643214128394" DF="6" EFFECT_SIZE="1.5322948439130848" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="43" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.36052711367634815" LOG_CI_START="0.010157566739398707" LOG_EFFECT_SIZE="0.18534234020787346" MODIFIED="2011-10-21 22:24:30 +0100" MODIFIED_BY="Leo H Bonati" NO="2" P_CHI2="0.46655933188120813" P_Z="0.038115856903864834" STUDIES="7" TAU2="0.0" TOTAL_1="804" TOTAL_2="782" WEIGHT="37.923683723534154" Z="2.0736066521396217">
<NAME>Female</NAME>
<DICH_DATA CI_END="505.2151532922644" CI_START="0.33451094825383093" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.7034763681946905" LOG_CI_START="-0.47558966358101695" LOG_EFFECT_SIZE="1.1139433523068367" MODIFIED="2011-04-14 07:47:45 +0100" MODIFIED_BY="Leo H Bonati" ORDER="196" O_E="0.0" SE="1.867399123695705" STUDY_ID="STD-Leicester-1998" TOTAL_1="2" TOTAL_2="6" VAR="3.487179487179487" WEIGHT="0.6305132557674982"/>
<DICH_DATA CI_END="3.875363479851643" CI_START="0.45186594453544615" EFFECT_SIZE="1.3233082706766917" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.5883124422979958" LOG_CI_START="-0.3449903886038678" LOG_EFFECT_SIZE="0.12166102684706401" MODIFIED="2011-03-30 10:08:47 +0100" MODIFIED_BY="Leo H Bonati" ORDER="197" O_E="0.0" SE="0.5482267027952769" STUDY_ID="STD-CAVATAS_x002d_CEA-2001" TOTAL_1="65" TOTAL_2="73" VAR="0.3005525176577808" WEIGHT="5.926633115944752"/>
<DICH_DATA CI_END="4.572545295310845" CI_START="0.32940042139157105" EFFECT_SIZE="1.2272727272727273" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6601580162602365" LOG_CI_START="-0.4822758495866744" LOG_EFFECT_SIZE="0.08894108333678108" MODIFIED="2011-03-30 10:08:46 +0100" MODIFIED_BY="Leo H Bonati" ORDER="198" O_E="0.0" SE="0.6710713079373163" STUDY_ID="STD-EVA_x002d_3S-2006" TOTAL_1="72" TOTAL_2="58" VAR="0.45033670033670037" WEIGHT="4.2490330914494985"/>
<DICH_DATA CI_END="3.246526105245649" CI_START="0.6037222361566985" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" LOG_CI_END="0.5114188993752778" LOG_CI_START="-0.21916282801880171" LOG_EFFECT_SIZE="0.146128035678238" MODIFIED="2011-03-30 10:08:46 +0100" MODIFIED_BY="Leo H Bonati" ORDER="199" O_E="0.0" SE="0.4291473231091581" STUDY_ID="STD-SPACE-2006" TOTAL_1="171" TOTAL_2="167" VAR="0.18416742493175614" WEIGHT="8.549449297990943"/>
<DICH_DATA CI_END="5.494146058001736" CI_START="8.089418077940443E-4" EFFECT_SIZE="0.06666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7399002006508034" LOG_CI_START="-3.092082718762166" LOG_EFFECT_SIZE="-1.1760912590556813" MODIFIED="2011-04-14 13:45:28 +0100" MODIFIED_BY="Leo H Bonati" ORDER="200" O_E="0.0" SE="2.250925735484551" STUDY_ID="STD-BACASS-2008" TOTAL_1="2" TOTAL_2="1" VAR="5.066666666666666" WEIGHT="0.4369674615428878"/>
<DICH_DATA CI_END="2.5855213522012717" CI_START="0.6366323731557573" EFFECT_SIZE="1.2829756795422032" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="15" LOG_CI_END="0.4125481286889813" LOG_CI_START="-0.1961112810065106" LOG_EFFECT_SIZE="0.10821842384123533" MODIFIED="2011-03-30 10:08:51 +0100" MODIFIED_BY="Leo H Bonati" ORDER="201" O_E="0.0" SE="0.3575295501678016" STUDY_ID="STD-ICSS-2010" TOTAL_1="252" TOTAL_2="251" VAR="0.12782737924319054" WEIGHT="10.880341409780666"/>
<DICH_DATA CI_END="7.630277043743233" CI_START="1.158354833953941" EFFECT_SIZE="2.972972972972973" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="6" LOG_CI_END="0.882540306812628" LOG_CI_START="0.06384161536983222" LOG_EFFECT_SIZE="0.47319096109123004" MODIFIED="2011-10-21 22:24:30 +0100" MODIFIED_BY="Leo H Bonati" ORDER="220" O_E="0.0" SE="0.48090766397738066" STUDY_ID="STD-CREST-2010" TOTAL_1="240" TOTAL_2="226" VAR="0.23127218127218127" WEIGHT="7.25074609105791"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.657096485377725" CI_END="2.4728340683627144" CI_START="1.3086094746453851" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="OR" EFFECT_SIZE="1.7988813443596945" ESTIMABLE="YES" EVENTS_1="233" EVENTS_2="139" I2="39.95074151800521" I2_Q="43.01056580951897" ID="CMP-001.04" LOG_CI_END="0.39319497539397924" LOG_CI_START="0.1168100603695827" LOG_EFFECT_SIZE="0.25500251788178097" METHOD="MH" MODIFIED="2012-06-06 14:33:16 +0100" MODIFIED_BY="Leo H Bonati" NO="4" P_CHI2="0.11241454748948765" P_Q="0.18528567547038655" P_Z="2.984237295216231E-4" Q="1.7547112270980056" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.07376340290532107" TOTALS="YES" TOTAL_1="2738" TOTAL_2="2724" WEIGHT="100.0" Z="3.6166644693412797">
<NAME>Death or any stroke between randomisation and 30 days after treatment according to minimum pre-trial experience in endovascular treatment of carotid stenosis</NAME>
<GROUP_LABEL_1>Endovascular</GROUP_LABEL_1>
<GROUP_LABEL_2>Endarterectomy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours endovascular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours endarterectomy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.82279206659787" CI_END="3.1211756761853158" CI_START="1.431174104804228" DF="4" EFFECT_SIZE="2.1135150352673744" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="78" I2="31.30443343588066" ID="CMP-001.04.01" LOG_CI_END="0.49431821373123996" LOG_CI_START="0.15569246964821193" LOG_EFFECT_SIZE="0.325005341689726" MODIFIED="2012-06-06 14:33:16 +0100" MODIFIED_BY="Leo H Bonati" NO="1" P_CHI2="0.21277898325764766" P_Z="1.6838598385944173E-4" STUDIES="5" TAU2="0.059241365217587716" TOTAL_1="1453" TOTAL_2="1472" WEIGHT="60.431846768913964" Z="3.762258337563435">
<NAME>10 or fewer procedures</NAME>
<DICH_DATA CI_END="1141.1781485259646" CI_START="1.870382816878338" EFFECT_SIZE="46.2" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="3.0573534471197634" LOG_CI_START="0.27193050399248764" LOG_EFFECT_SIZE="1.6646419755561255" MODIFIED="2011-04-15 14:23:02 +0100" MODIFIED_BY="Leo H Bonati" ORDER="164" O_E="0.0" SE="1.6361712248589013" STUDY_ID="STD-Leicester-1998" TOTAL_1="7" TOTAL_2="10" VAR="2.6770562770562774" WEIGHT="0.9581681989550588"/>
<DICH_DATA CI_END="8.610771955301907" CI_START="1.017223667936998" EFFECT_SIZE="2.9595744680851066" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.9350420876789284" LOG_CI_START="0.007416456433729546" LOG_EFFECT_SIZE="0.471229272056329" MODIFIED="2011-10-27 10:42:41 +0100" MODIFIED_BY="Leo H Bonati" ORDER="165" O_E="0.0" SE="0.5448918876143604" STUDY_ID="STD-Wallstent-2001" TOTAL_1="107" TOTAL_2="112" VAR="0.29690716918794074" WEIGHT="7.110755848553778"/>
<DICH_DATA CI_END="2.5511624133453887" CI_START="0.8883884817831615" EFFECT_SIZE="1.505464480874317" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="28" LOG_CI_END="0.4067381077569552" LOG_CI_START="-0.05139708084220649" LOG_EFFECT_SIZE="0.1776705134573744" MODIFIED="2011-10-22 23:47:55 +0100" MODIFIED_BY="Leo H Bonati" ORDER="166" O_E="0.0" SE="0.2691108775889059" STUDY_ID="STD-CAVATAS_x002d_CEA-2001" TOTAL_1="221" TOTAL_2="231" VAR="0.07242066443667108" WEIGHT="18.03033659087281"/>
<DICH_DATA CI_END="5.334916366746794" CI_START="1.256053307016904" EFFECT_SIZE="2.588617265087853" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="11" LOG_CI_END="0.7271276155608508" LOG_CI_START="0.09900807128972597" LOG_EFFECT_SIZE="0.4130678434252884" MODIFIED="2011-10-22 23:47:54 +0100" MODIFIED_BY="Leo H Bonati" ORDER="167" O_E="0.0" SE="0.36896052954674813" STUDY_ID="STD-EVA_x002d_3S-2006" TOTAL_1="265" TOTAL_2="262" VAR="0.13613187236341678" WEIGHT="12.557442920162334"/>
<DICH_DATA CI_END="3.0576936022033623" CI_START="1.303833544191394" EFFECT_SIZE="1.9966781128695132" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="34" LOG_CI_END="0.48539396454943984" LOG_CI_START="0.11522215009719003" LOG_EFFECT_SIZE="0.30030805732331495" MODIFIED="2011-10-22 23:47:54 +0100" MODIFIED_BY="Leo H Bonati" ORDER="231" O_E="0.0" SE="0.21744075618928535" STUDY_ID="STD-ICSS-2010" TOTAL_1="853" TOTAL_2="857" VAR="0.04728048245216824" WEIGHT="21.775143210369986"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.0131288582906866" CI_END="2.2536919758129206" CI_START="0.8551332513056981" DF="2" EFFECT_SIZE="1.388238793118268" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="61" I2="33.62381451105357" ID="CMP-001.04.02" LOG_CI_END="0.35289455840659345" LOG_CI_START="-0.067966205976259" LOG_EFFECT_SIZE="0.14246417621516722" MODIFIED="2011-04-18 21:49:06 +0100" MODIFIED_BY="Leo H Bonati" NO="2" P_CHI2="0.22167030653486963" P_Z="0.1845345632706489" STUDIES="3" TAU2="0.062382939948680105" TOTAL_1="1285" TOTAL_2="1252" WEIGHT="39.56815323108604" Z="1.3269217665293596">
<NAME>More than 10 procedures</NAME>
<DICH_DATA CI_END="1.761445054099918" CI_START="0.7239014738576496" EFFECT_SIZE="1.1292088694223925" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="39" LOG_CI_END="0.24586910049859123" LOG_CI_START="-0.1403205391505368" LOG_EFFECT_SIZE="0.052774280674027216" MODIFIED="2011-04-18 21:49:05 +0100" MODIFIED_BY="Leo H Bonati" ORDER="154" O_E="0.0" SE="0.22684970599944507" STUDY_ID="STD-SPACE-2006" TOTAL_1="607" TOTAL_2="589" VAR="0.051460789112034666" WEIGHT="21.048232741111466"/>
<DICH_DATA CI_END="8.33159693509127" CI_START="0.010916862780006007" EFFECT_SIZE="0.30158730158730157" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9207282515421643" LOG_CI_START="-1.9619021485436698" LOG_EFFECT_SIZE="-0.5205869485007528" MODIFIED="2011-04-18 21:49:06 +0100" MODIFIED_BY="Leo H Bonati" ORDER="160" O_E="0.0" SE="1.693271366261031" STUDY_ID="STD-BACASS-2008" TOTAL_1="10" TOTAL_2="10" VAR="2.8671679197994986" WEIGHT="0.8962289999940557"/>
<DICH_DATA CI_END="3.2880580036929823" CI_START="1.1175238282244249" EFFECT_SIZE="1.9168941461935092" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="21" LOG_CI_END="0.5169394702006163" LOG_CI_START="0.04825679207784766" LOG_EFFECT_SIZE="0.282598131139232" MODIFIED="2011-04-18 21:49:06 +0100" MODIFIED_BY="Leo H Bonati" ORDER="163" O_E="0.0" SE="0.2753065251459877" STUDY_ID="STD-CREST-2010" TOTAL_1="668" TOTAL_2="653" VAR="0.07579368278795835" WEIGHT="17.623691489980523"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.8161853535996757" CI_END="1.769486708473013" CI_START="0.9300029631866846" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="1.28282028445116" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="70" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.24784730477601669" LOG_CI_START="-0.03151566768953174" LOG_EFFECT_SIZE="0.10816581854324245" METHOD="MH" MODIFIED="2012-03-30 15:45:01 +0100" MODIFIED_BY="Leo H Bonati" NO="5" P_CHI2="0.5761727155349032" P_Q="1.0" P_Z="0.12907827731476074" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2016" TOTAL_2="2028" WEIGHT="100.0" Z="1.5177466564878737">
<NAME>Death or major or disabling stroke between randomisation and 30 days after treatment</NAME>
<GROUP_LABEL_1>Endovascular</GROUP_LABEL_1>
<GROUP_LABEL_2>Endarterectomy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours endovascular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours endarterectomy</GRAPH_LABEL_2>
<DICH_DATA CI_END="385.86353811271505" CI_START="0.6913785611426413" EFFECT_SIZE="16.333333333333332" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.586433742177016" LOG_CI_START="-0.16028409155931345" LOG_EFFECT_SIZE="1.2130748253088512" MODIFIED="2012-03-30 15:45:01 +0100" MODIFIED_BY="Leo H Bonati" ORDER="217" O_E="0.0" SE="1.6134356520092779" STUDY_ID="STD-Leicester-1998" TOTAL_1="7" TOTAL_2="10" VAR="2.6031746031746033" WEIGHT="1.0344502084509601"/>
<DICH_DATA CI_END="2.1105309091796767" CI_START="0.5214053643341762" EFFECT_SIZE="1.0490196078431373" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="0.3243917168732163" LOG_CI_START="-0.28282450502663214" LOG_EFFECT_SIZE="0.0207836059232921" MODIFIED="2011-10-27 10:45:27 +0100" MODIFIED_BY="Leo H Bonati" ORDER="11125" O_E="0.0" SE="0.3566818145127458" STUDY_ID="STD-CAVATAS_x002d_CEA-2001" TOTAL_1="221" TOTAL_2="231" VAR="0.1272219168041048" WEIGHT="21.16659282091031"/>
<DICH_DATA CI_END="7.903493981362571" CI_START="0.012526033124823309" EFFECT_SIZE="0.3146417445482866" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8978191269063819" LOG_CI_START="-1.902186444150841" LOG_EFFECT_SIZE="-0.5021836586222296" MODIFIED="2011-10-27 10:45:27 +0100" MODIFIED_BY="Leo H Bonati" ORDER="11126" O_E="0.0" SE="1.6447371326901248" STUDY_ID="STD-Kentucky-2001" TOTAL_1="53" TOTAL_2="51" VAR="2.705160235649733" WEIGHT="0.995451018169146"/>
<DICH_DATA CI_END="4.672097859698868" CI_START="0.599218396710862" EFFECT_SIZE="1.673202614379085" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6695119307400715" LOG_CI_START="-0.22241486175157" LOG_EFFECT_SIZE="0.22354853449425077" MODIFIED="2011-02-17 22:05:11 +0000" MODIFIED_BY="Leo H Bonati" ORDER="11128" O_E="0.0" SE="0.523922213018419" STUDY_ID="STD-EVA_x002d_3S-2006" TOTAL_1="265" TOTAL_2="262" VAR="0.27449448529411763" WEIGHT="9.810231735631598"/>
<DICH_DATA CI_END="2.2995161301761717" CI_START="0.762814870751092" EFFECT_SIZE="1.3244263285024154" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="23" LOG_CI_END="0.3616364603209866" LOG_CI_START="-0.11758084915750833" LOG_EFFECT_SIZE="0.12202780558173916" MODIFIED="2011-02-17 22:05:12 +0000" MODIFIED_BY="Leo H Bonati" ORDER="11129" O_E="0.0" SE="0.2814946197516076" STUDY_ID="STD-SPACE-2006" TOTAL_1="607" TOTAL_2="589" VAR="0.07923922094910217" WEIGHT="33.98385898591707"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-17 22:05:12 +0000" MODIFIED_BY="Leo H Bonati" ORDER="11130" O_E="0.0" SE="0.0" STUDY_ID="STD-BACASS-2008" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.200571169595974" CI_START="0.7182841186853713" EFFECT_SIZE="1.2572332015810277" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="23" LOG_CI_END="0.3425354188262496" LOG_CI_START="-0.14370373574344678" LOG_EFFECT_SIZE="0.09941584154140137" MODIFIED="2011-02-17 22:05:12 +0000" MODIFIED_BY="Leo H Bonati" ORDER="11131" O_E="0.0" SE="0.2856192863168731" STUDY_ID="STD-ICSS-2010" TOTAL_1="853" TOTAL_2="875" VAR="0.08157837671615993" WEIGHT="33.009415230920915"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.379491957999611" CI_END="2.3837900013805378" CI_START="0.8664156769792013" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4371336151598326" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="28" I2="0.0" I2_Q="39.02082536338681" ID="CMP-001.06" LOG_CI_END="0.3772679938288186" LOG_CI_START="-0.062273698160248026" LOG_EFFECT_SIZE="0.15749714783428528" METHOD="MH" MODIFIED="2012-04-26 12:28:32 +0100" MODIFIED_BY="Leo H Bonati" NO="6" P_CHI2="0.6137564326075317" P_Q="0.20033868704129498" P_Z="0.16014214232874913" Q="1.6399041245789163" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3593" TOTAL_2="3668" WEIGHT="200.0" Z="1.4045936622124038">
<NAME>Death of any cause between randomisation and 30 days after treatment</NAME>
<GROUP_LABEL_1>Endovascular</GROUP_LABEL_1>
<GROUP_LABEL_2>Endarterectomy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours endovascular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours endarterectomy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.73939251705467" CI_END="2.7040368847518224" CI_START="0.9373233811970305" DF="6" EFFECT_SIZE="1.5920292069233728" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="24" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.43201261135795954" LOG_CI_START="-0.02811054951784858" LOG_EFFECT_SIZE="0.2019510309200555" MODIFIED="2012-04-26 12:28:32 +0100" MODIFIED_BY="Leo H Bonati" NO="1" P_CHI2="0.7118943738939143" P_Z="0.08534491083748343" STUDIES="11" TAU2="0.0" TOTAL_1="3426" TOTAL_2="3501" WEIGHT="100.0" Z="1.720481735762389">
<NAME>Standard surgical risk</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-30 15:45:28 +0100" MODIFIED_BY="Leo H Bonati" ORDER="142" O_E="0.0" SE="0.0" STUDY_ID="STD-Leicester-1998" TOTAL_1="7" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.181502466249906" CI_START="0.6326116490994926" EFFECT_SIZE="2.131455399061033" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.8562153139553397" LOG_CI_START="-0.1988628151186073" LOG_EFFECT_SIZE="0.3286762494183662" MODIFIED="2012-04-21 22:18:26 +0100" MODIFIED_BY="Leo H Bonati" ORDER="167" O_E="0.0" SE="0.6197581157390063" STUDY_ID="STD-CAVATAS_x002d_CEA-2001" TOTAL_1="221" TOTAL_2="231" VAR="0.3841001220243635" WEIGHT="19.018617674895026"/>
<DICH_DATA CI_END="7.903493981362571" CI_START="0.012526033124823309" EFFECT_SIZE="0.3146417445482866" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8978191269063819" LOG_CI_START="-1.902186444150841" LOG_EFFECT_SIZE="-0.5021836586222296" MODIFIED="2012-04-22 22:33:15 +0100" MODIFIED_BY="Leo H Bonati" ORDER="169" O_E="0.0" SE="1.6447371326901248" STUDY_ID="STD-Kentucky-2001" TOTAL_1="53" TOTAL_2="51" VAR="2.705160235649733" WEIGHT="2.700414294648002"/>
<DICH_DATA CI_END="5.692419940608614" CI_START="0.04500914305811889" EFFECT_SIZE="0.5061728395061729" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7552969313211894" LOG_CI_START="-1.346699255639018" LOG_EFFECT_SIZE="-0.29570116215891423" MODIFIED="2012-04-26 12:28:32 +0100" MODIFIED_BY="Leo H Bonati" ORDER="233" O_E="0.0" SE="1.2347229652693616" STUDY_ID="STD-TESCAS_x002d_C-2006" TOTAL_1="82" TOTAL_2="84" VAR="1.5245408009635653" WEIGHT="4.791641761929124">
<FOOTNOTE>Includes data from patients with symptomatic and asymptomatic carotid stenosis</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.9614530970115265" CI_START="0.10880553650923566" EFFECT_SIZE="0.6565272496831432" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.597854518313933" LOG_CI_START="-0.9633490052423075" LOG_EFFECT_SIZE="-0.18274724346418728" MODIFIED="2012-04-22 22:33:17 +0100" MODIFIED_BY="Leo H Bonati" ORDER="234" O_E="0.0" SE="0.9170586778190142" STUDY_ID="STD-EVA_x002d_3S-2006" TOTAL_1="265" TOTAL_2="262" VAR="0.8409966185631585" WEIGHT="8.686186375092172"/>
<DICH_DATA CI_END="4.49762653299336" CI_START="0.4147079502785407" EFFECT_SIZE="1.3657237936772046" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6529833903183759" LOG_CI_START="-0.38225763878837293" LOG_EFFECT_SIZE="0.13536287576500153" MODIFIED="2012-04-22 22:33:17 +0100" MODIFIED_BY="Leo H Bonati" ORDER="11139" O_E="0.0" SE="0.6081057050230457" STUDY_ID="STD-SPACE-2006" TOTAL_1="607" TOTAL_2="689" VAR="0.36979254848157556" WEIGHT="19.754463413764167"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-22 22:33:18 +0100" MODIFIED_BY="Leo H Bonati" ORDER="11140" O_E="0.0" SE="0.0" STUDY_ID="STD-BACASS-2008" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-22 22:33:18 +0100" MODIFIED_BY="Leo H Bonati" ORDER="11141" O_E="0.0" SE="0.0" STUDY_ID="STD-Regensburg-2008" TOTAL_1="43" TOTAL_2="44" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-22 22:34:59 +0100" MODIFIED_BY="Leo H Bonati" ORDER="11143" O_E="0.0" SE="0.0" STUDY_ID="STD-Beijing-2009" TOTAL_1="23" TOTAL_2="23" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Includes data from patients with symptomatic and asymptomatic carotid stenosis</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="6.4344836313060965" CI_START="0.7701701240984129" EFFECT_SIZE="2.226128266033254" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.8085137004132962" LOG_CI_START="-0.1134133322347825" LOG_EFFECT_SIZE="0.34755018408925686" MODIFIED="2011-02-17 23:20:26 +0000" MODIFIED_BY="Leo H Bonati" ORDER="11144" O_E="0.0" SE="0.5415445025898941" STUDY_ID="STD-ICSS-2010" TOTAL_1="853" TOTAL_2="857" VAR="0.2932704482853357" WEIGHT="24.908931030631795"/>
<DICH_DATA CI_END="7.225956980385236" CI_START="0.6817175335695209" EFFECT_SIZE="2.2194732641660018" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.8588953716747213" LOG_CI_START="-0.16639553593470227" LOG_EFFECT_SIZE="0.3462499178700095" MODIFIED="2012-04-22 22:34:55 +0100" MODIFIED_BY="Leo H Bonati" ORDER="11145" O_E="0.0" SE="0.6022609544016211" STUDY_ID="STD-CREST-2010" TOTAL_1="1262" TOTAL_2="1240" VAR="0.36271825719675155" WEIGHT="20.139745449039722">
<FOOTNOTE>Includes data from patients with symptomatic and asymptomatic carotid stenosis</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.734041280425773" CI_START="0.08923644519632903" DF="0" EFFECT_SIZE="0.49393939393939396" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.4368050675565217" LOG_CI_START="-1.049457738504381" LOG_EFFECT_SIZE="-0.3063263354739297" MODIFIED="2011-04-19 22:19:39 +0100" MODIFIED_BY="Leo H Bonati" NO="2" P_CHI2="1.0" P_Z="0.41913830091238413" STUDIES="1" TAU2="0.0" TOTAL_1="167" TOTAL_2="167" WEIGHT="100.0" Z="0.8079171228623673">
<NAME>Elevated surgical risk</NAME>
<DICH_DATA CI_END="2.734041280425773" CI_START="0.08923644519632903" EFFECT_SIZE="0.49393939393939396" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4368050675565217" LOG_CI_START="-1.049457738504381" LOG_EFFECT_SIZE="-0.3063263354739297" MODIFIED="2011-04-19 22:19:39 +0100" MODIFIED_BY="Leo H Bonati" ORDER="216" O_E="0.0" SE="0.8730381293997184" STUDY_ID="STD-SAPPHIRE-2004" TOTAL_1="167" TOTAL_2="167" VAR="0.7621955753857594" WEIGHT="100.0">
<FOOTNOTE>Includes data from patients with symptomatic and asymptomatic carotid stenosis</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.348172106905878" CI_END="2.2890677828801924" CI_START="1.3853113802823074" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="OR" EFFECT_SIZE="1.7807503053099614" ESTIMABLE="YES" EVENTS_1="220" EVENTS_2="132" I2="4.170638823052757" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.35965865300437344" LOG_CI_START="0.14154740194858767" LOG_EFFECT_SIZE="0.25060302747648056" METHOD="MH" MODIFIED="2012-04-30 00:52:32 +0100" MODIFIED_BY="Leo H Bonati" NO="7" P_CHI2="0.4002195491591133" P_Q="0.5188120871300026" P_Z="6.672545517825095E-6" Q="0.4162541951492582" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0057604056805855555" TOTALS="SUB" TOTAL_1="2874" TOTAL_2="2955" WEIGHT="200.0" Z="4.503875026098287">
<NAME>Any stroke between randomisation and 30 days after treatment</NAME>
<GROUP_LABEL_1>Endovascular</GROUP_LABEL_1>
<GROUP_LABEL_2>Endarterectomy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours endovascular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours endarterectomy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.944050940052272" CI_END="2.3428105533746866" CI_START="1.4019876037094683" DF="7" EFFECT_SIZE="1.8123441598303094" ESTIMABLE="YES" EVENTS_1="214" EVENTS_2="127" I2="11.883747311998736" ID="CMP-001.07.01" LOG_CI_END="0.3697371716740328" LOG_CI_START="0.14674417364178477" LOG_EFFECT_SIZE="0.2582406726579088" MODIFIED="2012-04-22 22:37:18 +0100" MODIFIED_BY="Leo H Bonati" NO="1" P_CHI2="0.3375534116767852" P_Z="5.637804279546563E-6" STUDIES="9" TAU2="0.016460912154969434" TOTAL_1="2707" TOTAL_2="2788" WEIGHT="100.0" Z="4.539536417907644">
<NAME>Standard surgical risk</NAME>
<DICH_DATA CI_END="1141.1781485259646" CI_START="1.870382816878338" EFFECT_SIZE="46.2" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="3.0573534471197634" LOG_CI_START="0.27193050399248764" LOG_EFFECT_SIZE="1.6646419755561255" MODIFIED="2012-04-22 22:36:23 +0100" MODIFIED_BY="Leo H Bonati" ORDER="170" O_E="0.0" SE="1.6361712248589013" STUDY_ID="STD-Leicester-1998" TOTAL_1="7" TOTAL_2="10" VAR="2.6770562770562774" WEIGHT="0.6369977604986687"/>
<DICH_DATA CI_END="2.94372692051921" CI_START="0.9945392275454871" EFFECT_SIZE="1.7110382513661202" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="25" LOG_CI_END="0.4688975195199541" LOG_CI_START="-0.002378082352961143" LOG_EFFECT_SIZE="0.23325971858349648" MODIFIED="2012-04-22 22:36:23 +0100" MODIFIED_BY="Leo H Bonati" ORDER="242" O_E="0.0" SE="0.27682962139200346" STUDY_ID="STD-CAVATAS_x002d_CEA-2001" TOTAL_1="221" TOTAL_2="231" VAR="0.07663463928003998" WEIGHT="18.430143985881205"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-22 22:36:24 +0100" MODIFIED_BY="Leo H Bonati" ORDER="243" O_E="0.0" SE="0.0" STUDY_ID="STD-Kentucky-2001" TOTAL_1="53" TOTAL_2="53" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.806343259878928" CI_START="1.294342670300616" EFFECT_SIZE="2.7414225941422594" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="10" LOG_CI_END="0.7639027069115437" LOG_CI_START="0.112049268696905" LOG_EFFECT_SIZE="0.43797598780422436" MODIFIED="2012-04-22 22:36:24 +0100" MODIFIED_BY="Leo H Bonati" ORDER="11153" O_E="0.0" SE="0.38290193633383796" STUDY_ID="STD-EVA_x002d_3S-2006" TOTAL_1="265" TOTAL_2="262" VAR="0.14661389284820248" WEIGHT="10.521333552162522"/>
<DICH_DATA CI_END="2.1630680899475503" CI_START="0.8768193310511524" EFFECT_SIZE="1.377178243963324" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="37" LOG_CI_END="0.3350701905547012" LOG_CI_START="-0.05708988395516827" LOG_EFFECT_SIZE="0.13899015329976644" MODIFIED="2012-04-22 22:36:25 +0100" MODIFIED_BY="Leo H Bonati" ORDER="11154" O_E="0.0" SE="0.2303567689907738" STUDY_ID="STD-SPACE-2006" TOTAL_1="607" TOTAL_2="689" VAR="0.05306424101986874" WEIGHT="24.67832631849828"/>
<DICH_DATA CI_END="8.33159693509127" CI_START="0.010916862780006007" EFFECT_SIZE="0.30158730158730157" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9207282515421643" LOG_CI_START="-1.9619021485436698" LOG_EFFECT_SIZE="-0.5205869485007528" MODIFIED="2012-04-22 22:36:26 +0100" MODIFIED_BY="Leo H Bonati" ORDER="11155" O_E="0.0" SE="1.693271366261031" STUDY_ID="STD-BACASS-2008" TOTAL_1="10" TOTAL_2="10" VAR="2.8671679197994986" WEIGHT="0.5950018249156294"/>
<DICH_DATA CI_END="24.865351153969893" CI_START="0.17655180691208816" EFFECT_SIZE="2.0952380952380953" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3955945968139534" LOG_CI_START="-0.753127833309417" LOG_EFFECT_SIZE="0.3212333817522682" MODIFIED="2012-04-22 22:37:18 +0100" MODIFIED_BY="Leo H Bonati" ORDER="11156" O_E="0.0" SE="1.2621701918020378" STUDY_ID="STD-Beijing-2009" TOTAL_1="23" TOTAL_2="23" VAR="1.593073593073593" WEIGHT="1.066000394411293">
<FOOTNOTE>Includes data from patients with symptomatic and asymptomatic carotid stenosis</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.1302437627868738" CI_START="1.3045483913588223" EFFECT_SIZE="2.0207806573957017" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="32" LOG_CI_END="0.4955781588598981" LOG_CI_START="0.11546019360129464" LOG_EFFECT_SIZE="0.30551917623059643" MODIFIED="2011-02-18 15:17:35 +0000" MODIFIED_BY="Leo H Bonati" ORDER="11157" O_E="0.0" SE="0.22328317440717804" STUDY_ID="STD-ICSS-2010" TOTAL_1="853" TOTAL_2="857" VAR="0.049855375973346286" WEIGHT="25.87244349491322"/>
<DICH_DATA CI_END="3.0486872522798123" CI_START="1.0214742471851586" EFFECT_SIZE="1.764697003999698" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="21" LOG_CI_END="0.48411287481614834" LOG_CI_START="0.009227421926504546" LOG_EFFECT_SIZE="0.24667014837132642" MODIFIED="2011-04-19 16:19:32 +0100" MODIFIED_BY="Leo H Bonati" ORDER="11159" O_E="0.0" SE="0.2789500657482805" STUDY_ID="STD-CREST-2010" TOTAL_1="668" TOTAL_2="653" VAR="0.07781313918097002" WEIGHT="18.199752668719178"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.0358073313787814" CI_START="0.3612520698979869" DF="0" EFFECT_SIZE="1.2074534161490684" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="0.6059304249295133" LOG_CI_START="-0.4421896558127011" LOG_EFFECT_SIZE="0.0818703845584061" MODIFIED="2012-04-30 00:52:32 +0100" MODIFIED_BY="Leo H Bonati" NO="2" P_CHI2="1.0" P_Z="0.7594584443444314" STUDIES="1" TAU2="0.0" TOTAL_1="167" TOTAL_2="167" WEIGHT="100.0" Z="0.30619202529025125">
<NAME>Elevated surgical risk</NAME>
<DICH_DATA CI_END="4.0358073313787814" CI_START="0.3612520698979869" EFFECT_SIZE="1.2074534161490684" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6059304249295133" LOG_CI_START="-0.4421896558127011" LOG_EFFECT_SIZE="0.0818703845584061" MODIFIED="2012-04-30 00:52:32 +0100" MODIFIED_BY="Leo H Bonati" ORDER="217" O_E="0.0" SE="0.6156709237060519" STUDY_ID="STD-SAPPHIRE-2004" TOTAL_1="167" TOTAL_2="167" VAR="0.3790506862970632" WEIGHT="100.0">
<FOOTNOTE>Includes data from patients with symptomatic and asymptomatic carotid stenosis</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.499167065133458" CI_END="1.8356418131006225" CI_START="0.9719162622630168" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3356983678370145" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="70" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.2637879416964345" LOG_CI_START="-0.012371151126903608" LOG_EFFECT_SIZE="0.12570839528476546" METHOD="MH" MODIFIED="2012-04-24 23:16:53 +0100" MODIFIED_BY="Leo H Bonati" NO="8" P_CHI2="0.744080556341616" P_Q="0.43862823873978707" P_Z="0.07436482432434097" Q="0.5998688389596816" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2851" TOTAL_2="2848" WEIGHT="200.00000000000003" Z="1.784362229709955">
<NAME>Fatal, major or disabling stroke between randomisation and 30 days after treatment</NAME>
<GROUP_LABEL_1>Endovascular</GROUP_LABEL_1>
<GROUP_LABEL_2>Endarterectomy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours endovascular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours endarterectomy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.899982643834235" CI_END="1.8869817282278494" CI_START="0.9890269649477537" DF="5" EFFECT_SIZE="1.3661170563246243" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="67" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.275767694882346" LOG_CI_START="-0.004791867585458169" LOG_EFFECT_SIZE="0.1354879136484439" MODIFIED="2012-04-24 23:16:53 +0100" MODIFIED_BY="Leo H Bonati" NO="1" P_CHI2="0.7154023269640679" P_Z="0.058356158142844866" STUDIES="8" TAU2="0.0" TOTAL_1="2684" TOTAL_2="2681" WEIGHT="100.00000000000003" Z="1.8930128686802217">
<NAME>Standard surgical risk</NAME>
<DICH_DATA CI_END="385.86353811271505" CI_START="0.6913785611426413" EFFECT_SIZE="16.333333333333332" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.586433742177016" LOG_CI_START="-0.16028409155931345" LOG_EFFECT_SIZE="1.2130748253088512" MODIFIED="2012-03-30 15:57:13 +0100" MODIFIED_BY="Leo H Bonati" ORDER="144" O_E="0.0" SE="1.6134356520092779" STUDY_ID="STD-Leicester-1998" TOTAL_1="7" TOTAL_2="10" VAR="2.6031746031746033" WEIGHT="1.0433308680176012"/>
<DICH_DATA CI_END="2.687636188691834" CI_START="0.6207695761790765" EFFECT_SIZE="1.2916666666666667" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.42937048017903073" LOG_CI_START="-0.2070695759336973" LOG_EFFECT_SIZE="0.11115045212266668" MODIFIED="2011-10-27 10:56:21 +0100" MODIFIED_BY="Leo H Bonati" ORDER="145" O_E="0.0" SE="0.3738480393897037" STUDY_ID="STD-CAVATAS_x002d_CEA-2001" TOTAL_1="221" TOTAL_2="231" VAR="0.13976235655552544" WEIGHT="19.432789237869777"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-10-27 10:56:21 +0100" MODIFIED_BY="Leo H Bonati" ORDER="146" O_E="0.0" SE="0.0" STUDY_ID="STD-Kentucky-2001" TOTAL_1="53" TOTAL_2="51" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.465828459587843" CI_START="0.5974139076298036" EFFECT_SIZE="1.80703125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.7376559976048204" LOG_CI_START="-0.22372467135931823" LOG_EFFECT_SIZE="0.25696566312275104" MODIFIED="2011-04-13 14:36:07 +0100" MODIFIED_BY="Leo H Bonati" ORDER="147" O_E="0.0" SE="0.5647197638605972" STUDY_ID="STD-EVA_x002d_3S-2006" TOTAL_1="265" TOTAL_2="262" VAR="0.3189084116947687" WEIGHT="8.51646528825657"/>
<DICH_DATA CI_END="2.485594406036003" CI_START="0.7956438353945988" EFFECT_SIZE="1.406288685318148" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="21" LOG_CI_END="0.3954302628449106" LOG_CI_START="-0.09928129776284941" LOG_EFFECT_SIZE="0.1480744825410306" MODIFIED="2011-04-13 14:36:39 +0100" MODIFIED_BY="Leo H Bonati" ORDER="148" O_E="0.0" SE="0.29059601956271797" STUDY_ID="STD-SPACE-2006" TOTAL_1="607" TOTAL_2="589" VAR="0.08444604658569557" WEIGHT="32.16222106472887"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-04-13 14:19:17 +0100" MODIFIED_BY="Leo H Bonati" ORDER="149" O_E="0.0" SE="0.0" STUDY_ID="STD-BACASS-2008" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.1311014460984747" CI_START="0.6504088626671586" EFFECT_SIZE="1.1773220747889024" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="21" LOG_CI_END="0.3286041237790236" LOG_CI_START="-0.186813549546187" LOG_EFFECT_SIZE="0.07089528711641829" MODIFIED="2011-04-13 14:36:44 +0100" MODIFIED_BY="Leo H Bonati" ORDER="150" O_E="0.0" SE="0.30275889266985945" STUDY_ID="STD-ICSS-2010" TOTAL_1="853" TOTAL_2="875" VAR="0.09166294709067949" WEIGHT="29.629992320066915"/>
<DICH_DATA CI_END="3.787967208412431" CI_START="0.45101600391053465" EFFECT_SIZE="1.307070707070707" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5784062107570079" LOG_CI_START="-0.3458080472867446" LOG_EFFECT_SIZE="0.11629908173513166" MODIFIED="2012-04-24 23:16:53 +0100" MODIFIED_BY="Leo H Bonati" ORDER="151" O_E="0.0" SE="0.5428880301092611" STUDY_ID="STD-CREST-2010" TOTAL_1="668" TOTAL_2="653" VAR="0.29472741323591406" WEIGHT="9.215201221060282"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.01747951609014" CI_START="0.10929080339141609" DF="0" EFFECT_SIZE="0.6626262626262627" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="0.6039536711051522" LOG_CI_START="-0.9614163815489313" LOG_EFFECT_SIZE="-0.1787313552218896" MODIFIED="2011-10-29 22:32:20 +0100" MODIFIED_BY="Leo H Bonati" NO="2" P_CHI2="1.0" P_Z="0.6544629306815755" STUDIES="1" TAU2="0.0" TOTAL_1="167" TOTAL_2="167" WEIGHT="100.0" Z="0.4475708712441424">
<NAME>Elevated surgical risk</NAME>
<DICH_DATA CI_END="4.01747951609014" CI_START="0.10929080339141609" EFFECT_SIZE="0.6626262626262627" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6039536711051522" LOG_CI_START="-0.9614163815489313" LOG_EFFECT_SIZE="-0.1787313552218896" MODIFIED="2011-10-29 22:32:20 +0100" MODIFIED_BY="Leo H Bonati" ORDER="218" O_E="0.0" SE="0.9195061176357388" STUDY_ID="STD-SAPPHIRE-2004" TOTAL_1="167" TOTAL_2="167" VAR="0.8454915003695491" WEIGHT="100.0">
<FOOTNOTE>Includes data from patients with symptomatic and asymptomatic carotid stenosis.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8272897930933438" CI_END="0.7705861433830938" CI_START="0.23835064534708428" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="0.428567036262568" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-0.11317880470060175" LOG_CI_START="-0.6227836678598753" LOG_EFFECT_SIZE="-0.3679812362802385" METHOD="MH" MODIFIED="2012-04-30 00:56:17 +0100" MODIFIED_BY="Leo H Bonati" NO="9" P_CHI2="0.9913219069578472" P_Q="0.8384758463040675" P_Z="0.004646864764295893" Q="0.04155220453105263" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2857" TOTAL_2="2836" WEIGHT="200.0" Z="2.8305458689093235">
<NAME>Myocardial infarction between randomisation and 30 days after treatment</NAME>
<GROUP_LABEL_1>Endovascular</GROUP_LABEL_1>
<GROUP_LABEL_2>Endarterectomy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours endovascular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours endarterectomy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7877441567398076" CI_END="0.8727196575540761" CI_START="0.22570096503188947" DF="5" EFFECT_SIZE="0.4438171570728819" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="27" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="-0.059125241666927245" LOG_CI_START="-0.6464665840009776" LOG_EFFECT_SIZE="-0.3527959128339524" MODIFIED="2012-04-13 12:41:30 +0100" MODIFIED_BY="Leo H Bonati" NO="1" P_CHI2="0.9778084668009487" P_Z="0.018544298292844347" STUDIES="8" TAU2="0.0" TOTAL_1="2690" TOTAL_2="2669" WEIGHT="99.99999999999999" Z="2.3545670403504713">
<NAME>Standard surgical risk</NAME>
<DICH_DATA CI_END="2.8695293978765504" CI_START="0.007568645936376055" EFFECT_SIZE="0.1473718155433731" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.45781067838430684" LOG_CI_START="-2.1209818107192593" LOG_EFFECT_SIZE="-0.8315855661674761" MODIFIED="2011-03-02 16:33:56 +0000" MODIFIED_BY="Leo H Bonati" ORDER="210" O_E="0.0" SE="1.5147954733281306" STUDY_ID="STD-CAVATAS_x002d_CEA-2001" TOTAL_1="221" TOTAL_2="231" VAR="2.2946053260153954" WEIGHT="5.187383420375003"/>
<DICH_DATA CI_END="5.463785252982133" CI_START="0.04437978860804286" EFFECT_SIZE="0.49242424242424243" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7374936216255917" LOG_CI_START="-1.3528147707515803" LOG_EFFECT_SIZE="-0.3076605745629943" MODIFIED="2012-04-13 12:41:30 +0100" MODIFIED_BY="Leo H Bonati" ORDER="211" O_E="0.0" SE="1.2278574968757705" STUDY_ID="STD-EVA_x002d_3S-2006" TOTAL_1="265" TOTAL_2="262" VAR="1.5076340326340327" WEIGHT="7.895150525144592"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-03-01 09:51:50 +0000" MODIFIED_BY="Leo H Bonati" ORDER="212" O_E="0.0" SE="0.0" STUDY_ID="STD-SPACE-2006" TOTAL_1="607" TOTAL_2="589" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-04-28 12:13:48 +0100" MODIFIED_BY="Leo H Bonati" ORDER="212" O_E="0.0" SE="0.0" STUDY_ID="STD-BACASS-2008" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.410399935975454" CI_START="0.013211156658060183" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9248166480996348" LOG_CI_START="-1.87905915753896" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-04-28 12:14:34 +0100" MODIFIED_BY="Leo H Bonati" ORDER="213" O_E="0.0" SE="1.6470105276411926" STUDY_ID="STD-Regensburg-2008" TOTAL_1="43" TOTAL_2="44" VAR="2.71264367816092" WEIGHT="4.387969463260383"/>
<DICH_DATA CI_END="2.5244673689565453" CI_START="0.1432762075574563" EFFECT_SIZE="0.6014117647058823" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.4021697614154622" LOG_CI_START="-0.8438259225433602" LOG_EFFECT_SIZE="-0.220828080563949" MODIFIED="2011-03-01 09:52:52 +0000" MODIFIED_BY="Leo H Bonati" ORDER="214" O_E="0.0" SE="0.7319040325355205" STUDY_ID="STD-ICSS-2010" TOTAL_1="853" TOTAL_2="857" VAR="0.5356835128417563" WEIGHT="22.220205287506484"/>
<DICH_DATA CI_END="1.112004622401928" CI_START="0.18245064703016456" EFFECT_SIZE="0.4504286434694907" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="0.046106592533339104" LOG_CI_START="-0.7388545921451437" LOG_EFFECT_SIZE="-0.34637399980590233" MODIFIED="2011-03-01 09:52:56 +0000" MODIFIED_BY="Leo H Bonati" ORDER="215" O_E="0.0" SE="0.46109008550067143" STUDY_ID="STD-CREST-2010" TOTAL_1="668" TOTAL_2="653" VAR="0.2126040669470165" WEIGHT="55.98668828589629"/>
<DICH_DATA CI_END="8.25071507921647" CI_START="0.012345117057205592" EFFECT_SIZE="0.3191489361702128" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9164915899438332" LOG_CI_START="-1.9085047877039052" LOG_EFFECT_SIZE="-0.4960065988800362" MODIFIED="2011-04-28 13:25:39 +0100" MODIFIED_BY="Leo H Bonati" ORDER="215" O_E="0.0" SE="1.6594168561878815" STUDY_ID="STD-Beijing-2009" TOTAL_1="23" TOTAL_2="23" VAR="2.7536643026004723" WEIGHT="4.3226030178172525"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2539099287950246" CI_START="0.11837983693645748" DF="0" EFFECT_SIZE="0.3852760736196319" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="0.09826634125369885" LOG_CI_START="-0.9267222625872222" LOG_EFFECT_SIZE="-0.4142279606667617" MODIFIED="2012-04-30 00:56:17 +0100" MODIFIED_BY="Leo H Bonati" NO="2" P_CHI2="1.0" P_Z="0.1131577967528233" STUDIES="1" TAU2="0.0" TOTAL_1="167" TOTAL_2="167" WEIGHT="100.0" Z="1.584157875032004">
<NAME>Elevated surgical risk</NAME>
<DICH_DATA CI_END="1.2539099287950246" CI_START="0.11837983693645748" EFFECT_SIZE="0.3852760736196319" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.09826634125369885" LOG_CI_START="-0.9267222625872222" LOG_EFFECT_SIZE="-0.4142279606667617" MODIFIED="2012-04-30 00:56:17 +0100" MODIFIED_BY="Leo H Bonati" ORDER="214" O_E="0.0" SE="0.6020833796715749" STUDY_ID="STD-SAPPHIRE-2004" TOTAL_1="167" TOTAL_2="167" VAR="0.3625043960767458" WEIGHT="100.0">
<FOOTNOTE>Includes data from patients with symptomatic and asymptomatic stenosis</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.16014488125966" CI_END="1.671719421721706" CI_START="1.0803374785753868" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3438828613195168" ESTIMABLE="YES" EVENTS_1="229" EVENTS_2="173" I2="46.237257098021004" I2_Q="82.62882177529924" ID="CMP-001.10" LOG_CI_END="0.2231633880412311" LOG_CI_START="0.03355944269850511" LOG_EFFECT_SIZE="0.12836141536986814" METHOD="MH" MODIFIED="2012-04-30 00:59:04 +0100" MODIFIED_BY="Leo H Bonati" NO="10" P_CHI2="0.08355139885337859" P_Q="0.016426279817385425" P_Z="0.007959527465339775" Q="5.756661908966319" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.07250578712079837" TOTALS="SUB" TOTAL_1="2791" TOTAL_2="2769" WEIGHT="200.0" Z="2.6537818152968025">
<NAME>Death or any stroke or myocardial infarction between randomisation and 30 days after treatment</NAME>
<GROUP_LABEL_1>Endovascular</GROUP_LABEL_1>
<GROUP_LABEL_2>Endarterectomy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours endovascular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours endarterectomy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.382502480076048" CI_END="1.8032259051887425" CI_START="1.1489240306213657" DF="5" EFFECT_SIZE="1.4393642954826658" ESTIMABLE="YES" EVENTS_1="221" EVENTS_2="157" I2="7.106406016382247" ID="CMP-001.10.01" LOG_CI_END="0.25605013783230574" LOG_CI_START="0.06029131313328262" LOG_EFFECT_SIZE="0.15817072548279418" MODIFIED="2012-04-03 05:30:23 +0100" MODIFIED_BY="Leo H Bonati" NO="1" P_CHI2="0.3710020356613405" P_Z="0.001538860338528343" STUDIES="6" TAU2="0.005845421403624566" TOTAL_1="2624" TOTAL_2="2602" WEIGHT="100.0" Z="3.1672536431650884">
<NAME>Standard surgical risk</NAME>
<DICH_DATA CI_END="2.2421014795301186" CI_START="0.8004723815190911" EFFECT_SIZE="1.3396791820906047" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="31" LOG_CI_END="0.3506552652627779" LOG_CI_START="-0.09665364783059943" LOG_EFFECT_SIZE="0.1270008087160892" MODIFIED="2012-04-03 05:30:23 +0100" MODIFIED_BY="Leo H Bonati" ORDER="202" O_E="0.0" SE="0.2627514697658801" STUDY_ID="STD-CAVATAS_x002d_CEA-2001" TOTAL_1="221" TOTAL_2="231" VAR="0.06903833486413019" WEIGHT="17.65754333724969"/>
<DICH_DATA CI_END="4.952567258767092" CI_START="1.22322546524245" EFFECT_SIZE="2.461322081575246" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="12" LOG_CI_END="0.6948303822243276" LOG_CI_START="0.08750651368872861" LOG_EFFECT_SIZE="0.3911684479565281" MODIFIED="2011-03-01 10:10:31 +0000" MODIFIED_BY="Leo H Bonati" ORDER="203" O_E="0.0" SE="0.3567450466794451" STUDY_ID="STD-EVA_x002d_3S-2006" TOTAL_1="265" TOTAL_2="262" VAR="0.12726702833031947" WEIGHT="9.93342977457609"/>
<DICH_DATA CI_END="1.761445054099918" CI_START="0.7239014738576496" EFFECT_SIZE="1.1292088694223925" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="39" LOG_CI_END="0.24586910049859123" LOG_CI_START="-0.1403205391505368" LOG_EFFECT_SIZE="0.052774280674027216" MODIFIED="2011-03-01 09:56:47 +0000" MODIFIED_BY="Leo H Bonati" ORDER="204" O_E="0.0" SE="0.22684970599944507" STUDY_ID="STD-SPACE-2006" TOTAL_1="607" TOTAL_2="589" VAR="0.051460789112034666" WEIGHT="23.073645241166442"/>
<DICH_DATA CI_END="8.33159693509127" CI_START="0.010916862780006007" EFFECT_SIZE="0.30158730158730157" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9207282515421643" LOG_CI_START="-1.9619021485436698" LOG_EFFECT_SIZE="-0.5205869485007528" MODIFIED="2011-03-01 09:55:40 +0000" MODIFIED_BY="Leo H Bonati" ORDER="205" O_E="0.0" SE="1.693271366261031" STUDY_ID="STD-BACASS-2008" TOTAL_1="10" TOTAL_2="10" VAR="2.8671679197994986" WEIGHT="0.4602356531349078"/>
<DICH_DATA CI_END="2.6040122789754916" CI_START="1.149499121824909" EFFECT_SIZE="1.730118443316413" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="39" LOG_CI_END="0.4156430277758496" LOG_CI_START="0.06050864382039849" LOG_EFFECT_SIZE="0.23807583579812408" MODIFIED="2011-03-01 10:10:43 +0000" MODIFIED_BY="Leo H Bonati" ORDER="206" O_E="0.0" SE="0.20860769507898433" STUDY_ID="STD-ICSS-2010" TOTAL_1="853" TOTAL_2="857" VAR="0.04351717044616651" WEIGHT="26.78674522556537"/>
<DICH_DATA CI_END="2.0113017452201407" CI_START="0.8087467813311282" EFFECT_SIZE="1.2753955514790185" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="35" LOG_CI_END="0.303477230444309" LOG_CI_START="-0.09218743473488053" LOG_EFFECT_SIZE="0.10564489785471425" MODIFIED="2011-03-01 10:11:36 +0000" MODIFIED_BY="Leo H Bonati" ORDER="207" O_E="0.0" SE="0.23241538289793598" STUDY_ID="STD-CREST-2010" TOTAL_1="668" TOTAL_2="653" VAR="0.054016910207594186" WEIGHT="22.08840076830751"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.150311569957029E-32" CI_END="1.141853666017428" CI_START="0.19746457918671645" DF="0" EFFECT_SIZE="0.4748427672955975" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" I2="100.0" ID="CMP-001.10.02" LOG_CI_END="0.05761045057075723" LOG_CI_START="-0.7045107959532838" LOG_EFFECT_SIZE="-0.32345017269126325" MODIFIED="2012-04-30 00:59:04 +0100" MODIFIED_BY="Leo H Bonati" NO="2" P_CHI2="0.0" P_Z="0.09618282219281107" STUDIES="1" TAU2="0.0" TOTAL_1="167" TOTAL_2="167" WEIGHT="100.0" Z="1.663647856976886">
<NAME>Elevated surgical risk</NAME>
<DICH_DATA CI_END="1.141853666017428" CI_START="0.19746457918671645" EFFECT_SIZE="0.4748427672955975" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="0.05761045057075723" LOG_CI_START="-0.7045107959532838" LOG_EFFECT_SIZE="-0.32345017269126325" MODIFIED="2012-04-30 00:59:04 +0100" MODIFIED_BY="Leo H Bonati" ORDER="215" O_E="0.0" SE="0.4476737927692351" STUDY_ID="STD-SAPPHIRE-2004" TOTAL_1="167" TOTAL_2="167" VAR="0.20041182473239202" WEIGHT="100.0">
<FOOTNOTE>Includes data from patients with symptomatic and asymptomatic stenosis</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.585294562861065" CI_END="1.7491550401956437" CI_START="1.1046327956983697" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3900266264216696" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="143" I2="0.0" I2_Q="49.249429406135185" ID="CMP-001.11" LOG_CI_END="0.24282830582930232" LOG_CI_START="0.04321793294831224" LOG_EFFECT_SIZE="0.14302311938880724" METHOD="MH" MODIFIED="2012-04-29 21:01:12 +0100" MODIFIED_BY="Leo H Bonati" NO="11" P_CHI2="0.4732957972797067" P_Q="0.16040347679495226" P_Z="0.00497460992722012" Q="1.9704211958572324" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1890" TOTAL_2="1863" WEIGHT="100.0" Z="2.8086733060286857">
<NAME>Death or any stroke between randomisation and 30 days after treatment or ipsilateral stroke until the end of follow-up</NAME>
<GROUP_LABEL_1>Endovascular</GROUP_LABEL_1>
<GROUP_LABEL_2>Endarterectomy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours endovascular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours endarterectomy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2626564831893687" CI_END="1.6373135878839635" CI_START="0.7525237345456866" DF="3" EFFECT_SIZE="1.1100078088810175" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="52" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="0.21413186600012737" LOG_CI_START="-0.12347979790067441" LOG_EFFECT_SIZE="0.04532603404972648" MODIFIED="2012-04-29 21:01:12 +0100" MODIFIED_BY="Leo H Bonati" NO="1" P_CHI2="0.7380192721998161" P_Z="0.5987008355013453" STUDIES="4" TAU2="0.0" TOTAL_1="693" TOTAL_2="673" WEIGHT="34.95677242328931" Z="0.5262696985824673">
<NAME>18 to 24 months follow-up</NAME>
<DICH_DATA CI_END="7.903493981362571" CI_START="0.012526033124823309" EFFECT_SIZE="0.3146417445482866" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8978191269063819" LOG_CI_START="-1.902186444150841" LOG_EFFECT_SIZE="-0.5021836586222296" MODIFIED="2012-04-03 23:18:16 +0100" MODIFIED_BY="Leo H Bonati" ORDER="162" O_E="0.0" SE="1.6447371326901248" STUDY_ID="STD-Kentucky-2001" TOTAL_1="53" TOTAL_2="51" VAR="2.705160235649733" WEIGHT="0.5082161021514654"/>
<DICH_DATA CI_END="1.633485103307256" CI_START="0.7348440799486291" EFFECT_SIZE="1.0956079854809437" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="50" LOG_CI_END="0.21311517824766246" LOG_CI_START="-0.13380480023739194" LOG_EFFECT_SIZE="0.03965518900513526" MODIFIED="2012-04-22 22:45:15 +0100" MODIFIED_BY="Leo H Bonati" ORDER="171" O_E="0.0" SE="0.20378251264371047" STUDY_ID="STD-SPACE-2006" TOTAL_1="607" TOTAL_2="589" VAR="0.041527312459384014" WEIGHT="33.106067049286715"/>
<DICH_DATA CI_END="91.60140785423062" CI_START="0.12002500934582783" EFFECT_SIZE="3.3157894736842106" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9619021485436698" LOG_CI_START="-0.9207282515421643" LOG_EFFECT_SIZE="0.5205869485007527" MODIFIED="2012-04-22 22:45:16 +0100" MODIFIED_BY="Leo H Bonati" ORDER="185" O_E="0.0" SE="1.693271366261031" STUDY_ID="STD-BACASS-2008" TOTAL_1="10" TOTAL_2="10" VAR="2.8671679197994986" WEIGHT="0.47949964184629523"/>
<DICH_DATA CI_END="24.865351153969893" CI_START="0.17655180691208816" EFFECT_SIZE="2.0952380952380953" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3955945968139534" LOG_CI_START="-0.753127833309417" LOG_EFFECT_SIZE="0.3212333817522682" MODIFIED="2012-04-29 21:01:12 +0100" MODIFIED_BY="Leo H Bonati" ORDER="204" O_E="0.0" SE="1.2621701918020378" STUDY_ID="STD-Beijing-2009" TOTAL_1="23" TOTAL_2="23" VAR="1.593073593073593" WEIGHT="0.862989630004831">
<FOOTNOTE>Includes data from patients with symptomatic and asymptomatic carotid stenosis</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.349279822448587" CI_END="2.1649003686411716" CI_START="1.1614855172447618" DF="3" EFFECT_SIZE="1.5857176370509873" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="91" I2="10.42850525977361" ID="CMP-001.11.02" LOG_CI_END="0.3354379143868427" LOG_CI_START="0.06501379888020888" LOG_EFFECT_SIZE="0.20022585663352577" MODIFIED="2012-04-21 22:39:00 +0100" MODIFIED_BY="Leo H Bonati" NO="2" P_CHI2="0.340842573133442" P_Z="0.0037035041901267614" STUDIES="4" TAU2="0.011527917925414514" TOTAL_1="1197" TOTAL_2="1190" WEIGHT="65.04322757671069" Z="2.902370352881964">
<NAME>4 years follow-up or longer</NAME>
<DICH_DATA CI_END="2.3302863019812525" CI_START="0.9263407038951065" EFFECT_SIZE="1.4692307692307693" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="40" LOG_CI_END="0.36740928228441183" LOG_CI_START="-0.03322925240263025" LOG_EFFECT_SIZE="0.1670900149408908" MODIFIED="2011-04-28 12:08:33 +0100" MODIFIED_BY="Leo H Bonati" ORDER="175" O_E="0.0" SE="0.23533705846789976" STUDY_ID="STD-CAVATAS_x002d_CEA-2001" TOTAL_1="221" TOTAL_2="231" VAR="0.055383531088323674" WEIGHT="24.823371923768374"/>
<DICH_DATA CI_END="4.221203279957881" CI_START="1.12249137648542" EFFECT_SIZE="2.1767554479418885" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="14" LOG_CI_END="0.6254362669230008" LOG_CI_START="0.050183013230654654" LOG_EFFECT_SIZE="0.33780964007682773" MODIFIED="2011-04-28 12:08:33 +0100" MODIFIED_BY="Leo H Bonati" ORDER="176" O_E="0.0" SE="0.3379066087684146" STUDY_ID="STD-EVA_x002d_3S-2006" TOTAL_1="265" TOTAL_2="262" VAR="0.11418087624937043" WEIGHT="12.040597653625271"/>
<DICH_DATA CI_END="237.40081743062237" CI_START="0.6809288315602833" EFFECT_SIZE="12.714285714285714" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.3754822100060933" LOG_CI_START="-0.16689827674478128" LOG_EFFECT_SIZE="1.1042919666306559" MODIFIED="2012-04-21 22:39:00 +0100" MODIFIED_BY="Leo H Bonati" ORDER="181" O_E="0.0" SE="1.4934068829038412" STUDY_ID="STD-Regensburg-2008" TOTAL_1="43" TOTAL_2="44" VAR="2.2302641179045675" WEIGHT="0.6164319192601899"/>
<DICH_DATA CI_END="2.1319057094499785" CI_START="0.8883007067620936" EFFECT_SIZE="1.3761443777651232" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="37" LOG_CI_END="0.3287679926757692" LOG_CI_START="-0.0514399923515189" LOG_EFFECT_SIZE="0.13866400016212513" MODIFIED="2011-04-28 12:08:46 +0100" MODIFIED_BY="Leo H Bonati" ORDER="209" O_E="0.0" SE="0.2233360524649084" STUDY_ID="STD-CREST-2010" TOTAL_1="668" TOTAL_2="653" VAR="0.049878992330608315" WEIGHT="27.56282608005686"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.841201420688547" CI_END="1.8440085171431748" CI_START="1.072824241106636" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4065194765797948" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="170" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.26576292265022444" LOG_CI_START="0.03052857809848807" LOG_EFFECT_SIZE="0.1481457503743563" METHOD="MH" MODIFIED="2012-04-30 10:15:48 +0100" MODIFIED_BY="Leo H Bonati" NO="12" P_CHI2="0.44559931030151056" P_Q="0.9286799943270275" P_Z="0.013560864564490524" Q="0.008011277055121913" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="804" TOTAL_2="817" WEIGHT="100.00000000000001" Z="2.4686899844468844">
<NAME>Death or any stroke between randomisation and end of follow-up</NAME>
<GROUP_LABEL_1>Endovascular</GROUP_LABEL_1>
<GROUP_LABEL_2>Endarterectomy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours endovascular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours endarterectomy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.942242433492232" CI_END="4.098019096166843" CI_START="0.5257189482488943" DF="3" EFFECT_SIZE="1.4677895929392324" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="16" I2="39.29880938923966" ID="CMP-001.12.01" LOG_CI_END="0.6125739778183638" LOG_CI_START="-0.27924636962103544" LOG_EFFECT_SIZE="0.1666638040986642" MODIFIED="2012-04-29 21:03:21 +0100" MODIFIED_BY="Leo H Bonati" NO="1" P_CHI2="0.17607577117642603" P_Z="0.46382807676852544" STUDIES="4" TAU2="0.41186384541105303" TOTAL_1="265" TOTAL_2="270" WEIGHT="14.985311897997732" Z="0.7325579742550508">
<NAME>6 to 24 months follow-up</NAME>
<DICH_DATA CI_END="11.84307402804237" CI_START="1.1773188072649048" EFFECT_SIZE="3.734042553191489" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="1.0734644439526229" LOG_CI_START="0.07089408177962792" LOG_EFFECT_SIZE="0.5721792628661254" MODIFIED="2012-04-03 23:31:19 +0100" MODIFIED_BY="Leo H Bonati" ORDER="143" O_E="0.0" SE="0.5889147935437491" STUDY_ID="STD-Wallstent-2001" TOTAL_1="107" TOTAL_2="112" VAR="0.3468206340546766" WEIGHT="5.505182687567269"/>
<DICH_DATA CI_END="7.903493981362571" CI_START="0.012526033124823309" EFFECT_SIZE="0.3146417445482866" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8978191269063819" LOG_CI_START="-1.902186444150841" LOG_EFFECT_SIZE="-0.5021836586222296" MODIFIED="2012-04-03 23:32:07 +0100" MODIFIED_BY="Leo H Bonati" ORDER="163" O_E="0.0" SE="1.6447371326901248" STUDY_ID="STD-Kentucky-2001" TOTAL_1="53" TOTAL_2="51" VAR="2.705160235649733" WEIGHT="0.7058032737311494"/>
<DICH_DATA CI_END="2.1399946311717475" CI_START="0.2990661708574334" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.3304126837905884" LOG_CI_START="-0.5242327098067012" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2012-04-03 23:31:20 +0100" MODIFIED_BY="Leo H Bonati" ORDER="164" O_E="0.0" SE="0.5020229347619759" STUDY_ID="STD-TESCAS_x002d_C-2006" TOTAL_1="82" TOTAL_2="84" VAR="0.25202702702702706" WEIGHT="7.575818247795134">
<FOOTNOTE>Includes data from patients with symptomatic and asymptomatic carotid stenosis</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="24.865351153969893" CI_START="0.17655180691208816" EFFECT_SIZE="2.0952380952380953" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3955945968139534" LOG_CI_START="-0.753127833309417" LOG_EFFECT_SIZE="0.3212333817522682" MODIFIED="2012-04-29 21:03:21 +0100" MODIFIED_BY="Leo H Bonati" ORDER="172" O_E="0.0" SE="1.2621701918020378" STUDY_ID="STD-Beijing-2009" TOTAL_1="23" TOTAL_2="23" VAR="1.593073593073593" WEIGHT="1.1985076889041792">
<FOOTNOTE>Includes data from patients with symptomatic and asymptomatic carotid stenosis</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8957711811178255" CI_END="1.8751942500815604" CI_START="1.0421274473405695" DF="3" EFFECT_SIZE="1.3979239597006734" ESTIMABLE="YES" EVENTS_1="179" EVENTS_2="154" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="0.2730462626604805" LOG_CI_START="0.0179208344069803" LOG_EFFECT_SIZE="0.14548354853373038" MODIFIED="2012-04-30 10:15:48 +0100" MODIFIED_BY="Leo H Bonati" NO="2" P_CHI2="0.5943191991427295" P_Z="0.02539684717485488" STUDIES="4" TAU2="0.0" TOTAL_1="539" TOTAL_2="547" WEIGHT="85.01468810200228" Z="2.235312390624353">
<NAME>4 years follow-up or longer</NAME>
<DICH_DATA CI_END="1.9136944595870407" CI_START="0.9100668370998468" EFFECT_SIZE="1.319693094629156" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="119" LOG_CI_END="0.2818725995287116" LOG_CI_START="-0.040926711066022456" LOG_EFFECT_SIZE="0.12047294423134457" MODIFIED="2011-04-19 18:32:19 +0100" MODIFIED_BY="Leo H Bonati" ORDER="138" O_E="0.0" SE="0.18961391292570456" STUDY_ID="STD-CAVATAS_x002d_CEA-2001" TOTAL_1="221" TOTAL_2="231" VAR="0.03595343597499667" WEIGHT="53.10510382419953"/>
<DICH_DATA CI_END="3.2829800439466816" CI_START="1.032720776836472" EFFECT_SIZE="1.8413043478260869" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="20" LOG_CI_END="0.5162682428176197" LOG_CI_START="0.013982914480645956" LOG_EFFECT_SIZE="0.26512557864913283" MODIFIED="2011-04-19 19:14:41 +0100" MODIFIED_BY="Leo H Bonati" ORDER="192" O_E="0.0" SE="0.29504488821761304" STUDY_ID="STD-EVA_x002d_3S-2006" TOTAL_1="265" TOTAL_2="262" VAR="0.08705148606334377" WEIGHT="21.933122989992178"/>
<DICH_DATA CI_END="5.879954860249064" CI_START="0.03359394228226504" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7693739920591326" LOG_CI_START="-1.4737390282818577" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2011-04-19 18:55:58 +0100" MODIFIED_BY="Leo H Bonati" ORDER="196" O_E="0.0" SE="1.3176156917368247" STUDY_ID="STD-BACASS-2008" TOTAL_1="10" TOTAL_2="10" VAR="1.7361111111111112" WEIGHT="1.0997631073664116"/>
<DICH_DATA CI_END="2.85705871834597" CI_START="0.4638500337225898" EFFECT_SIZE="1.1511936339522546" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.4559191661060858" LOG_CI_START="-0.33362240749265015" LOG_EFFECT_SIZE="0.061148379306717834" MODIFIED="2011-04-28 22:10:27 +0100" MODIFIED_BY="Leo H Bonati" ORDER="219" O_E="0.0" SE="0.46378062862571895" STUDY_ID="STD-Regensburg-2008" TOTAL_1="43" TOTAL_2="44" VAR="0.21509247148846702" WEIGHT="8.876698180444144"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.0037088845771116" CI_END="2.041135084121539" CI_START="0.771915365535927" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2552225040079081" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="52" I2="33.41565122142063" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.3098717476593537" LOG_CI_START="-0.1124303140368947" LOG_EFFECT_SIZE="0.09872071681122949" METHOD="MH" MODIFIED="2012-04-30 10:15:58 +0100" MODIFIED_BY="Leo H Bonati" NO="13" P_CHI2="0.22271683071807669" P_Q="0.42604233297158345" P_Z="0.35948136921641805" Q="0.6335884287699608" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.06254448707365272" TOTALS="YES" TOTAL_1="1163" TOTAL_2="1156" WEIGHT="100.00000000000001" Z="0.9163537999355524">
<NAME>Any stroke during follow-up (peri-procedural events and patients dying in the peri-procedural period excluded)</NAME>
<GROUP_LABEL_1>Endovascular</GROUP_LABEL_1>
<GROUP_LABEL_2>Endarterectomy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours endovascular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours endarterectomy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2665790107659934E-31" CI_END="1.8236391771970633" CI_START="0.5167339898594728" DF="0" EFFECT_SIZE="0.9707401032702238" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" I2="100.0" ID="CMP-001.13.01" LOG_CI_END="0.26093891356816734" LOG_CI_START="-0.28673297038214424" LOG_EFFECT_SIZE="-0.012897028406988443" MODIFIED="2012-04-30 01:01:07 +0100" MODIFIED_BY="Leo H Bonati" NO="1" P_CHI2="0.0" P_Z="0.9264519889568537" STUDIES="4" TAU2="0.0" TOTAL_1="686" TOTAL_2="668" WEIGHT="37.060584487778" Z="0.09230969098855804">
<NAME>18 to 24 months follow-up</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-03 23:37:01 +0100" MODIFIED_BY="Leo H Bonati" ORDER="165" O_E="0.0" SE="0.0" STUDY_ID="STD-Kentucky-2001" TOTAL_1="53" TOTAL_2="51" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.823639177197063" CI_START="0.5167339898594728" EFFECT_SIZE="0.9707401032702238" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.2609389135681673" LOG_CI_START="-0.28673297038214424" LOG_EFFECT_SIZE="-0.012897028406988443" MODIFIED="2012-04-22 23:11:16 +0100" MODIFIED_BY="Leo H Bonati" ORDER="173" O_E="0.0" SE="0.3217051756519613" STUDY_ID="STD-SPACE-2006" TOTAL_1="601" TOTAL_2="584" VAR="0.10349422004125927" WEIGHT="37.060584487778"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-30 01:01:07 +0100" MODIFIED_BY="Leo H Bonati" ORDER="199" O_E="0.0" SE="0.0" STUDY_ID="STD-BACASS-2008" TOTAL_1="9" TOTAL_2="10" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>1 patient in the endovascular arm who was lost to follow-up after the peri-procedural period was excluded</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-22 23:14:05 +0100" MODIFIED_BY="Leo H Bonati" ORDER="205" O_E="0.0" SE="0.0" STUDY_ID="STD-Beijing-2009" TOTAL_1="23" TOTAL_2="23" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Includes data of patients with symptomatic and asymptomatic carotid stenosis</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7136339747187077" CI_END="2.863549020086954" CI_START="0.707067397964782" DF="1" EFFECT_SIZE="1.4229273187965306" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="32" I2="41.644480982926964" ID="CMP-001.13.02" LOG_CI_END="0.45690462204723337" LOG_CI_START="-0.15053918709544756" LOG_EFFECT_SIZE="0.15318271747589285" MODIFIED="2012-04-30 10:15:58 +0100" MODIFIED_BY="Leo H Bonati" NO="2" P_CHI2="0.19051465279833324" P_Z="0.32290219583886415" STUDIES="2" TAU2="0.11597747316733548" TOTAL_1="477" TOTAL_2="488" WEIGHT="62.93941551222201" Z="0.9885115455550016">
<NAME>4 years follow-up or longer</NAME>
<DICH_DATA CI_END="3.236427764792732" CI_START="1.0605949998921604" EFFECT_SIZE="1.8527112848070346" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="23" LOG_CI_END="0.5100659182589367" LOG_CI_START="0.02554957533358821" LOG_EFFECT_SIZE="0.2678077467962624" MODIFIED="2012-04-03 16:32:47 +0100" MODIFIED_BY="Leo H Bonati" ORDER="200" O_E="0.0" SE="0.28460729822892794" STUDY_ID="STD-CAVATAS_x002d_CEA-2001" TOTAL_1="215" TOTAL_2="228" VAR="0.08100131420516994" WEIGHT="42.86779187167662"/>
<DICH_DATA CI_END="2.3130113081882246" CI_START="0.33357785276553414" EFFECT_SIZE="0.8783902012248469" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.36417775601823776" LOG_CI_START="-0.4768027911908001" LOG_EFFECT_SIZE="-0.056312517586281204" MODIFIED="2011-10-27 12:11:53 +0100" MODIFIED_BY="Leo H Bonati" ORDER="201" O_E="0.0" SE="0.49399613635143624" STUDY_ID="STD-EVA_x002d_3S-2006" TOTAL_1="262" TOTAL_2="260" VAR="0.24403218273014676" WEIGHT="20.071623640545393"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7169567044524674" CI_END="1.453524907746083" CI_START="0.600765960228854" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9344668463453543" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.16242247828325898" LOG_CI_START="-0.22129468270092711" LOG_EFFECT_SIZE="-0.029436102208834077" METHOD="MH" MODIFIED="2012-04-30 10:16:04 +0100" MODIFIED_BY="Leo H Bonati" NO="14" P_CHI2="0.6331706311174266" P_Q="0.9162873135958598" P_Z="0.7636360149672277" Q="0.011048433168735758" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1831" TOTAL_2="1809" WEIGHT="100.00000000000001" Z="0.30070951232192855">
<NAME>Ipsilateral stroke during follow-up (peri-procedural events and patients dying in the peri-procedural period excluded)</NAME>
<GROUP_LABEL_1>Endovascular</GROUP_LABEL_1>
<GROUP_LABEL_2>Endarterectomy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours endovascular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours endarterectomy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.257738996716801" CI_START="0.4177644554699814" DF="0" EFFECT_SIZE="0.9711864406779661" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" I2="0.0" ID="CMP-001.14.01" LOG_CI_END="0.3536737343837325" LOG_CI_START="-0.37906851373324096" LOG_EFFECT_SIZE="-0.01269738967475421" MODIFIED="2012-04-30 01:00:26 +0100" MODIFIED_BY="Leo H Bonati" NO="1" P_CHI2="1.0" P_Z="0.9458438864728749" STUDIES="4" TAU2="0.0" TOTAL_1="686" TOTAL_2="668" WEIGHT="27.42331674905739" Z="0.06792682290162197">
<NAME>18 to 24 months follow-up</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-03 23:39:44 +0100" MODIFIED_BY="Leo H Bonati" ORDER="166" O_E="0.0" SE="0.0" STUDY_ID="STD-Kentucky-2001" TOTAL_1="53" TOTAL_2="51" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.257738996716801" CI_START="0.4177644554699814" EFFECT_SIZE="0.9711864406779661" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.3536737343837325" LOG_CI_START="-0.37906851373324096" LOG_EFFECT_SIZE="-0.01269738967475421" MODIFIED="2011-10-27 12:15:45 +0100" MODIFIED_BY="Leo H Bonati" ORDER="183" O_E="0.0" SE="0.4304164236765361" STUDY_ID="STD-SPACE-2006" TOTAL_1="601" TOTAL_2="584" VAR="0.1852582977704994" WEIGHT="27.42331674905739"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-30 01:00:26 +0100" MODIFIED_BY="Leo H Bonati" ORDER="206" O_E="0.0" SE="0.0" STUDY_ID="STD-BACASS-2008" TOTAL_1="9" TOTAL_2="10" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>1 patient in the endovascular arm who was lost to follow-up after the peri-procedural period was excluded</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-10-27 12:12:21 +0100" MODIFIED_BY="Leo H Bonati" ORDER="217" O_E="0.0" SE="0.0" STUDY_ID="STD-Beijing-2009" TOTAL_1="23" TOTAL_2="23" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Includes data of patients with symptomatic and asymptomatic carotid stenosis</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.705906509246244" CI_END="1.5468440504698435" CI_START="0.5483170103919559" DF="2" EFFECT_SIZE="0.9209565165067286" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="32" I2="0.0" ID="CMP-001.14.02" LOG_CI_END="0.1894465312595581" LOG_CI_START="-0.26096828082677065" LOG_EFFECT_SIZE="-0.03576087478360628" MODIFIED="2012-04-30 10:16:04 +0100" MODIFIED_BY="Leo H Bonati" NO="2" P_CHI2="0.426154835448166" P_Z="0.7556300799553105" STUDIES="3" TAU2="0.0" TOTAL_1="1145" TOTAL_2="1141" WEIGHT="72.57668325094262" Z="0.31122434143254213">
<NAME>4 years follow-up or longer</NAME>
<DICH_DATA CI_END="2.834260470080207" CI_START="0.6238558732334779" EFFECT_SIZE="1.3297255508310786" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.45243975964483885" LOG_CI_START="-0.20491573193486542" LOG_EFFECT_SIZE="0.12376201385498672" MODIFIED="2011-10-27 12:17:04 +0100" MODIFIED_BY="Leo H Bonati" ORDER="184" O_E="0.0" SE="0.3861338697160809" STUDY_ID="STD-CAVATAS_x002d_CEA-2001" TOTAL_1="215" TOTAL_2="228" VAR="0.1490993653419153" WEIGHT="34.07390077416633"/>
<DICH_DATA CI_END="3.9765329254297215" CI_START="0.10920246705583123" EFFECT_SIZE="0.658974358974359" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5995045827332594" LOG_CI_START="-0.9617675501236687" LOG_EFFECT_SIZE="-0.18113148369520468" MODIFIED="2011-10-27 12:17:14 +0100" MODIFIED_BY="Leo H Bonati" ORDER="186" O_E="0.0" SE="0.9170989792618596" STUDY_ID="STD-EVA_x002d_3S-2006" TOTAL_1="262" TOTAL_2="260" VAR="0.8410705377631447" WEIGHT="6.040393465288992"/>
<DICH_DATA CI_END="1.447384379351619" CI_START="0.3069796943125415" EFFECT_SIZE="0.6665715372907154" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.1605838812664042" LOG_CI_START="-0.5128903507106642" LOG_EFFECT_SIZE="-0.17615323472213007" MODIFIED="2011-10-27 12:23:14 +0100" MODIFIED_BY="Leo H Bonati" ORDER="202" O_E="0.0" SE="0.39560209761454435" STUDY_ID="STD-CREST-2010" TOTAL_1="668" TOTAL_2="653" VAR="0.15650101963702748" WEIGHT="32.462389011487296">
<FOOTNOTE>Patients who died in the peri-procedural period are included, because the numbers of peri-procedural deaths were not available for symptomatic and asymptomatic patients separately.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.631713472698596" CI_END="4.534488546797646" CI_START="1.2762273197636105" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="2.40562635597849" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="50" I2="54.76282242364082" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.6565283092947257" LOG_CI_START="0.10592803717995428" LOG_EFFECT_SIZE="0.38122817323734004" METHOD="MH" MODIFIED="2012-04-30 01:02:05 +0100" MODIFIED_BY="Leo H Bonati" NO="15" P_CHI2="0.08461050086984778" P_Q="0.35683671175539344" P_Z="0.006645508912931773" Q="0.8489956021464885" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.1997861734686329" TOTALS="YES" TOTAL_1="1112" TOTAL_2="1128" WEIGHT="100.0" Z="2.7141050496300227">
<NAME>Severe restenosis during follow-up</NAME>
<GROUP_LABEL_1>Endovascular</GROUP_LABEL_1>
<GROUP_LABEL_2>Endarterectomy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours endovascular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours endarterectomy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.07464106799797" CI_START="1.992742000915635" DF="0" EFFECT_SIZE="3.4792517006802717" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="20" I2="0.0" ID="CMP-001.15.01" LOG_CI_END="0.7835206218928895" LOG_CI_START="0.29945107449992137" LOG_EFFECT_SIZE="0.5414858481964054" MODIFIED="2012-04-29 21:14:47 +0100" MODIFIED_BY="Leo H Bonati" NO="1" P_CHI2="1.0" P_Z="1.1605122730857295E-5" STUDIES="1" TAU2="0.0" TOTAL_1="200" TOTAL_2="213" WEIGHT="37.27359770213746" Z="4.384877199232362">
<NAME>Angioplasty with or without stenting</NAME>
<DICH_DATA CI_END="6.07464106799797" CI_START="1.992742000915635" EFFECT_SIZE="3.479251700680272" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="20" LOG_CI_END="0.7835206218928895" LOG_CI_START="0.29945107449992137" LOG_EFFECT_SIZE="0.5414858481964056" MODIFIED="2012-04-29 21:14:47 +0100" MODIFIED_BY="Leo H Bonati" ORDER="156" O_E="0.0" SE="0.2843448483215343" STUDY_ID="STD-CAVATAS_x002d_CEA-2001" TOTAL_1="200" TOTAL_2="213" VAR="0.08085199276699634" WEIGHT="37.27359770213746">
<FOOTNOTE>Includes data from patients with symptomatic and asymptomatic carotid stenosis</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.799751905279822" CI_END="5.785510867687099" CI_START="0.667495016013635" DF="2" EFFECT_SIZE="1.9651462208379964" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="30" I2="58.33117962201421" ID="CMP-001.15.02" LOG_CI_END="0.7623417137150177" LOG_CI_START="-0.17555197269875356" LOG_EFFECT_SIZE="0.293394870508132" MODIFIED="2012-04-30 01:02:05 +0100" MODIFIED_BY="Leo H Bonati" NO="2" P_CHI2="0.09072924841491492" P_Z="0.22010678945846995" STUDIES="5" TAU2="0.503350132669708" TOTAL_1="912" TOTAL_2="915" WEIGHT="62.726402297862535" Z="1.2262442700590679">
<NAME>Primary stenting</NAME>
<DICH_DATA CI_END="2.4831658290514835" CI_START="0.24348988539790423" EFFECT_SIZE="0.7775768535262206" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.39500572327473976" LOG_CI_START="-0.6135190747249633" LOG_EFFECT_SIZE="-0.10925667572511172" MODIFIED="2011-10-22 21:15:01 +0100" MODIFIED_BY="Leo H Bonati" ORDER="155" O_E="0.0" SE="0.5924124586232901" STUDY_ID="STD-EVA_x002d_3S-2006" TOTAL_1="242" TOTAL_2="265" VAR="0.35095252113209136" WEIGHT="18.99338871715927"/>
<DICH_DATA CI_END="3.9693963380024573" CI_START="1.454755415838708" EFFECT_SIZE="2.403019105275572" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="23" LOG_CI_END="0.5987244646954788" LOG_CI_START="0.1627899826824187" LOG_EFFECT_SIZE="0.38075722368894876" MODIFIED="2012-04-26 12:30:19 +0100" MODIFIED_BY="Leo H Bonati" ORDER="157" O_E="0.0" SE="0.25607007264495985" STUDY_ID="STD-SPACE-2006" TOTAL_1="607" TOTAL_2="589" VAR="0.06557188210439502" WEIGHT="39.41992296236759">
<FOOTNOTE>Total number of patients with ultrasound follow-up not available; totals are numbers of randomised patients</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-04-14 08:06:51 +0100" MODIFIED_BY="Leo H Bonati" ORDER="158" O_E="0.0" SE="0.0" STUDY_ID="STD-BACASS-2008" TOTAL_1="8" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="269.3678033672462" CI_START="0.7774873004933172" EFFECT_SIZE="14.471698113207546" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.430345684721906" LOG_CI_START="-0.10930669602552202" LOG_EFFECT_SIZE="1.1605194943481918" MODIFIED="2011-04-28 12:12:10 +0100" MODIFIED_BY="Leo H Bonati" ORDER="211" O_E="0.0" SE="1.491804379933074" STUDY_ID="STD-Regensburg-2008" TOTAL_1="32" TOTAL_2="29" VAR="2.225480307987503" WEIGHT="4.31309061833567"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-30 01:02:05 +0100" MODIFIED_BY="Leo H Bonati" ORDER="218" O_E="0.0" SE="0.0" STUDY_ID="STD-Beijing-2009" TOTAL_1="23" TOTAL_2="23" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Total number of patients with ultrasound follow-up not available; totals are numbers of randomised patients; includes data from patients with symptomatic and asymptomatic carotid stenosis</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2012-03-09 13:54:25 +0000" MODIFIED_BY="Leo H Bonati" NO="2">
<NAME>Endovascular treatment with or without protection for symptomatic carotid stenosis (per-protocol)</NAME>
<DICH_OUTCOME CHI2="8.929526395845826" CI_END="2.405543524078711" CI_START="0.37779513669346254" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9533114100341977" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="49" I2="77.60239556567709" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.3812132191043952" LOG_CI_START="-0.42274363699329426" LOG_EFFECT_SIZE="-0.0207652089444495" METHOD="MH" MODIFIED="2012-03-09 13:54:25 +0000" MODIFIED_BY="Leo H Bonati" NO="1" P_CHI2="0.011507479747032368" P_Q="1.0" P_Z="0.9193544830479345" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.5146066638898269" TOTALS="YES" TOTAL_1="974" TOTAL_2="705" WEIGHT="99.99999999999999" Z="0.10124687998835762">
<NAME>Death or any stroke within 30 days after treatment</NAME>
<GROUP_LABEL_1>Protected</GROUP_LABEL_1>
<GROUP_LABEL_2>Unprotected</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours protected</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours unprotected</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8383823625378769" CI_START="0.1220565023410799" EFFECT_SIZE="0.3198906356801094" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="7" LOG_CI_END="-0.07655786673087137" LOG_CI_START="-0.9134390793715021" LOG_EFFECT_SIZE="-0.49499847305118677" MODIFIED="2011-04-24 06:23:01 +0100" MODIFIED_BY="Leo H Bonati" ORDER="160" O_E="0.0" SE="0.4915881669339206" STUDY_ID="STD-EVA_x002d_3S-2006" TOTAL_1="227" TOTAL_2="33" VAR="0.24165892586945217" WEIGHT="29.489428091962484"/>
<DICH_DATA CI_END="2.3724488853229055" CI_START="0.6145826482822871" EFFECT_SIZE="1.2075040036604896" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="31" LOG_CI_END="0.3751968642768465" LOG_CI_START="-0.21141970548808997" LOG_EFFECT_SIZE="0.08188857939437831" MODIFIED="2011-04-18 09:10:58 +0100" MODIFIED_BY="Leo H Bonati" ORDER="161" O_E="0.0" SE="0.3445814768787759" STUDY_ID="STD-SPACE-2006" TOTAL_1="154" TOTAL_2="437" VAR="0.11873639420795835" WEIGHT="35.212890458789175"/>
<DICH_DATA CI_END="3.6681629585621787" CI_START="0.9585226832685784" EFFECT_SIZE="1.8751046375355767" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="11" LOG_CI_END="0.5644486210089656" LOG_CI_START="-0.01839760516274642" LOG_EFFECT_SIZE="0.2730255079231096" MODIFIED="2011-04-18 09:12:20 +0100" MODIFIED_BY="Leo H Bonati" ORDER="162" O_E="0.0" SE="0.3423667583886141" STUDY_ID="STD-ICSS-2010" TOTAL_1="593" TOTAL_2="235" VAR="0.11721499724952764" WEIGHT="35.29768144924833"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2012-03-09 13:54:49 +0000" MODIFIED_BY="Leo H Bonati" NO="3">
<NAME>Endovascular treatment or endarterectomy for asymptomatic carotid stenosis</NAME>
<DICH_OUTCOME CHI2="0.24547737576139747" CI_END="3.756512526348035" CI_START="0.7793258435144953" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.7110076835797523" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.5747848413628547" LOG_CI_START="-0.10828092172098712" LOG_EFFECT_SIZE="0.23325195982093377" METHOD="MH" MODIFIED="2012-03-09 13:54:40 +0000" MODIFIED_BY="Leo H Bonati" NO="1" P_CHI2="0.6202777857811226" P_Q="1.0" P_Z="0.18071091604211495" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="667" TOTAL_2="651" WEIGHT="99.99999999999999" Z="1.338569330450544">
<NAME>Death or any stroke between randomisation and 30 days after treatment</NAME>
<GROUP_LABEL_1>Endovascular</GROUP_LABEL_1>
<GROUP_LABEL_2>Endarterectomy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours endovascular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours endarterectomy</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.283928151945704" CI_START="0.16949204817523997" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8623656532997895" LOG_CI_START="-0.7708506721784393" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2011-03-24 12:58:38 +0000" MODIFIED_BY="Leo H Bonati" ORDER="193" O_E="0.0" SE="0.9593593541371087" STUDY_ID="STD-CAVATAS_x002d_CEA-2001" TOTAL_1="30" TOTAL_2="22" VAR="0.9203703703703704" WEIGHT="17.491925182677956"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-03-24 12:58:39 +0000" MODIFIED_BY="Leo H Bonati" ORDER="11247" O_E="0.0" SE="0.0" STUDY_ID="STD-Kentucky-2004" TOTAL_1="43" TOTAL_2="42" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.456544003311425" CI_START="0.7888680101414286" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.6489981990453635" LOG_CI_START="-0.10299565491788822" LOG_EFFECT_SIZE="0.27300127206373764" MODIFIED="2011-03-24 12:58:39 +0000" MODIFIED_BY="Leo H Bonati" ORDER="11248" O_E="0.0" SE="0.4417249122476258" STUDY_ID="STD-CREST-2010" TOTAL_1="594" TOTAL_2="587" VAR="0.19512089810017272" WEIGHT="82.50807481732203"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2541827757860337" CI_END="3.331067443590997" CI_START="0.919740580787069" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.7503479383280571" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.5225834258712695" LOG_CI_START="-0.036334651154510365" LOG_EFFECT_SIZE="0.24312438735837955" METHOD="MH" MODIFIED="2012-03-09 13:54:49 +0000" MODIFIED_BY="Leo H Bonati" NO="2" P_CHI2="0.6141451715394852" P_Q="1.0" P_Z="0.08816947926709157" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="667" TOTAL_2="651" WEIGHT="100.0" Z="1.7051337667284296">
<NAME>Death or any stroke between randomisation and 30 days after treatment or ipsilateral stroke until the end of follow-up</NAME>
<GROUP_LABEL_1>Endovascular</GROUP_LABEL_1>
<GROUP_LABEL_2>Endarterectomy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours endovascular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours endarterectomy</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.283928151945704" CI_START="0.16949204817523997" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8623656532997895" LOG_CI_START="-0.7708506721784393" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2011-10-27 12:29:13 +0100" MODIFIED_BY="Leo H Bonati" ORDER="195" O_E="0.0" SE="0.9593593541371087" STUDY_ID="STD-CAVATAS_x002d_CEA-2001" TOTAL_1="30" TOTAL_2="22" VAR="0.9203703703703704" WEIGHT="11.711401969414917"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-10-27 12:29:13 +0100" MODIFIED_BY="Leo H Bonati" ORDER="196" O_E="0.0" SE="0.0" STUDY_ID="STD-Kentucky-2004" TOTAL_1="43" TOTAL_2="42" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.6874145780155487" CI_START="0.9373200001996398" EFFECT_SIZE="1.8591093117408908" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="13" LOG_CI_END="0.5667219683147121" LOG_CI_START="-0.028112116054209248" LOG_EFFECT_SIZE="0.2693049261302514" MODIFIED="2011-10-27 12:29:12 +0100" MODIFIED_BY="Leo H Bonati" ORDER="197" O_E="0.0" SE="0.3494084856345099" STUDY_ID="STD-CREST-2010" TOTAL_1="594" TOTAL_2="587" VAR="0.12208628983340152" WEIGHT="88.28859803058508"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2012-04-30 01:04:39 +0100" MODIFIED_BY="Leo H Bonati" NO="4">
<NAME>Access complications in endovascular treatment or endarterectomy</NAME>
<DICH_OUTCOME CHI2="5.713467187689154" CI_END="0.1446084991252402" CI_START="0.04864952933883676" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="OR" EFFECT_SIZE="0.08387571413012543" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="195" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-0.8398061813518554" LOG_CI_START="-1.312921356968801" LOG_EFFECT_SIZE="-1.0763637691603283" METHOD="MH" MODIFIED="2012-04-30 01:03:29 +0100" MODIFIED_BY="Leo H Bonati" NO="1" P_CHI2="0.7682177887513877" P_Q="0.8323875648663904" P_Z="4.745370963229562E-19" Q="0.3669143556751306" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3561" TOTAL_2="3525" WEIGHT="100.00000000000001" Z="8.918057718470138">
<NAME>Cranial nerve palsy within 30 days of procedure</NAME>
<GROUP_LABEL_1>Endovascular</GROUP_LABEL_1>
<GROUP_LABEL_2>Endarterectomy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours endovascular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours endarterectomy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.8720515723256215" CI_END="0.16185702953783063" CI_START="0.04988339010793687" DF="6" EFFECT_SIZE="0.08985531339963967" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="159" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="-0.7908684342089218" LOG_CI_START="-1.3020440392524466" LOG_EFFECT_SIZE="-1.0464562367306842" MODIFIED="2012-04-30 01:03:29 +0100" MODIFIED_BY="Leo H Bonati" NO="1" P_CHI2="0.5603253212729957" P_Z="1.0177079530242E-15" STUDIES="9" TAU2="0.0" TOTAL_1="2757" TOTAL_2="2729" WEIGHT="85.66304698672276" Z="8.024704290083738">
<NAME>Symptomatic carotid stenosis</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-09-23 12:35:59 +0100" MODIFIED_BY="Leo H Bonati" ORDER="456" O_E="0.0" SE="0.0" STUDY_ID="STD-Leicester-1998" TOTAL_1="7" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.33911726607051956" CI_START="0.0012338179438098815" EFFECT_SIZE="0.020455047492820854" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="22" LOG_CI_END="-0.46965009766439697" LOG_CI_START="-2.908748917962239" LOG_EFFECT_SIZE="-1.689199507813318" MODIFIED="2012-04-30 01:03:29 +0100" MODIFIED_BY="Leo H Bonati" ORDER="457" O_E="0.0" SE="1.4327387207768354" STUDY_ID="STD-CAVATAS_x002d_CEA-2001" TOTAL_1="251" TOTAL_2="253" VAR="2.052740242013243" WEIGHT="3.7624866275865214">
<FOOTNOTE>Includes data from patients with symptomatic and asymptomatic carotid stenosis</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.88057394767647" CI_START="0.005174926918484579" EFFECT_SIZE="0.09865005192107996" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2742904153635336" LOG_CI_START="-2.286095779034907" LOG_EFFECT_SIZE="-1.0059026818356867" MODIFIED="2011-10-27 12:33:12 +0100" MODIFIED_BY="Leo H Bonati" ORDER="458" O_E="0.0" SE="1.5039835247057118" STUDY_ID="STD-Kentucky-2001" TOTAL_1="53" TOTAL_2="51" VAR="2.2619664425862163" WEIGHT="3.414466088034886"/>
<DICH_DATA CI_END="0.47212146470431016" CI_START="0.040659021399947065" EFFECT_SIZE="0.1385496183206107" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="20" LOG_CI_END="-0.32594625419546636" LOG_CI_START="-1.3908430783717995" LOG_EFFECT_SIZE="-0.8583946662836329" MODIFIED="2011-09-23 12:35:59 +0100" MODIFIED_BY="Leo H Bonati" ORDER="459" O_E="0.0" SE="0.6255256658454725" STUDY_ID="STD-EVA_x002d_3S-2006" TOTAL_1="265" TOTAL_2="262" VAR="0.39128235863142174" WEIGHT="19.738706691243404"/>
<DICH_DATA CI_END="0.30709610114990976" CI_START="0.03818028692562846" EFFECT_SIZE="0.10828211881767633" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="34" LOG_CI_END="-0.5127256972652624" LOG_CI_START="-1.4181608121982732" LOG_EFFECT_SIZE="-0.9654432547317678" MODIFIED="2011-10-27 12:33:20 +0100" MODIFIED_BY="Leo H Bonati" ORDER="460" O_E="0.0" SE="0.5318570684877538" STUDY_ID="STD-SPACE-2006" TOTAL_1="607" TOTAL_2="589" VAR="0.2828719413003873" WEIGHT="27.303548294604116"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-10-27 12:33:21 +0100" MODIFIED_BY="Leo H Bonati" ORDER="461" O_E="0.0" SE="0.0" STUDY_ID="STD-BACASS-2008" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.410399935975454" CI_START="0.013211156658060183" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9248166480996348" LOG_CI_START="-1.87905915753896" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-10-27 12:33:21 +0100" MODIFIED_BY="Leo H Bonati" ORDER="462" O_E="0.0" SE="1.6470105276411926" STUDY_ID="STD-Regensburg-2008" TOTAL_1="43" TOTAL_2="44" VAR="2.71264367816092" WEIGHT="2.8471884356443575"/>
<DICH_DATA CI_END="0.15400087159074488" CI_START="0.002912625601704115" EFFECT_SIZE="0.021178925404277515" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="45" LOG_CI_END="-0.8124768212026291" LOG_CI_START="-2.535715337399108" LOG_EFFECT_SIZE="-1.6740960793008686" MODIFIED="2012-04-23 23:40:38 +0100" MODIFIED_BY="Leo H Bonati" ORDER="463" O_E="0.0" SE="1.0122388345820397" STUDY_ID="STD-ICSS-2010" TOTAL_1="853" TOTAL_2="857" VAR="1.024627458236006" WEIGHT="7.537771556288497"/>
<DICH_DATA CI_END="0.27775774945112575" CI_START="0.02586357370702109" EFFECT_SIZE="0.08475734791524266" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="33" LOG_CI_END="-0.556333815386512" LOG_CI_START="-1.5873114665396395" LOG_EFFECT_SIZE="-1.0718226409630758" MODIFIED="2012-04-29 21:44:08 +0100" MODIFIED_BY="Leo H Bonati" ORDER="464" O_E="0.0" SE="0.6056013757090272" STUDY_ID="STD-CREST-2010" TOTAL_1="668" TOTAL_2="653" VAR="0.3667530262606663" WEIGHT="21.058879293320967"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.46822830033763363" CI_END="0.2928310970003023" CI_START="0.010495127680465533" DF="1" EFFECT_SIZE="0.05543734979081304" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="28" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="-0.5333828055558626" LOG_CI_START="-1.979012273557586" LOG_EFFECT_SIZE="-1.2561975395567244" MODIFIED="2012-04-29 21:45:25 +0100" MODIFIED_BY="Leo H Bonati" NO="2" P_CHI2="0.4938033990598877" P_Z="6.585708391390714E-4" STUDIES="2" TAU2="0.0" TOTAL_1="637" TOTAL_2="629" WEIGHT="10.710747287942214" Z="3.4062697108718245">
<NAME>Asymptomatic carotid stenosis</NAME>
<DICH_DATA CI_END="2.5907930846628235" CI_START="0.006495115347292284" EFFECT_SIZE="0.1297208538587849" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4134327291658666" LOG_CI_START="-2.1874131318507346" LOG_EFFECT_SIZE="-0.8869902013424339" MODIFIED="2012-04-29 21:44:44 +0100" MODIFIED_BY="Leo H Bonati" ORDER="174" O_E="0.0" SE="1.527749733155799" STUDY_ID="STD-Kentucky-2004" TOTAL_1="43" TOTAL_2="42" VAR="2.334019247157615" WEIGHT="3.3090591347475677"/>
<DICH_DATA CI_END="0.2807019485400331" CI_START="0.0051196208570845544" EFFECT_SIZE="0.03790893760539629" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="25" LOG_CI_END="-0.5517545726265264" LOG_CI_START="-2.290762200307952" LOG_EFFECT_SIZE="-1.421258386467239" MODIFIED="2012-04-29 21:45:25 +0100" MODIFIED_BY="Leo H Bonati" ORDER="454" O_E="0.0" SE="1.0215016887266581" STUDY_ID="STD-CREST-2010" TOTAL_1="594" TOTAL_2="587" VAR="1.0434657000714145" WEIGHT="7.4016881531946455"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9784794230151551" CI_START="0.003206580980090896" DF="0" EFFECT_SIZE="0.056014047410008774" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="-0.009448302928756397" LOG_CI_START="-2.49395778778712" LOG_EFFECT_SIZE="-1.251703045357938" MODIFIED="2011-09-23 12:35:30 +0100" MODIFIED_BY="Leo H Bonati" NO="3" P_CHI2="1.0" P_Z="0.048282787075756915" STUDIES="1" TAU2="0.0" TOTAL_1="167" TOTAL_2="167" WEIGHT="3.626205725335044" Z="1.9748710183575908">
<NAME>Increased surgical risk</NAME>
<DICH_DATA CI_END="0.9784794230151551" CI_START="0.003206580980090896" EFFECT_SIZE="0.05601404741000878" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.009448302928756397" LOG_CI_START="-2.49395778778712" LOG_EFFECT_SIZE="-1.251703045357938" MODIFIED="2011-09-23 12:35:30 +0100" MODIFIED_BY="Leo H Bonati" ORDER="455" O_E="0.0" SE="1.4594131699261006" STUDY_ID="STD-SAPPHIRE-2004" TOTAL_1="167" TOTAL_2="167" VAR="2.1298868005537495" WEIGHT="3.626205725335044"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.44588253551558" CI_END="1.0716445606060119" CI_START="0.537950129043755" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="OR" EFFECT_SIZE="0.759270261281872" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="237" I2="43.75649954894886" I2_Q="26.164709089611513" ID="CMP-004.02" LOG_CI_END="0.030050763934812583" LOG_CI_START="-0.2692579839711819" LOG_EFFECT_SIZE="-0.11960361001818468" METHOD="MH" MODIFIED="2012-04-29 21:50:46 +0100" MODIFIED_BY="Leo H Bonati" NO="2" P_CHI2="0.08681682429776882" P_Q="0.24451647937158927" P_Z="0.11725475798822006" Q="1.3543658969444134" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08171669755192552" TOTALS="YES" TOTAL_1="2089" TOTAL_2="2074" WEIGHT="99.99999999999997" Z="1.5664010470568754">
<NAME>Death or neurological complication up to 30 days after treatment</NAME>
<GROUP_LABEL_1>Endovascular</GROUP_LABEL_1>
<GROUP_LABEL_2>Endarterectomy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours endovascular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours endarterectomy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.100949318848471" CI_END="1.0918272207214648" CI_START="0.5522625239770079" DF="6" EFFECT_SIZE="0.776514814193804" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="234" I2="45.95056848144952" ID="CMP-004.02.01" LOG_CI_END="0.038153917650614315" LOG_CI_START="-0.2578544265974368" LOG_EFFECT_SIZE="-0.10985025447341124" MODIFIED="2012-04-29 21:50:46 +0100" MODIFIED_BY="Leo H Bonati" NO="1" P_CHI2="0.08530623915133573" P_Z="0.14575069842785351" STUDIES="7" TAU2="0.07716847873338334" TOTAL_1="2046" TOTAL_2="2032" WEIGHT="98.72042848668741" Z="1.454705900317629">
<NAME>Symptomatic carotid stenosis</NAME>
<DICH_DATA CI_END="1141.1781485259646" CI_START="1.870382816878338" EFFECT_SIZE="46.2" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="3.0573534471197634" LOG_CI_START="0.27193050399248764" LOG_EFFECT_SIZE="1.6646419755561255" MODIFIED="2012-04-29 21:50:46 +0100" MODIFIED_BY="Leo H Bonati" ORDER="183" O_E="0.0" SE="1.6361712248589013" STUDY_ID="STD-Leicester-1998" TOTAL_1="7" TOTAL_2="10" VAR="2.6770562770562774" WEIGHT="1.1204643973919306"/>
<DICH_DATA CI_END="1.2492437536708259" CI_START="0.489440073223269" EFFECT_SIZE="0.781939866147238" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="47" LOG_CI_END="0.09664718660926165" LOG_CI_START="-0.310300475386245" LOG_EFFECT_SIZE="-0.10682664438849167" MODIFIED="2011-10-27 12:34:28 +0100" MODIFIED_BY="Leo H Bonati" ORDER="184" O_E="0.0" SE="0.23904307107957568" STUDY_ID="STD-CAVATAS_x002d_CEA-2001" TOTAL_1="251" TOTAL_2="253" VAR="0.05714158983115507" WEIGHT="22.260874426657843"/>
<DICH_DATA CI_END="1.467383752650051" CI_START="0.004254703154785951" EFFECT_SIZE="0.0790144435004248" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.16654370611568572" LOG_CI_START="-2.371130734694685" LOG_EFFECT_SIZE="-1.1022935142894996" MODIFIED="2011-10-27 12:34:28 +0100" MODIFIED_BY="Leo H Bonati" ORDER="185" O_E="0.0" SE="1.4906425282230862" STUDY_ID="STD-Kentucky-2001" TOTAL_1="53" TOTAL_2="51" VAR="2.222015146947314" WEIGHT="1.341782423990165"/>
<DICH_DATA CI_END="1.5679211446095795" CI_START="0.5347469855043522" EFFECT_SIZE="0.9156642974302898" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="31" LOG_CI_END="0.19532421694402463" LOG_CI_START="-0.2718516549705824" LOG_EFFECT_SIZE="-0.03826371901327887" MODIFIED="2011-04-19 17:31:27 +0100" MODIFIED_BY="Leo H Bonati" ORDER="187" O_E="0.0" SE="0.2744214197205026" STUDY_ID="STD-EVA_x002d_3S-2006" TOTAL_1="265" TOTAL_2="262" VAR="0.07530711560141624" WEIGHT="19.685593136863265"/>
<DICH_DATA CI_END="0.8905333696790267" CI_START="0.4136779229392242" EFFECT_SIZE="0.60695468914647" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="73" LOG_CI_END="-0.050349802201931554" LOG_CI_START="-0.38333765580622964" LOG_EFFECT_SIZE="-0.2168437290040806" MODIFIED="2011-04-19 17:31:26 +0100" MODIFIED_BY="Leo H Bonati" ORDER="188" O_E="0.0" SE="0.1955987135236237" STUDY_ID="STD-SPACE-2006" TOTAL_1="607" TOTAL_2="589" VAR="0.03825885673209661" WEIGHT="25.764472745988268"/>
<DICH_DATA CI_END="8.33159693509127" CI_START="0.010916862780006007" EFFECT_SIZE="0.30158730158730157" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9207282515421643" LOG_CI_START="-1.9619021485436698" LOG_EFFECT_SIZE="-0.5205869485007528" MODIFIED="2011-04-19 17:31:25 +0100" MODIFIED_BY="Leo H Bonati" ORDER="189" O_E="0.0" SE="1.693271366261031" STUDY_ID="STD-BACASS-2008" TOTAL_1="10" TOTAL_2="10" VAR="2.8671679197994986" WEIGHT="1.0482291780245503"/>
<DICH_DATA CI_END="1.1975518589269138" CI_START="0.6026315046342458" EFFECT_SIZE="0.8495189689598839" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="77" LOG_CI_END="0.0782943292332734" LOG_CI_START="-0.2199481678316681" LOG_EFFECT_SIZE="-0.07082691929919732" MODIFIED="2011-04-19 17:31:19 +0100" MODIFIED_BY="Leo H Bonati" ORDER="190" O_E="0.0" SE="0.17518911910011697" STUDY_ID="STD-ICSS-2010" TOTAL_1="853" TOTAL_2="857" VAR="0.030691227451074974" WEIGHT="27.499012177771395"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5907930846628235" CI_START="0.006495115347292284" DF="0" EFFECT_SIZE="0.12972085385878487" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="0.4134327291658666" LOG_CI_START="-2.1874131318507346" LOG_EFFECT_SIZE="-0.886990201342434" MODIFIED="2011-09-23 12:47:38 +0100" MODIFIED_BY="Leo H Bonati" NO="2" P_CHI2="1.0" P_Z="0.18127199246774753" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="42" WEIGHT="1.279571513312556" Z="1.3368488116335975">
<NAME>Asymptomatic carotid stenosis</NAME>
<DICH_DATA CI_END="2.5907930846628235" CI_START="0.006495115347292284" EFFECT_SIZE="0.1297208538587849" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4134327291658666" LOG_CI_START="-2.1874131318507346" LOG_EFFECT_SIZE="-0.8869902013424339" MODIFIED="2011-09-23 12:47:38 +0100" MODIFIED_BY="Leo H Bonati" ORDER="465" O_E="0.0" SE="1.527749733155799" STUDY_ID="STD-Kentucky-2004" TOTAL_1="43" TOTAL_2="42" VAR="2.334019247157615" WEIGHT="1.279571513312556"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.242001393694713" CI_END="0.7729698081262746" CI_START="0.1760112879744138" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="0.36885147619826747" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="58" I2="27.202147713902185" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-0.11183746910914175" LOG_CI_START="-0.7544594790733568" LOG_EFFECT_SIZE="-0.4331484740912493" METHOD="MH" MODIFIED="2012-04-30 01:04:39 +0100" MODIFIED_BY="Leo H Bonati" NO="3" P_CHI2="0.22090450703161624" P_Q="1.0" P_Z="0.008237888394179901" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.25903846144058995" TOTALS="YES" TOTAL_1="2148" TOTAL_2="2132" WEIGHT="100.0" Z="2.642161009158725">
<NAME>Access site haematoma</NAME>
<GROUP_LABEL_1>Endovascular</GROUP_LABEL_1>
<GROUP_LABEL_2>Endarterectomy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours endovascular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours endarterectomy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.242001393694713" CI_END="0.7729698081262746" CI_START="0.1760112879744138" DF="6" EFFECT_SIZE="0.36885147619826747" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="58" I2="27.202147713902185" ID="CMP-004.03.01" LOG_CI_END="-0.11183746910914175" LOG_CI_START="-0.7544594790733568" LOG_EFFECT_SIZE="-0.4331484740912493" MODIFIED="2012-04-30 01:04:39 +0100" MODIFIED_BY="Leo H Bonati" NO="1" P_CHI2="0.22090450703161624" P_Z="0.008237888394179901" STUDIES="8" TAU2="0.25903846144058995" TOTAL_1="2105" TOTAL_2="2090" WEIGHT="100.0" Z="2.642161009158725">
<NAME>Symptomatic carotid stenosis</NAME>
<DICH_DATA CI_END="0.5804524504643037" CI_START="0.048584603410997025" EFFECT_SIZE="0.16793168880455409" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="17" LOG_CI_END="-0.23623335102751122" LOG_CI_START="-1.3135013380019311" LOG_EFFECT_SIZE="-0.7748673445147212" MODIFIED="2012-04-30 01:04:33 +0100" MODIFIED_BY="Leo H Bonati" ORDER="166" O_E="0.0" SE="0.6327925481113122" STUDY_ID="STD-CAVATAS_x002d_CEA-2001" TOTAL_1="251" TOTAL_2="253" VAR="0.40042640894520737" WEIGHT="21.607012873015755">
<FOOTNOTE>Includes data from patients with symptomatic and asymptomatic carotid stenosis</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="29.828981993757417" CI_START="0.3017199850093279" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4746384319729284" LOG_CI_START="-0.5203959225336037" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-04-19 15:33:23 +0100" MODIFIED_BY="Leo H Bonati" ORDER="214" O_E="0.0" SE="1.171893055416463" STUDY_ID="STD-Kentucky-2001" TOTAL_1="53" TOTAL_2="51" VAR="1.3733333333333333" WEIGHT="8.729056694894085"/>
<DICH_DATA CI_END="5.463785252982133" CI_START="0.04437978860804286" EFFECT_SIZE="0.49242424242424243" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7374936216255917" LOG_CI_START="-1.3528147707515803" LOG_EFFECT_SIZE="-0.3076605745629943" MODIFIED="2012-04-19 15:33:23 +0100" MODIFIED_BY="Leo H Bonati" ORDER="215" O_E="0.0" SE="1.2278574968757705" STUDY_ID="STD-EVA_x002d_3S-2006" TOTAL_1="265" TOTAL_2="262" VAR="1.5076340326340327" WEIGHT="8.06548242049311"/>
<DICH_DATA CI_END="8.755765613168812" CI_START="0.24271170222300825" EFFECT_SIZE="1.4577814569536425" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.942294127236932" LOG_CI_START="-0.6149092838726042" LOG_EFFECT_SIZE="0.1636924216821639" MODIFIED="2012-04-19 15:33:24 +0100" MODIFIED_BY="Leo H Bonati" ORDER="216" O_E="0.0" SE="0.9147089919669441" STUDY_ID="STD-SPACE-2006" TOTAL_1="607" TOTAL_2="589" VAR="0.836692539985183" WEIGHT="13.004164274978622"/>
<DICH_DATA CI_END="1.3101739480606862" CI_START="0.017355500888515812" EFFECT_SIZE="0.15079365079365079" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.11732895952427246" LOG_CI_START="-1.76056284785374" LOG_EFFECT_SIZE="-0.821616944164734" MODIFIED="2012-04-21 22:44:08 +0100" MODIFIED_BY="Leo H Bonati" ORDER="217" O_E="0.0" SE="1.1030829433682106" STUDY_ID="STD-Regensburg-2008" TOTAL_1="43" TOTAL_2="44" VAR="1.2167919799498748" WEIGHT="9.654947847736981"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-19 15:33:32 +0100" MODIFIED_BY="Leo H Bonati" ORDER="218" O_E="0.0" SE="0.0" STUDY_ID="STD-BACASS-2008" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.030154710030236" CI_START="0.008307674426324888" EFFECT_SIZE="0.1829787234042553" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6053217182063122" LOG_CI_START="-2.0805205315906115" LOG_EFFECT_SIZE="-0.7375994066921497" MODIFIED="2012-04-30 01:04:39 +0100" MODIFIED_BY="Leo H Bonati" ORDER="219" O_E="0.0" SE="1.5776770326642706" STUDY_ID="STD-Beijing-2009" TOTAL_1="23" TOTAL_2="23" VAR="2.4890648193963383" WEIGHT="5.185054740514727">
<FOOTNOTE>Includes data from patients with symptomatic and asymptomatic carotid stenosis</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.6193258567936928" CI_START="0.12717081835308844" EFFECT_SIZE="0.28064243448858833" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="28" LOG_CI_END="-0.20808078785995443" LOG_CI_START="-0.8956125339878339" LOG_EFFECT_SIZE="-0.5518466609238941" MODIFIED="2011-04-13 22:42:21 +0100" MODIFIED_BY="Leo H Bonati" ORDER="220" O_E="0.0" SE="0.403859551012548" STUDY_ID="STD-ICSS-2010" TOTAL_1="853" TOTAL_2="858" VAR="0.16310253694405688" WEIGHT="33.754281148366715"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-23 12:57:57 +0100" MODIFIED_BY="Leo H Bonati" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>Asymptomatic carotid stenosis</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-09-23 12:57:57 +0100" MODIFIED_BY="Leo H Bonati" ORDER="482" O_E="0.0" SE="0.0" STUDY_ID="STD-Kentucky-2004" TOTAL_1="43" TOTAL_2="42" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2012-03-30 07:55:33 +0100" MODIFIED_BY="Leo H Bonati" NO="5">
<NAME>Endovascular treatment or medical care in patients considered not suitable for surgery</NAME>
<DICH_OUTCOME CHI2="4.826227286374981" CI_END="7.918725110218064" CI_START="0.005986804166671066" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.2177334528375837" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" I2="79.27988176555381" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.8986552671747067" LOG_CI_START="-2.222804947754621" LOG_EFFECT_SIZE="-0.6620748402899572" METHOD="MH" MODIFIED="2012-03-09 14:53:28 +0000" MODIFIED_BY="Leo H Bonati" NO="1" P_CHI2="0.02803001433181862" P_Q="1.0" P_Z="0.4057289530486706" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="5.450791437706037" TOTALS="YES" TOTAL_1="28" TOTAL_2="33" WEIGHT="100.00000000000001" Z="0.83143320926024">
<NAME>Death or any stroke between randomisation and end of follow-up</NAME>
<GROUP_LABEL_1>Endovascular</GROUP_LABEL_1>
<GROUP_LABEL_2>Medical</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours endovascular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours medical</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5971136063367846" CI_START="0.0013002384562498673" EFFECT_SIZE="0.02786377708978328" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" LOG_CI_END="-0.2239430325032672" LOG_CI_START="-2.885976993280289" LOG_EFFECT_SIZE="-1.554960012891778" MODIFIED="2011-10-24 22:04:53 +0100" MODIFIED_BY="Leo H Bonati" ORDER="11239" O_E="0.0" SE="1.5636919258410489" STUDY_ID="STD-Beijing-2003" TOTAL_1="8" TOTAL_2="13" VAR="2.4451324389404885" WEIGHT="42.578255054847915"/>
<DICH_DATA CI_END="3.4758355298206016" CI_START="0.28770060937020603" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.5410592182423203" LOG_CI_START="-0.5410592182423203" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-03-31 19:16:56 +0100" MODIFIED_BY="Leo H Bonati" ORDER="11240" O_E="0.0" SE="0.6356417261637283" STUDY_ID="STD-CAVATAS_x002d_MED-2009" TOTAL_1="20" TOTAL_2="20" VAR="0.4040404040404041" WEIGHT="57.4217449451521"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-05-08 16:18:13 +0100" MODIFIED_BY="Leo H Bonati"/>
<FEEDBACK/>
<APPENDICES MODIFIED="2012-06-17 12:10:19 +0100" MODIFIED_BY="Leo H Bonati">
<APPENDIX ID="APP-01" MODIFIED="2012-06-17 12:10:19 +0100" MODIFIED_BY="Leo H Bonati" NO="1">
<TITLE MODIFIED="2012-06-17 12:10:19 +0100" MODIFIED_BY="Leo H Bonati">CENTRAL (<I>The Cochrane Library</I>) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-05-08 16:07:39 +0100" MODIFIED_BY="Leo H Bonati">
<P>#1.( (carotid in All Text near/6 angioplasty in All Text) or (carotid in All Text near/6 stent* in All Text) ) <BR/>#2.MeSH descriptor carotid artery diseases this term only <BR/>#3.MeSH descriptor carotid artery thrombosis this term only <BR/>#4.MeSH descriptor carotid stenosis this term only <BR/>#5.MeSH descriptor carotid arteries explode all trees <BR/>#6.MeSH descriptor Constriction, Pathologic this term only <BR/>#7.(#5 and #6) <BR/>#8.carotid in All Text<BR/> #9.(stenosis in All Text or thrombo* in All Text or disease* in All Text or narrow* in All Text or plaque* in All Text or arterioscler* in All Text or atheroscler* in All Text) <BR/>#10.(#8 and #9) <BR/>#11.(#2 or #3 or #4 or #7 or #10) <BR/>#12.MeSH descriptor angioplasty explode all trees <BR/>#13.MeSH descriptor Balloon Dilatation this term only<BR/>#14.MeSH descriptor stents this term only <BR/>#15.(angioplasty in All Text or stent* in All Text or endovascular in All Text) <BR/>#16.(balloon in All Text near/6 dilat* in All Text) <BR/>#17.(balloon in All Text near/6 catheter* in All Text) <BR/>#18.(endoluminal in All Text near/6 repair* in All Text) <BR/>#19.(transluminal in All Text near/6 repair* in All Text) <BR/>#20.(#12 or #13 or #14 or #15 or #16 or #17 or #18 or #19)<BR/> #21.(#11 and #20) <BR/>#22.(#1 or #21)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-05-08 16:08:20 +0100" MODIFIED_BY="Leo H Bonati" NO="2">
<TITLE MODIFIED="2011-09-22 10:57:59 +0100" MODIFIED_BY="Leo H Bonati">MEDLINE (Ovid) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-05-08 16:08:20 +0100" MODIFIED_BY="Leo H Bonati">
<P>1. (carotid adj10 (stent$ or angioplasty)).tw.<BR/>2. carotid artery diseases/ or carotid artery thrombosis/ or carotid stenosis/<BR/>3. carotid arteries/ or carotid artery, common/ or carotid artery, external/ or carotid artery, internal/<BR/>4. constriction, pathologic/<BR/>5. 3 and 4<BR/>6. (carotid adj5 (stenosis or thrombo$ or disease$ or narrow$ or plaque$ or arterioscler$ or atheroscler$)).tw.<BR/>7. 2 or 5 or 6<BR/>8. angioplasty/ or angioplasty, balloon/ or angioplasty, balloon, laser-assisted/ or angioplasty, laser/<BR/>9. Balloon Dilation/<BR/>10. Stents/<BR/>11. (angioplasty or stent$ or endovascular).tw.<BR/>12. (balloon adj5 (dilat$ or catheter$)).tw.<BR/>13. ((endoluminal or transluminal) adj5 repair$).tw.<BR/>14. 8 or 9 or 10 or 11 or 12 or 13<BR/>15. 7 and 14<BR/>16. 1 or 15<BR/>17. Randomized Controlled Trials as Topic/<BR/>18. random allocation/<BR/>19. Controlled Clinical Trials as Topic/<BR/>20. control groups/<BR/>21. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or clinical trials, phase iv as topic/<BR/>22. double-blind method/<BR/>23. single-blind method/<BR/>24. Therapies, Investigational/<BR/>25. Research Design/<BR/>26. randomized controlled trial.pt.<BR/>27. controlled clinical trial.pt.<BR/>28. clinical trial.pt.<BR/>29. random$.tw.<BR/>30. (controlled adj5 (trial$ or stud$)).tw.<BR/>31. (clinical$ adj5 trial$).tw.<BR/>32. ((control or treatment or experiment$ or intervention or surgical) adj5 (group$ or subject$ or patient$)).tw.<BR/>33. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.<BR/>34. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.<BR/>35. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.<BR/>36. (coin adj5 (flip or flipped or toss$)).tw.<BR/>37. latin square.tw.<BR/>38. versus.tw.<BR/>39. controls.tw.<BR/>40. or/17-39<BR/>41. 16 and 40<BR/>42. limit 41 to humans</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2012-05-08 16:09:13 +0100" MODIFIED_BY="Leo H Bonati" NO="3">
<TITLE MODIFIED="2011-09-22 10:58:16 +0100" MODIFIED_BY="Leo H Bonati">EMBASE (Ovid) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-05-08 16:09:13 +0100" MODIFIED_BY="Leo H Bonati">
<P>1. carotid angioplasty/ or carotid artery stenting/<BR/>2. (carotid adj10 (stent$ or angioplasty)).tw.<BR/>3. carotid artery disease/ or carotid artery obstruction/ or carotid artery thrombosis/ or internal carotid artery occlusion/ or carotid atherosclerosis/<BR/>4. carotid artery/ or common carotid artery/ or external carotid artery/ or internal carotid artery/<BR/>5. "stenosis, occlusion and obstruction"/ or stenosis/ or artery constriction/<BR/>6. 4 and 5<BR/>7. (carotid adj5 (stenosis or thrombo$ or disease$ or narrow$ or plaque$ or arterioscler$ or atheroscler$)).tw.<BR/>8. 3 or 6 or 7<BR/>9. angioplasty/ or laser angioplasty/ or percutaneous transluminal angioplasty/<BR/>10. balloon dilatation/<BR/>11. stent/<BR/>12. (angioplasty or stent$ or endovascular).tw.<BR/>13. (balloon adj5 (dilat$ or catheter$)).tw.<BR/>14. ((endoluminal or transluminal) adj5 repair$).tw.<BR/>15. 9 or 10 or 11 or 12 or 13 or 14<BR/>16. 8 and 15<BR/>17. 1 or 2 or 16<BR/>18. Randomized Controlled Trial/<BR/>19. Randomization/<BR/>20. Controlled Study/<BR/>21. control group/<BR/>22. exp Clinical Trial/<BR/>23. Double Blind Procedure/<BR/>24. Single Blind Procedure/<BR/>25. latin square design/<BR/>26. Parallel Design/<BR/>27. "types of study"/<BR/>28. research subject/<BR/>29. Comparative Study/<BR/>30. random$.tw.<BR/>31. (controlled adj5 (trial$ or stud$)).tw.<BR/>32. (clinical$ adj5 trial$).tw.<BR/>33. ((control or treatment or experiment$ or intervention or surgical) adj5 (group$ or subject$ or patient$)).tw.<BR/>34. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.<BR/>35. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.<BR/>36. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.<BR/>37. (coin adj5 (flip or flipped or toss$)).tw.<BR/>38. latin square.tw.<BR/>39. versus.tw.<BR/>40. controls.tw.<BR/>41. or/18-40<BR/>42. 17 and 41<BR/>43. limit 42 to human</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2011-09-22 10:58:41 +0100" MODIFIED_BY="Leo H Bonati" NO="4">
<TITLE MODIFIED="2011-09-22 10:58:41 +0100" MODIFIED_BY="Leo H Bonati">Science Citation Index search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-09-22 09:52:05 +0100" MODIFIED_BY="Leo H Bonati">
<P>TS=carotid AND TS=(angioplasty or balloon or stent* or endovascular) AND TS=(trial* or random* or versus)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>

<EXTENSION ID="AFF_71406078076224379990110119135409_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="71406078076224379990110119135409"><ADDRESS><DEPARTMENT>Department of Brain Repair &amp; Rehabilitation</DEPARTMENT><ORGANISATION>UCL Institute of Neurology</ORGANISATION><CITY>London</CITY><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></ALIAS></EXTENSION></EXTENSIONS>
</COCHRANE_REVIEW>